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Factor (GM-CSF) to Reverse Cerebral Amyloidosis and Cognitive Impairment in 
Alzheimer’s Disease Mouse Models: Insights from the Investigation of Rheumatoid 
Arthritis as a Negative Risk Factor for Alzheimer’s Disease 
 
Timothy David Boyd 
 
ABSTRACT 
 
 For many years, it has been known that Rheumatoid arthritis (RA) is a negative 
risk factor for the development of Alzheimer’s disease (AD). It has been commonly 
assumed that RA patients’ usage of non-steroidal anti-inflammatory drugs (NSAIDs) 
have helped prevent the onset and progression of AD pathogenesis. Furthermore, 
experiments in animal models of Alzheimer’s disease have looked to inhibit 
inflammation, and have demonstrated some efficacy against AD-like pathology in these 
models. Thus many NSAID clinical trials have been performed over the years, but all 
have proven unsuccessful in AD patients. This suggests that intrinsic factors within RA 
pathogenesis itself may underlie RA’s protective effect.  
 My dissertation research goal was to investigate this inverse relationship between 
RA and AD, in order to more precisely pinpoint critical events in AD pathogenesis 
toward developing therapeutic strategies against AD. It seemed improbable that any 
secreted factors, produced in RA pathogenesis, could maintain high enough 
concentrations in the circulatory system to cross the blood brain barrier and inhibit AD 
pathogenesis, without affecting all other organ systems. It did seem possible that the 
vii 
 
leukocyte populations induced in RA, could traverse the circulatory system, extravasate 
into the brain parenchyma, and impede or reverse AD pathogenesis. We thus investigated 
the colony-stimulating factors, which are up-regulated in RA and which induce most of 
RA’s leukocytosis, on the pathology and behavior of transgenic AD mice. We found that 
G-CSF and more significantly, GM-CSF, reduced amyloidosis throughout the treated 
brain hemisphere one week following bolus intrahippocampal administration into AD 
mice. We then found that 20 days of subcutaneous injections of GM-CSF (the most 
amyloid-reducing CSF in the bolus experiment) significantly reduced brain amyloidosis 
and completely reversed cognitive impairment in aged cognitively-impaired AD mice, 
while increasing hippocampal synaptic area and microglial density. These findings, along 
with two decades of accrued safety data using Leukine, the recombinant human GM-CSF 
analogue, in elderly leukopenic patients, suggested that Leukine should be tested as a 
treatment to reverse cerebral amyloid pathology and cognitive impairment in AD 
patients. It was also implied that age-related depressed hematopoiesis may contribute to 
AD pathogenesis. 
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CHAPTER 1 - INTRODUCTION 
 
The Inverse Relationship Between Rheumatoid Arthritis and Alzheimer’s Disease 
 
Epidemiological Studies. Several case-control and population-based studies 
suggest that patients with Rheumatoid arthritis (RA) are protected from developing 
Alzheimer’s disease (AD). The case-control study of Jenkinson et al., a survey of 96 AD 
and 92 non-AD cases, looking for the presence or absence of RA, found that only 2% of 
AD patients had RA as compared to 13% of control cases (Jenkinson, Bliss, Brain, & 
Scott, 1989).  In a population-based study of McGeer et al., of 973 RA patients, who 
were 65 years and older and had extensive clinical history records, only 4 (0.41%) were 
demented (P. L. McGeer, McGeer, Rogers, & Sibley, 1990).  Similarly, the authors 
examined the discharge records of 7,490 RA patients, 65 years or older, and found that 
only 0.39% had concomitant AD.  However, using data gathered in the Rochester AD 
Incidence cohort collected between 1950 to 1975, Beard et al. reported that only 23 
(4.4%) of the 521 RA cases subsequently developed AD (Beard, Kokman, & Kurland, 
1991).  Another population-based study, examining the causes of death within the whole 
Finnish population covering the year of 1989, found that only 2 (0.12%) RA patients died 
with concomitant AD (Myllykangas-Luosujarvi & Isomaki, 1994). The study also 
revealed that 227 of the Finnish people that died in 1989, or only 0.54% of the whole 
population cohort, had been diagnosed with AD. To put these numbers into perspective 
today, it has recently been reported in the United States, that there was a 46.1% increase 
in deaths attributable to Alzheimer’s disease from year 2000 to 2006, with an overall 
average of 22.6% mortality rate (Alzheimer's_Association, 2010). 
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 Although it was concluded that RA is a negative risk factor for AD, the small 
population of patients with concomitant RA and AD suggests that genetic predispositions 
for AD may override RA’s protective effects. There have not been any epidemiological 
studies that have examined this inverse relationship between RA and AD in regards to 
AD-positive genetic risk factors, such as Apolipoprotein E type 4 (ApoE4) positivity, 
amyloid precursor protein (APP) or presenilin-1 (PS1) mutations found in Familial 
Alzheimer’s disease (FAD), or mutations in genes that encode immune system 
components, such as complement receptor-1(CR1) or Clusterin. However, two studies 
have examined the prevalence of ApoE4 in RA patients with systemic reactive 
amyloidosis, and both concluded that ApoE4 may be a risk factor for developing reactive 
amyloidosis (Hasegawa et al., 1996; Maury et al., 2001). Whether ApoE4 or other genetic 
polymorphisms influence cerebral amyloidosis in RA patients will need to be specifically 
addressed in future epidemiological studies, although the very small population of 
concomitant RA and AD patients may make these analyses difficult to conduct. 
NSAID Usage.  Concurrent with the studies that examined RA as a negative risk 
factor for AD, were similar epidemiological studies that investigated nonsteroidal anti-
inflammatory drugs (NSAIDs), which RA patients chronically used to ameliorate RA 
symptoms, as protective against AD. A meta-analysis study reviewed 17 epidemiological 
studies in which RA or NSAIDs were considered as risk factors for AD (P. L. McGeer, 
Schulzer, & McGeer, 1996). In the meta-analysis, there were several case-control and 3 
population-based studies that concluded that NSAID usage may be protective against AD 
onset. The 3 population-based studies examined the NSAID and AD relationship by 
different approaches. In an Italian study, 195 AD patients were surveyed as to whether 
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their NSAID usage was greater or less than in people of similar age (Lucca, Tettamanti, 
Forloni, & Spagnoli, 1994). The authors found that NSAID usage was much less than 
expected in AD patients as compared to NSAID usage in an elderly control group. 
Another population-based study in Rotterdam examined 365 NSAID users, which had 
only 1.4% afflicted with AD, and concluded that NSAIDs possibly prevented the risk of 
developing AD (Andersen et al., 1995). In a third population-based study of 210 patients 
in the Johns Hopkins Alzheimer Disease Research Center, a review of medical records of 
32 AD patients who used NSAIDs compared to 177 AD patients who did not use 
NSAIDs (Rich et al., 1995). The clinical, cognitive, and psychiatric measures of each 
group were compared to examine which group progressed faster with AD within a one 
year longitudinal study. The authors concluded that the AD patients who took NSAIDs 
had a slower progression of AD pathogenesis. Altogether in the meta-analysis 
examination of McGeer et al. (1996), it was likewise concluded that NSAID usage was 
protective against developing AD, although the data did not deduce which specific 
NSAID, or combination of NSAIDs, would be most protective against AD. It was also 
concluded that anti-inflammatory drugs would reduce neuroinflammation, which was 
commonly assumed to drive the pathogenesis of AD, and that clinical trials were needed 
to investigate NSAIDs in order to halt the onset or progression of AD. 
 Since the meta-analysis of McGeer (1996), many pre-clinical and clinical research 
studies have focused on investigating the reduction of inflammation as a therapeutic 
approach to ameliorate AD pathogenesis.  Animal studies have shown some promise in 
lowering inflammation and reducing AD-like symptoms (Heneka et al., 2005; Jantzen et 
al., 2002; Kukar et al., 2005; Lim et al., 2000; Q. Yan et al., 2003). However, large 
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NSAID clinical trials have been disappointing, and some have failed to show efficacy or 
have even been discontinued due to adverse events (Aisen et al., 2003; Aisen, 
Schmeidler, & Pasinetti, 2002; P. L. McGeer, Rogers, & McGeer, 2006; Reines et al., 
2004; Rogers et al., 1993; Scharf, Mander, Ugoni, Vajda, & Christophidis, 1999).  
Moreover, the recent Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) 
study, that investigated celecoxib and naproxen, was halted due to adverse 
cardio/cerebrovascular events by celecoxib and because test subjects who already had 
mild cognitive impairment at the beginning of the trial tended to have accelerated 
impairment and progression to AD by naproxen (Meinert, McCaffrey, & Breitner, 2009; 
Strobel, 2009). However, a two-year follow-up study of the ADAPT participants, who 
were cognitively normal at the beginning of the trial, and who took naproxen versus 
placebo, were found to be significantly protected against incidence of AD, as well as 
having a more favorable biomarker profile (Tau/Aβ1-42, proteins explained below). It was 
suggested by Dr. Brietner at the 2009 International Conference of Alzheimer’s Disease 
(ICAD) that “Primary prevention, not disease modification, is the ultimate cure, and 
timing is everything” (Strobel, 2009). This suggestion echoes the findings of another 
large epidemiology study of veterans over the age of 55 years who were on long-term 
NSAID usage, particularly ibuprofen, and who were also protected against AD onset 
(Vlad, Miller, Kowall, & Felson, 2008). 
NSAIDs act mainly to inhibit the action of cyclooxygenases (Cox), which are 
enzymes that catalyze the formation of eicosanoids, such as thromboxanes or 
prostaglandins, from an arachadonic acid precursor. There are two isoforms of 
cyclooxygenases,Cox-1 and Cox-2, which differ in their expression and biological 
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functions (Kaufmann, Andreasson, Isakson, & Worley, 1997; O'Banion, Sadowski, 
Winn, & Young, 1991). Cox-1 and Cox-2 are constitutively expressed at low levels in 
most tissues, and induced expression of Cox-2 occurs during inflammation. Traditional 
NSAIDs, such as aspirin or ibuprofen, are non-selective and inhibit both Cox-1 and 
Cox-2. In the brain and especially around AD-vulnerable pyramidal neurons, Cox-2 is 
constitutively expressed at higher levels than Cox-1, and has enhanced expression in AD 
brain (Seibert et al., 1994; Yasojima, Schwab, McGeer, & McGeer, 1999; Yermakova, 
Rollins, Callahan, Rogers, & O'Banion, 1999). However, it has been found that Cox-2 is 
not detectable in microglia and astrocytes in AD, but it is instead expressed in neurons. 
Exposure of human microglial cultures to inflammatory mediators over-expressed in AD 
brain, such as interleukin (IL)-1, IL-6, tumor necrosis factor alpha (TNFα), and amyloid 
beta 1-42 (Aβ1-42), did not induce Cox-2 activity, and it was only after exposure to 
bacterial lipopolysaccharide (LPS) that the microglia express Cox-2 (Hoozemans et al., 
2001). On the other hand, Cox-1 is up-regulated in AD-activated microglia and may 
provide a more selective target to reduce AD-associated neuroinflammation (Hoozemans 
et al., 2002). Therefore, it can be predicted that the Cox-2-selective NSAIDs, such as 
celecoxib, would act mainly to inhibit peripheral pro-inflammatory effects, instead of 
acting directly against AD-related neuroinflammation. As of today, there are no 
clinically-approved selective Cox-1 inhibitors, and traditional NSAIDs are the only 
available options for inhibiting Cox-1.   
Leprosy and Dementia. It has been well known among physicians in Japan that 
elderly leprosy patients who inhabit well-monitored leprosy hospitals do not tend to 
develop cognitive impairment. Bacterial infection by Mycobacterium leprae causes a 
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chronic granulomatous disease of the skin and chronic inflammation of the peripheral 
nervous system (Dastur & Razzak, 1971; Jacobs, Shetty, & Antia, 1987; Job, 1971; Save, 
Shetty, Shetty, & Antia, 2004; Swift, 1974). A study by McGeer et al. in 1992 surveyed 
living leprosy patients in Japan, aged 65 and older, for the usage of anti-leprosy drugs 
and for dementia. In the 1,410 leprosy patients that had been treated with anti-leprosy 
drugs, there was a 2.9% prevalence of dementia compared to 6.25% of the 1,761 leprosy 
patients that had not been treated for at least 5 years. Since dapsone and other anti-
leprosy drugs have anti-inflammatory activity, it was proposed that these drugs might 
also be protective against AD, similar to the proposed efficacy of NSAIDs against AD (P. 
L. Mcgeer, Harada N., Kimura H., McGeer E.G., Schulzer M., 1992; P. L. McGeer et al., 
1996). However, another epidemiological study examining inpatients in a Japanese 
leprosarium with an average age of 70 and who were free from active leprosy did not 
show protection against AD as compared to previous Japanese general population-based 
data (Goto et al., 1995). The latest study that examined whether anti-leprosy drugs were 
efficacious against AD showed that anti-leprosy drugs (dapsone, rifampicin, clofazimine, 
minomycin, or ofloxacin) did not have any protective effect on the neurotoxicity of 
amyloid beta (Aβ) peptides, the main component of the cerebral amyloidosis in AD 
(Endoh, Kunishita, & Tabira, 1999). The authors also reviewed the medical records of 
196 lepromatous patients, and found that there was no significant difference in 
prevalence of dementia of those patients that were treated with anti-leprosy drugs 
compared to untreated lepromatous patients. Taking into account their previous study that 
did show significantly lower cerebral amyloidosis in elderly lepromatous patients 
compared to controls (Chui, Tabira, Izumi, Koya, & Ogata, 1994), the authors concluded 
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that intrinsic mechanisms of Mycobacterium leprae infection itself in the central nervous 
system (CNS) may underlie the protection against AD pathogenesis in active lepromatous 
patients.  Indeed it is a striking similarity with RA, that another chronic peripheral 
inflammatory disease, such as Mycobacterium leprae infection, also confers a reported 
decreased risk of AD onset, independent of anti-inflammatory pharmaceutical 
intervention. 
Rheumatoid Arthritis 
 Pathogenesis of Rheumatoid Arthritis. Rheumatoid arthritis is the most 
common systemic inflammatory disorder and the most serious and disabling type of 
arthritis. RA is an autoimmune disease in which the joint synovium becomes inflamed 
and a highly vascularized inflammatory pannus forms that irreparably damages the 
cartilage and bone, causing joint disfigurement and excruciating pain. This systemic 
autoimmunity is characterized by autoantibodies against a wide range of autoantigens. 
The first autoantibody, described in 1940 and named rheumatoid factor (RF) (Waaler, 
1940), was later found to have specificity for the Fc region of IgG immunoglobulins. 
Since then, other RA autoantigens, such as cartilage components, stress proteins, 
enzymes, nuclear proteins, and citrullinated proteins have been discovered (Reviewed in 
(Duskin & Eisenberg)).  The autoimmunity of RA involves not only the B lymphocytic 
arm of the adaptive immune system, but also a recently-described class of T helper (Th) 
cell lymphocytes. This new pro-inflammatory CD4+ effector cell lineage, separate from 
Th1, Th2, and Treg differentiations (Harrington et al., 2005; H. Park et al., 2005; Wynn, 
2005) is termed Th17, due to their release of cytokines, IL-17A/F. These Th17 
lymphocytes also secrete many other proinflammatory cytokines and chemokines that 
work in the recruitment and activation of innate leukocytes, as well as the proliferation of 
more autoimmune T and B lymphocytes. RA is not the only autoimmune disease with a 
Th17 phenotype, as Th17 lymphocytes have also been found to be greatly implicated in 
the pathogenesis of Multiple Sclerosis, Crohn’s disease, Inflammatory Bowel Disease 
and Systemic Lupus Erythematosus (Furuzawa-Carballeda, Vargas-Rojas, & Cabral, 
2007; Nalbandian, Crispin, & Tsokos, 2009; Sarkar, Tesmer, Hindnavis, Endres, & Fox, 
2007; Thakker et al., 2007).  
Of the innate leukocytes involved in RA, differentiated myeloid-lineage 
monocytic cells are major contributors to the pathogenesis of RA. The hematopoietic 
growth factor, M-CSF (Macrophage Colony-Stimulating Factor), produced by synovial 
endothelial cells and macrophages, is highly expressed and drives macrophage and 
osteoclast production and differentiation. The TNF  family member, RANKL (receptor 
activator of NF-κB ligand), secreted by bone marrow stromal cells and T lymphocytes, 
binds to their RANK receptors on these macrophage/osteoclast progenitors and activates 
an intracellular transduction cascade involving TRAFs, JNK, and NF-κB in order to 
induce functional osteoclasts.  Secreted osteoprotegerin (OPG) is induced in RA synovial 
fluid to work as a negative regulator of this process (Karsenty, 1999).  Besides increased 
bone resorption due to osteoclasts in RA, the innate leukocytes work in combination with 
the above-mentioned autoimmune lymphocytes in the production of inflammatory-related 
cytokines,chemokines, hematopoietic factors, enzymes, and other soluble factors, such as 
TNFα, IL-1, IL-6, IL-8, IL-15, IL-17A/F, IL-18, CXCL16, ADAM10, M-CSF, G-CSF, 
GM-CSF, MCP-1 (monocyte chemotactic protein 1), and MIF (macrophage migration 
inhibitory factor). There is also elevated expression of angiogenic factors, VEGF-A 
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(vascular endothelial growth factor – A) and IGF-1 (insulin-like growth factor 1), by 
synovial macrophages, fibroblasts, and vascular smooth muscle cells, as well as, the 
increased expression of their receptors, VEGFR-1,2 on endothelial cells and 
macrophages, and secreted IGF Binding Protein (IGFBP)-3 (Matsumoto & Tsurumoto, 
2002; Murakami et al., 2006). Thus the combined innate and adaptive autoimmunity in 
the inflammatory pannus of RA cause a chronic feed-forward mechanism to increase 
leukocyte populations, further cytokine and chemokine induction, increased 
osteoclastogenesis, resultant synovial joint deformation, and extensive 
neovascualarization as the pannus grows. 
Alzheimer’s Disease 
History of Alzheimer’s Disease. Alzheimer’s disease was first described at a 
scientific meeting in November 1906 by German physician, Alois Alzheimer. He was the 
physician of a 51 year old patient, Frau Auguste D., who was brought to him by her 
family for memory problems, unfounded suspicions, and increasing difficulty in the 
ability to process new events. During Dr. Alzheimer’s care, these symptoms rapidly 
progressed until the death of Mrs. Auguste D. in the spring of 1906. Since Dr. Alzheimer 
had never encountered these symptoms in a patient, he requested the permission to 
perform an autopsy on Mrs. Auguste D. Examination of her brain revealed atrophy of the 
cerebral cortex, fatty deposits in the cerebral microvasculature, abnormal extracellular 
and intracellular deposits, and evidence of active neurodegeneration. Dr. Alzheimer 
published his work in 1907, and the disease was named after him in 1910 (Graeber et al., 
1997; Graeber, Kosel, Grasbon-Frodl, Moller, & Mehraein, 1998).  
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Statistics of Alzheimer’s Disease. Alzheimer’s disease is the most common type 
of dementia today, accounting for 60 – 80% of all cases of dementia, followed secondly 
by vascular dementia, although many patients may have hallmark pathologies of both 
(Alzheimer's_Association, 2010). Approximately 1 out of 8 people over the age of 65, 
and 1 out of 2 over the age of 85 will be diagnosed with AD. As of 2010, there were over 
5.3 million Alzheimer’s patients in the United States, costing $172 Billion in annual 
costs. AD is the 7th leading cause of death, and although its prevalence is increasing, the 
mortality from cardiovascular disease, cancer, and other diseases are decreasing. It is 
estimated that by 2030, there will be 7.7 million Alzheimer’s patients over the age of 65, 
and between 11 and 16 million by 2050. The disease is characterized initially by short-
term forgetfulness with the inability of the individual to learn any new things, along with 
fluctuations in the individual’s mood and attention span. As the disease progresses, the 
AD patient gradually withdraws from daily life, can become easily agitated, and starts to 
forget the names and identities of family and loved ones. Slowly and inexorably, the 
ability of carry out familiar tasks, to reason and exercise judgment, and to carry on 
conversation declines to the state of bedrest, followed by certain fatality. The lifespan of 
Alzheimer’s patients averages about 10 years from diagnosis, and the overall physical 
condition and age of onset may influence how fast the disease progresses. The cause of 
death is usually by AD directly, such as by dehydration and malnutrition from the 
inability of patients to swallow, or by other diseases, such as pneumonia, stroke, etc., as 
the body’s general health slowly deteriorates (Alzheimer's_Association, 2010). 
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Pathological Hallmarks of Alzheimer’s Disease.  
Overview. Alzheimer’s disease is a fatal, age-related, and progressive 
neurodegenerative disorder that presents clinically in patients as a progressive decline in 
cognitive and executive functions. Its dementia is associated with extracellular deposits 
of amyloid, intracellular aggregates of neurofibrillary tangles (NFTs), and cerebral 
microvascular occlusions and other ischemic defects. The hippocampus, amygdala, and 
cerebral cortex are the major areas of the brain in which these hallmark pathologies occur 
(Hopper & Vogel, 1976; Woodard, 1966). Although Dr. Alzheimer described these 
pathologies in his 1907 publication, it took over 7 decades to develop the laboratory 
techniques and tools in which to identify the principle components of the then-called 
senile plaques and neurofibrillary tangles (Glenner & Wong, 1984). It is now known that 
oxidative stress, neuroinflammation, excitotoxicity, apoptosis, and aneuploidy may all 
contribute to the pathogenesis of AD. 
 Amyloidosis. Amyloid beta (Aβ) peptides are the primary component of amyloid 
deposits in the Alzheimer’s disease brain. Aβ is proteolytically derived from the amyloid 
precursor protein (APP), a transmembrane protein expressed in almost all tissues 
(Glenner & Wong, 1984). Three APP isoforms (APP695, APP751, and APP 770) are 
found in mammals, with APP695 being the isoform mainly expressed on the surface of 
neurons (Tanaka et al., 1988; Tanaka et al., 1989).  Whether APP contains a chondroitin 
sulfate glycosaminoglycan site or a Kunitz protease inhibitor domain differentiates the 
three isoforms from each other (Sisodia & Price, 1995).  
APP is a synaptic receptor whose function has not been elucidated completely, 
but its processing is thought to influence dendritic spine development and maintenance 
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(Dewji & Singer, 1996; Ho & Sudhof, 2004; K. J. Lee et al., 2010; Lorenzo et al., 2000; 
P. Wang et al., 2005). The processing of APP occurs by three enzymes, α, β, and γ-
secretases, and depending on whether α or β-secretase cleaves the APP will determine 
whether the resultant peptides are non-amyloidogenic or amyloidogenic, respectively. For 
the amyloidogenic pathway, cleavage by β-secretase is the rate-limiting step for Aβ 
generation (Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; R. Yan et al., 
1999). There are two isoforms of β-secretase, BACE1 and BACE2, and although both 
isoforms compete for the same substrate and cleave at the same β-site of APP, BACE2 
activity is much less abundant and thought to be masked in the brain (Ahmed et al., 2010; 
Basi et al., 2003; Farzan, Schnitzler, Vasilieva, Leung, & Choe, 2000; Hussain et al., 
2000; Sun et al., 2005; R. Yan, Munzner, Shuck, & Bienkowski, 2001). Cleavage of APP 
by BACE1 results in the extracellular release of soluble APP beta (sAPPβ), a large 
N-terminal ectodomain of APP with unknown function, leaving a transmembrane 
C-terminal fragment of 99 amino acids (C99), which is then intramembranely-cleaved by 
γ-secretase to produce extracellular Aβ peptides of either 39, 40, or 42 amino acid 
residues in length. The C-terminal APP intracellular domain (AICD) is thought to play a 
feed-back regulatory role in the transcription of genes implicated in AD pathogenesis 
(Slomnicki & Lesniak, 2008). For the non-amyloidogenic pathway, cleavage by 
α-secretase at the APP α-site, which lies within the Aβ sequence, generates a 
transmembrane C-terminal fragment of 83 amino acids in length (C83), with the 
extracellular release of the large N-terminal soluble APP alpha (sAPPα). It is interesting 
to note that the gene for BACE2 is located in the Down’s syndrome critical region of 
Chromosome 21, and although purified BACE2 cleaves at the β-site of APP, it can also 
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process APP downstream of the α-site (R. Yan et al., 2001). Overexpression of BACE2 
in a human embryonic kidney (HEK) cell line stably-expressing the Swedish mutant of 
APP, resulted in reduced Aβ production, but an increase in soluble APP species (sAPP, 
which includes sAPPα, sAPPβ, and BACE2-generated sAPP) (Sun et al., 2005). 
Although the authors did not determine relative levels of each type of sAPP, they did find 
that knockdown of BACE2 results in an increase of APP C83, indicative of the non-
amyloidogenic pathway. Although the authors concluded that BACE2 is not involved in 
the formation of amyloid plaques, Down’s patients chronically overexpressing BACE2, 
as well as BACE1, would have both species of BACE competing against α-secretase, 
which may have yet undescribed physiological effects, since the biological functions of 
sAPPα and over-expressed BACE2-generated sAPP have not been completely elucidated. 
The γ-secretase is a multiprotein intramembrane-cleaving aspartyl protease 
complex, which consisits of Presenilin (PS, which can be either of two isofoms, PS1 or 
PS2),  Pen2, Aph1 (anterior pharynx-defective 1 protein), and nicastrin (NCT). PS 
contains the catalytic site (De Strooper et al., 1998; Y. M. Li et al., 2000; Wolfe et al., 
1999), Pen2 and Aph1 have functions that have not been fully elucidated, and NCT is 
thought to contain the substrate binding site (Shah et al., 2005), as well as stabilizing 
γ-secretase, since the trimeric PS/Pen2/Aph1 complex is highly unstable (Zhao, Liu, 
Ilagan, & Kopan, 2010). Mutations in PS1 and PS2, as well as the APP gene, have been 
found to lead to increased production of pathogenic Aβ and cause early onset familial AD 
(FAD) (Chartier-Harlin et al., 1991; Fidani et al., 1992; Goldgaber, Lerman, McBride, 
Saffiotti, & Gajdusek, 1987; St George-Hyslop et al., 1990; Tanzi, George-Hyslop, & 
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Gusella, 1991). There are over 160 known mutations that predispose individuals to FAD, 
with PS1 mutations accounting for the majority of FAD.  
Amyloid-associated Proteins. Over 30 other proteins have also been found to be 
associated with extracellular amyloid plaques, including complement proteins, 
complement regulatory proteins, growth factors, proteases, protease inhibitors, 
coagulation factors, proteoglycans, acute phase reactants, receptors, adhesion molecules, 
and other soluble factors (P. L. McGeer, Klegeris, Walker, Yasuhara, & McGeer, 1994). 
The majority of these proteins are directly associated with the immune system, but the 
characterization and determination of each protein’s role in amyloid deposition and 
subsequent AD pathogenic pathways have not yet been fully elucidated. It is known that 
the plaque-associated proteins, apolipoprotein E (ApoE) and Alpha-1-antichymotrypsin 
(ACT) work to catalyze the formation of Aβ filaments in vitro (Ma, Brewer, & Potter, 
1996; Wisniewski & Frangione, 1992) and formation of amyloid beta-pleated sheets in 
vivo (Abraham, Selkoe, & Potter, 1988; Bales et al., 1999; Ma, Yee, Brewer, Das, & 
Potter, 1994; Nilsson et al., 2001; Potter, Wefes, & Nilsson, 2001). ApoE acts 
systemically in the transport of lipid proteins, but in the brain, it is released by astrocytes 
and microglia during neuroinflammation. ApoE allele ε4 (ApoE4) confers a very high 
risk for developing AD, ApoE allele ε2 (ApoE2) is associated with low risk and high age 
of onset, and ApoE allele ε3 (ApoE3) confers intermediate risk and age of onset 
(Strittmatter et al., 1993).  ACT is an acute-phase serine protease inhibitor (serpin) that is 
released systemically by hepatocytes and monocytes during inflammatory responses, and 
by neutrophils to work as a suicide inhibitor of Cathepsin G during vascular remodeling 
(Kalsheker, 1996). However, in the brain, ACT is induced and released by astrocytes in 
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response to microglial release of IL-1β, trauma, infection, or amyloidosis (Abraham, 
2001; Das & Potter, 1995). Not only does ACT work to catalyze amyloid plaque 
formation, it also induces intracellular neuronal Tau hyperphosphorylation 
(Padmanabhan, Levy, Dickson, & Potter, 2006). 
Tauopathy. The hyperphosprorylation of Tau leads to paired helical filaments 
(PHFs), which themselves aggregate intracellularly to form neurofibrillary tangles 
(NFTs), another major hallmark pathology of AD(Grundke-Iqbal, Iqbal, Quinlan et al., 
1986; Grundke-Iqbal, Iqbal, Tung et al., 1986). Tau is a cytosolic protein that is involved 
in the assembly and stabilization of microtubules (MT), and the hyperphosphorylation of 
Tau, impedes Tau from binding MTs and performing this role, since it undergoes 
misfolding, dissociation from MTs, and aggregation (Chung, 2009; V. M. Lee, Balin, 
Otvos, & Trojanowski, 1991). Tau is primarily expressed in neurons, and mutations in 
the Tau gene, encoded by 16 exons on Chromosome 17, leads to tauopathies, such as 
Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration, Pick’s disease, and 
parkinsonism linked to chromosome 17 (FTDP-17) (Baker et al., 1997). Although, these 
tauopathies also present with progressive dementia, Tau mutations have not been 
identified in AD pathogenesis, and the various taupathies present in different brain 
regions and specific types of neurons (Arima, Murayama, Oyanagi, Akashi, & Inose, 
1992; Delisle et al., 1999; Galloway, 1988; Hauw et al., 1990; Kertesz et al., 2000; 
Ksiezak-Reding et al., 1994; Mori, Nishimura, Namba, & Oda, 1994; Nasreddine et al., 
1999; Poorkaj et al., 1998; Schneider & Mandelkow, 2008; Spillantini et al., 2000). There 
are 85 reported phosphorylation sites that have been identified on Tau, and 45 of these 
have been identified to contribute to AD pathogenesis. Tau is primarily phosphorylated 
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by glycogen synthase kinase-3beta (GSK-3β), cyclin-dependent kinase 5 (cdk5), 
calcium/calmodulin-dependent protein kinase 2 (CaMKII) and secondarily by 
extracellular signal-related kinase (ERK), casein kinases 1 (CK1) (Singh, Grundke-Iqbal, 
& Iqbal, 1995; Singh, Grundke-Iqbal, McDonald, & Iqbal, 1994), and cAMP-dependent 
protein Kinase A (PKA) (G. Li, Yin, & Kuret, 2004; F. Liu et al., 2006; Pei et al., 2002; 
Trojanowski, Mawal-Dewan, Schmidt, Martin, & Lee, 1993). Regulation and 
dephosphorylation occurs by known phosphatases, PP2A, PP1, and PP2B. A 
peptidyl-prolyl cis-isomerase, Pin-1, is involved in the assembly, folding, and transport of 
Tau. For example in AD, Pin-1 binds Tau when Tau is phosphorylated at its Threonine 
residue 231 (Thr231), in order to facilitate dephosphorylation of Thr231 by PP2A 
(Butterfield et al., 2006). The mechanisms into the hyperphosphorylation of Tau, and its 
subsequent aggregation into NFTs, are currently a very active area of research, as levels 
of NFTs correlate closely with AD prognosis.  
Cerebrovasculature Dysfunction. Another major hallmark pathology of AD is the 
extensive cerebrovascular damage that occurs as AD progresses. Cerebrovascular damage 
was noted as early as 1911, by Dr. Alois Alzheimer from his second senile dementia case 
study of a 56 year-old demented man, Johann Feigel, who was admitted to the Royal 
Psychiatric Clinic in Munich on November 12, 1907 with possible vascular dementia and 
who died on October 3, 1910 with pneumonia-like symptoms, and was described by Dr. 
Alzheimer to have degeneration of the smaller cerebral blood vessels (Graeber et al., 
1997). An immunohistochemical study that looked at deceased AD patients and age-
matched control subjects found that over 90% of those with AD had an absence of 
endothelial staining for capillaries, even though it appeared that their basement 
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membranes remained, suggesting that the capillaries had collapsed and degenerated, 
concomitant with Aβ deposition (Kalaria & Hedera, 1995). Other studies have shown in 
the cerebrovasculature of AD patients that the basement membranes thicken, that the 
pericytes degenerate, that endothelial cell morphology is altered, and that luminal 
buckling occurs (Buee et al., 1994; Claudio, 1996; Mancardi, Perdelli, Rivano, Leonardi, 
& Bugiani, 1980; Perlmutter, Myers, & Barron, 1994; Prasher et al., 1998; Scheibel, 
1987; Scheibel, Duong, & Tomiyasu, 1987; Zarow, Barron, Chui, & Perlmutter, 1997). 
These microvascular abnormalities and degeneration of capillary vessels result in reduced 
cerebral blood flow and deficient delivery of oxygen and glucose to the brain (de la 
Torre, 2004, 2009, 2010; de la Torre & Stefano, 2000). As discussed later, this damage to 
the cerebral vasculature may also impair the clearance mechanisms of Aβ from the brain 
(Chapters 2 and 6).   
Although these capillary abnormalities can be examined post-mortem in AD 
patients, non-invasive techniques are not available to longitudinally study these 
microvascular effects in vivo. However, experimental animal models, such as chronic 
cerebral hypoperfusion in aged rats over one year, induced by permanent surgical 
occlusion of both common carotid arteries (two-vessel occlusion), results in almost 
identical microvascular pathology as in AD patients, such as basement membrane 
thickening, deposition of collagen, distortion of endothelial cell morphology, 
degeneration of pericytes, and vessel lumen buckling, all within the CA1 hippocampal 
region and which also correlates with a progressive decline in spatial memory function 
(De Jong et al., 1999; Farkas, De Jong et al., 2000; Farkas, De Vos, Jansen Steur, & 
Luiten, 2000).  The immense cerebrovascular damage found in AD pathogenesis can also 
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be demonstrated by vascular corrosion casting (VCC) of Tg AD mice. A recent study 
which used the VCC technique, employed a new polyurethane low-viscosity resin and 
other special resins to perfuse young and old Tg AD mice (Heinzer et al., 2006; Krucker, 
Lang, & Meyer, 2006; Meyer et al., 2007; Meyer, Ulmann-Schuler, Staufenbiel, & 
Krucker, 2008). After perfusion and time for the resins to polymerize, chemical removal 
of the surrounding tissue was performed. These resins that were used have minimal 
shrinkage, leaving high quality replicas of the lumens of even the smallest capillaries. 
VCC allows for 3-dimensional, very high resolution examination of the 
microvasculature’s morphology under scanning electron microscopy, which can even 
determine endothelial cell imprints and show distinction between arterial versus veinal 
vessels within the vascular tree (Heinzer et al., 2008; Weiger, Lametschwandtner, & 
Stockmayer, 1986). The authors found that amyloid deposits begin to accumulate on the 
capillary vessels at very early ages in the AD mice, in shapes described as ‘pompoms or 
cubes’ of Aβ species, as determined by mass spectrometry analysis, and in doing so, the 
microvessels begin to crimp and become occluded. These ‘pompoms or cubes’ are not 
found in normal age-matched control mice, and also would not be detectable by 
conventional histochemistry, since conventional histochemistry does not retain the 3D 
architecture of the entire cerebral vasculature and capillary vessels. As the AD mice age 
and plaques became large enough to view by conventional histochemistry, VCC showed 
that the vasculature becomes deformed, truncated, or occluded surrounding the amyloid 
plaques, forming significant holes in the vascular system (Figure 1) (Beckmann et al., 
2003; Meyer et al., 2008). There also was extensive increased vascular remodeling 
around the truncated ends of the vessels, as the vessels were studded with knobs, 
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budding, and other abnormal protrusions, in an apparent attempt to circumvent the 
amyloid plaques. However, the intrinsic nature of Aβ itself is anti-angiogenic and 
accelerates the senescence of endothelial cells at very early stages of vascular 
development (Donnini et al., 2010), possibly by mechanisms, such as the direct binding 
of Aβ to the receptor for VEGF (Patel et al., 2010). Indeed, a ten amino acid peptide with 
Aβ itself, has been recently reported to inhibit tumorigenesis via anti-angiogenic effects 
(Paris et al., 2010). Thus, although the vasculature attempts to circumvent the amyloid 
plaques, it is prevented by the intrinsic anti-angiogenic nature of Aβ, and only after 
physical enzymatic dissolution, degradation, or phagocytic removal of Aβ, would the 
vascular remodeling have a chance to be successful and restore cerebral blood flow. 
Down’s Sydrome, Aneuploidy, Cell Cycle, and Alzheimer’s Disease. Down’s 
Syndrome (DS) individuals invariably develop Alzheimer’s disease by their third or 
fourth decade of life (Epstein, 1990; Glenner & Wong, 1984; Olson & Shaw, 1969). DS 
individuals are born with three copies of Chromosome 21 in every cell because of meiotic 
chromosome mis-segregation (Lejeune, Gautier, & Turpin, 1959; Mrak & Griffin, 2004), 
and the gene encoding amyloid precursor protein (APP)  is located on Chromosome 21. 
Genetic mutations in APP have been found to result in FAD (Goate et al., 1991; Naruse 
et al., 1991; Tanzi et al., 1991), and it has been thought that DS individuals should 
overexpress APP throughout their life more than non-DS individuals. DS individuals 
begin accumulating fibrillar Aβ deposition in their brains by age of adolescence (Lemere 
et al., 1996; Mrak & Griffin, 2004; Rumble et al., 1989).  A specific case of a DS 78 year 
old woman, who had only partial trisomy 21 with only two alleles of APP and who died 
without any clinical or AD pathology, showed that extra expression of APP is necessary 
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for AD onset in DS patients, but not for development of DS (Mrak & Griffin, 2004; 
Prasher et al., 1998). However, extra APP expression does not completely account for the 
onset of AD in non-DS individuals. For instance, autopsy of deceased individuals from 
the Nun Study (Davis, Schmitt, Wekstein, & Markesbery, 1999; Gold et al., 2000; Riley, 
Snowdon, & Markesbery, 2002), showed that there were subjects with high levels of 
cerebral amyloidosis but who had no documented cognitive impairment, indicative of 
AD, before their death. Moreover, in the halted AN1792 immunotherapy clinical trial, 
follow-up autopsy of some individuals who had received anti-Aβ therapy and who had 
died with progressive dementia, were found to be almost devoid of cerebral amyloid 
deposition (Holmes et al., 2008). Furthermore, DS fetal tissues and cultured primary 
fibroblasts do not show an overexpression of APP, arguing against a gene dosaging effect 
for APP (Argellati et al., 2006; Cheon et al., 2003; Engidawork et al., 2001; Farrer et al., 
1997). On the other hand, duplication of the APP locus on Chromosome 21(Sleegers et 
al., 2006), along with just 5-12 adjacent genes in the centomeric Down syndrome critical 
region (Fuentes et al., 1995; Rahmani et al., 1989), has been reported in families with 
autosomal-dominant early-onset AD, which coincided with cerebral amyloid angiopathy 
(CAA) (Rovelet-Lecrux et al., 2006).  Thus, these seemingly-conflicting observations 
actually suggest that there may be other factors contained within the genes of the extra 
Chromosome 21 that also predispose DS individuals to AD, especially since some DS 
individuals develop onset of AD dementia by as early as their thirties. Besides APP, there 
are about 323 other genes expressed on Chromosome 21 (Antonarakis, Lyle, 
Dermitzakis, Reymond, & Deutsch, 2004),and some such as S100B, Dual-specificity 
tryrosine (Y)-phosphorylation Regulated Kinase 1A (DYRK1A) and Down’s Syndrome 
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Candidate Region-1(DSCR1, also known as RCAN1), have been described to contribute 
to pathology consistent with AD. 
S100B is an astrocyte-secreted cytokine, which stimulates phosphoinositide 
hydrolysis by phospholipase C in order to mobilize intracellular calcium stores (Barger & 
Van Eldik, 1992; Griffin et al., 1989). These actions are neurotrophic to neurons, 
promoting neurite outgrowth, and to glia, promoting proliferation and differentiation 
(Selinfreund, Barger, Welsh, & Van Eldik, 1990). However, lifelong overexpression of 
S100B in DS individuals may actually cause a decrease in any trophic actions. For 
instance, transgenic mice that overexpress human S100B have increased hippocampal 
dendrites when they are young, but this dendritic density decreases throughout the age of 
the mice, and young S100B mice also show behavioral and learning defects that may also 
be analogous to DS developmental abnormalities (Whitaker-Azmitia et al., 1997). S100B 
has been reported to have levels much more than 1.5 times as expected in DS brains than 
for normal brains, throughout the entire life of the DS individual (Griffin et al., 1998). 
These levels correlate with chronic overexpression of Interleukin-1 (IL-1) (Griffin et al., 
1989), and S100B regulates the expression of IL-1 in neurons by transcription factor, 
Sp1, and in microglia and astrocytes by transcription factor, NFκB (nuclear factor kappa-
light-chain-enhancer of activated B cells) (L. Liu, Li, Van Eldik, Griffin, & Barger, 
2005). IL-1 has been shown to induce Aβ production (Forloni, Demicheli, Giorgi, 
Bendotti, & Angeretti, 1992; Goldgaber et al., 1989),  and in turn, S100B and Aβ induce 
IL-1 (Barger & Harmon, 1997; L. Liu et al., 2005), forming a feed-forward mechanism 
that can contribute to AD pathogenesis, through Tau-related and other 
neuroinflammatory actions. 
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The kinase DYRK1A has also been shown to directly affect AD pathogenesis. For 
instance, DYRK1A has been shown to interact with and directly phosphorylate tau and 
APP in immortalized H19-7 hippocampal progenitor cells (J. Park, Yang, Yoon, & 
Chung, 2007).  It is known that DYRK1A mRNA levels in the hippocampus are 
significantly elevated in patients with AD. In the brain of AD Tg mice, DYRK1A mRNA 
levels were found to be upregulated along with an increase in Aβ deposition.  In 
neuroblastoma cells overexpressing tau, it was shown that Aβ induces an increase in the 
DYRK1A transcript, which also leads to tau phosphorylation at Thr212 (R. Kimura et al., 
2007). Another study has shown that Tg mice that over-express human DYRK1A protein 
have elevated phospho-Tau at serine-202 and serine-204, which are two 
hyperphosphorylated Tau residues that are indicated in the formation of neurofibrillary 
tangles (NFTs) (Ryoo et al., 2007). This group also demonstrated in mammalian cells that 
APP is phosphorylated at Thr668 by DYRK1A , and that phospho-APP, Aβ, and 
DYRK1A are elevated in the transgenic mice and in DS brains (Ryoo et al., 2008). Taken 
together, DYRK1A over-expression induces a feed-forward mechanism with increased 
Aβ deposition, which then induces additional DYRK1A expression, resulting in more Aβ 
deposition and phosphorylation of both APP and Tau at sites consistent with AD 
pathogenesis.  
However, DYRK1A’s involvement with Aβ and Tau may be only a portion of its 
role in AD pathogenesis. In a recent publication by Baek et. al., DYRK1A and DSCR1, 
another gene mapped to Chromosome 21, were both shown to significantly inhibit 
angiogenesis and provide compelling reason for why DS individuals do not develop solid 
tumors (Hasle, Clemmensen, & Mikkelsen, 2000), since all solid tumors require 
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neovascularization to grow larger than 2mm, invade tissues, and metastasize (Folkman, 
1992). Both DSCR1 and DYRK1A suppress the VEGF-calcineurin angiogenic pathway. 
This pathway is activated by VEGF binding to its receptor (VEGFR), which then causes 
an intracellular cascade of events in which the transcription factor, Nuclear Factor of 
Activated T-cells, cytoplasmic 2 (NFATc2), is dephosphorylated and activated and 
translocates to the nucleus to induce Cox-2 expression (Hernandez et al., 2001).  
Cox-2 expression and activity is also induced by various stimuli, including 
hypoxia (Schmedtje, Ji, Liu, DuBois, & Runge, 1997), TNFα (Jones, Carlton, McIntyre, 
Zimmerman, & Prescott, 1993), basic fibroblast growth factor (Kage et al., 1999), IL-1α 
(Karim, Habib, Levy-Toledano, & Maclouf, 1996), and LPS (Inoue, Yokoyama, Hara, 
Tone, & Tanabe, 1995). As mentioned above, Cox-2 is only expressed in reactive 
microglia by LPS, and these other stimuli would only affect neuronal Cox-2 expression, 
especially in AD-vulnerable pyramidal neurons (Hoozemans et al., 2001; Hoozemans et 
al., 2002). Prostaglandin E2 (PGE2), the major end product from Cox-2 activity, is a 
stimulator of angiogenesis (Form & Auerbach, 1983) and works by inducing the 
up-regulation of the transcription factor Hypoxia-inducible Factor-1α (HIF-1α) (X. H. 
Liu et al., 2002), which can then bind to promoter/enhancer elements of VEGF and other 
hypoxia-sensitive genes (G. L. Wang, Jiang, Rue, & Semenza, 1995).  
 In the study of Baek et al., the authors report that just one extra allelic copy of 
DSCR1 and DYRK1A are sufficient to prevent tumor growth and that this tumor 
inhibition is directly related to DSCR1 and DYRK1A suppression of angiogenesis 
through the VEGF-calicineurin pathway (Baek et al., 2009). One mechanism by which 
DSCR1 could inhibit angiogenesis may be by binding to Raf-1 (Cho, Abe, Kim, & Sato, 
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2005), putatively causing disruption of the retinoblastoma (Rb)-Raf-1interaction, and 
preventing Raf-1 from phosphorylating and inactivating Rb, which when Rb is 
inactivated, is involved in cell proliferation and VEGF-mediated angiogenesis (Dasgupta 
et al., 2004).  While the supernumerary expression of DYRK1A and DSCR1 may prevent 
tumorigenesis, the resultant reduction in cerebral blood flow throughout life may also 
predispose DS individuals to the deficient neurodevelopment observed in all DS 
individuals. DS individuals have smaller brains than normal and also have less density of 
neurons. Their neurons have ramified dendritic trees, but the number and complexity of 
them does not progress through age, causing the neurons to be described from 
histochemistry as having “a tree in winter” type of appearance (Takashima, Becker, 
Armstrong, & Chan, 1981; Takashima, Iida, Mito, & Arima, 1994).  
The vascular and nervous systems are intricately associated throughout 
neurodevelopment, with the same classical axonal-guidance proteins, such as netrins, 
ephrins,  semaphorins, and slits, also being used as the cues to direct the cerebral blood 
vessel growth down predestined tracks (Carmeliet, 2003; Carmeliet & Tessier-Lavigne, 
2005; Weinstein, 2005; Zacchigna, Lambrechts, & Carmeliet, 2008). Both nerves and 
blood vessels grow together to their ultimate destination, and VEGF regulates neuronal 
patterning of some types of neurons (Schwarz et al., 2004). One could thus hypothesize 
that the reduced cerebral blood flow from birth may contribute to the developmental 
cognitive deficits seen in DS individuals, as well as contributing to the later onset of 
severe AD pathogenesis, by both anti-angiogenic and amyloidogenic mechanisms. In 
support of this hypothesis, an epidemiological study in 1987 of 14 DS individuals, 46 AD 
patients, and 114 age-matched controls showed that DS patients have a similar reduction 
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in cerebral blood flow throughout their brains as do AD patients (Melamed, Mildworf, 
Sharav, Belenky, & Wertman, 1987).  It is similarly noteworthy that people with the 
ApoE4 genotype, who are at very high risk for developing AD, have widespread decline 
in regional cerebral blood flow over time and before they develop onset of dementia 
(Thambisetty, Beason-Held, An, Kraut, & Resnick, 2010).  Furthermore, it is plausible 
that the anti-angiogenic effects from Cox-2 inhibition (Hyde & Missailidis, 2009; Raut et 
al., 2004; L. Wang, Chen, Xie, He, & Bai, 2008) may indeed be an underlying factor for 
many of the failures of the NSAID clinical trials against AD, as reversal of AD would not 
only require removal of cerebral amyloidosis, but also would subsequently require 
neovascularization to correct the truncated and occluded microvasculature where the 
plaques were located (Meyer et al., 2008).  
Besides the greater than 1.5 times overexpression from gene loading of the APP, 
S100B, DYRK1A, and DSCR1 genes described above, there are other factors within 
trisomy 21 cells that may also contribute to AD pathogenesis, such as the involvement of 
kinesins and dyneins, which play roles in the chromosomal duplication and mis-
segregation during mitosis and meiosis, as well as in axonal transport in mature neurons. 
It has been hypothesized that in normal individuals, defective mitosis, likely due to 
microtubule (MT) dysfunction, may generate the accumulation of trisomy 21 cells in 
their bodies throughout life, and within the brain it could contribute to the development 
of AD, just as trisomy 21 invariably predisposes DS individuals to AD (Potter, 1991).  
Many studies have confirmed that trisomy 21 mosaicism may indeed contribute to AD 
pathogenesis, as trisomy 21 and other aneuploid cells have been found in primary skin 
fibroblast cultures of both familial (genetically predispositioned to develop AD early in 
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life) AD patients and sporadic (occurring later in life) AD patients (Geller & Potter, 
1999), as well as trisomy 21 being found in peripheral leukocytes, buccal cells, and brain 
neurons of sporadic AD patients (Iourov, Vorsanova, Liehr, & Yurov, 2009; Migliore et 
al., 1999; Mosch et al., 2007; Thomas & Fenech, 2008; Yang, Geldmacher, & Herrup, 
2001).  Mothers, who have a DS child before the age of 35, have a five times greater risk 
of developing dementia, with trisomy 21 mosaicism being found in their lymphocytes, 
than that of control mothers (Migliore et al., 2006; Schupf, Kapell, Lee, Ottman, & 
Mayeux, 1994).  Sporadic AD patients, who develop AD in mid-life, have been found to 
have between 1-10% trisomy 21 mosaicism, suggesting that even minimal amounts of 
aneuploidic mechanisms are sufficient to induce their early AD onset (Puri, Zhang, & 
Singh, 1994; Ringman, Rao, Lu, & Cederbaum, 2008; Rowe, Ridler, & Gibberd, 1989).  
It can also be predicted under this chromosome mis-segregation/MT hypothesis 
for AD that the same genes that are responsible for familial AD onset when mutated 
might also participate in the cell cycle, mitotic machinery, and contribute to trisomy 21 
mosaicism. Indeed it has been shown that polymorphisms in PS-1 cause an increased risk 
of both AD onset and propensity to have DS children (Higuchi, Muramatsu, Matsushita, 
Arai, & Sasaki, 1996; Lucarelli et al., 2004; Petersen et al., 2000; Wragg, Hutton, & 
Talbot, 1996). It has also been shown that endogenous PS-1, APP, their proteolytic 
products, and their interacting proteins are intricately involved in the mitotic process and 
cell cycle, being localized at the nuclear envelope, centrosomes, or kinetochores and also 
being involved in microtubular transport (Honda et al., 2000; Johnsingh et al., 2000; N. 
Kimura et al., 2001; J. Li, Xu, Zhou, Ma, & Potter, 1997; Nizzari et al., 2007; Tezapsidis, 
Merz, Merz, & Hong, 2003; Zimmermann et al., 1988; Zitnik, Wang, Martin, & Hu, 
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2007). Aberrant incomplete neuronal re-entry of the cell cycle has been implicated in the 
neurodegeneration of AD pathogenesis (Ogawa et al., 2003; Varvel et al., 2008; Vincent, 
Rosado, & Davies, 1996), as evidenced by about 3% tetraploid neurons and about 30% 
aneuploid cells (between 2n and 4n) in late-stage AD patients (Mosch et al., 2007; Yang 
et al., 2001). It is also known that APP and Tau are hyperphosphorylated during mitosis  
and contribute to paired helical filaments, the precursors of  NFTs (Pope et al., 1994; 
Preuss, Doring, Illenberger, & Mandelkow, 1995; Suzuki et al., 1994).  
As mentioned above, trisomic overexpression of S100B induces chronic IL-1 
expression (Griffin et al., 1989), which in turn induces the expression of 
alpha-1-antichymotrypsin (ACT), an acute phase serine protease inhibitor, which 
promotes polymerization of Aβ (Abraham, Shirahama, & Potter, 1990; Das & Potter, 
1995), Tau hyperphosphorylation, and neuronal apoptosis (Padmanabhan et al., 2006). A 
recent study examining transgenic (Tg) mice with FAD mutant forms of APP or PS-1 
showed that aneuploidy is significantly induced in both the spleen and in the brain of the 
mice compared to wild-type age-matched controls, and that these findings are confirmed 
in transfected mammalian cells. Moreover, the authors showed that administration of 
either of the prevalent Aβ species (1-40 and 1-42), and only to normal cells containing 
APP and Tau, induce rapid chromosome mis-segregation and aneuploidy, highlighting a 
mechanism by which Aβ disrupts MT function and induces more aneuploidy.  Thus DS 
individuals, who are predisposed to accumulation of cerebral Aβ deposition as they age, 
will have more aneuploidy and MT defects, which will affect neurogenesis and neuronal 
function, and which will also contribute in a feed-forward mechanism for additional 
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amyloidosis, aneugenesis, and progressive dementia (Granic, Padmanabhan, Norden, & 
Potter, 2010).   
Conclusions and Research Theory. The above-described feed-forward 
mechanisms of Aβ to propagate itself through DYRK1A’s up-regulation and vice versa, 
for Aβ to disrupt MT function and result in more aneuploidic and trisomic 21 cells, for 
these effects to reduce cerebral blood flow and prevent neovascularization through 
DSCR1 and DYRK1A, and for the resultant up-regulated and self-propagating S100B-
IL-1-ACT-Aβ neuroinflammatory Aβ polymerization pathway, which all work in 
combination to deposit extracellular amyloid plaque, to induce intraneuronal tauopathy, 
and to cause cerebral microvascular occlusions and dystrophic neurites surrounding the 
amyloid plaques, portrays the insidious but progressive nature of Alzheimer’s disease. 
Thus in theory, to inhibit and reverse AD pathology, there must first be simultaneous 
strategies to remove the cerebral amyloidosis and to provide neuroprotection to the 
micro-penumbras that surround the plaques and occluded vessels. Then after removal of 
amyloid, there must be strategies to immediately induce neovascularization in the 
infarcted areas where the plaques were located and to also induce neuritogenesis and/or 
neurogenesis to rebuild the neural and vascular networks in order to restore cognitive 
function. The following chapters report on the investigation of a biological therapeutic, 
whose human analogue has been safely used for two decades in leukopenic patients, and 
which has actions that attack all of these defects just described in the preceding theory. 
The next chapter will first outline the rationale, investigative plan, and working 
hypotheses, and the following chapters continue with the results and conclusions of the 
experiments. These experiments shed light on the inverse relationship between 
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Rheumatoid arthritis and Alzheimer’s disease, and putatively indicates a therapeutic for 
AD which quickly removes amyloid deposition in aged transgenic AD mice by two 
different routes of administration, which quickly reverses cognitive impairment following 
daily peripheral subcutaneous administration, while also increasing synaptic area and 
microglial density, and which has been reported to be neuroprotective in the penumbras 
of ischemic infarcts, to induce cerebral neovascularization  after ischemic infarct, and to 
stimulate the proliferation and differentiation of neural stem cells, which are known to 
migrate to sites of cerebral injury.  
 Figure 1. Extensive Cerebrovascular Damage in AD. Artistic rendition of scanning 
electron microscopy results (Meyer et al., 2008) in which specialized polurethane resin 
was perfused into aged APP23 mice, and in which the resultant corrosion casting reveals 
microvessel distortions, occlusions, and truncations in  the cerebrovasulature that 
surrounds the area which contained an amyloid plaque, that was chemically removed 
during the VCC processing of the tissue. 
 
  
30 
31 
References 
Abraham, C. R. (2001). Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's 
disease. Neurobiol Aging, 22(6), 931-936. 
Abraham, C. R., Selkoe, D. J., & Potter, H. (1988). Immunochemical identification of the 
serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits 
of Alzheimer's disease. Cell, 52(4), 487-501. 
Abraham, C. R., Shirahama, T., & Potter, H. (1990). Alpha 1-antichymotrypsin is 
associated solely with amyloid deposits containing the beta-protein. Amyloid and 
cell localization of alpha 1-antichymotrypsin. Neurobiol Aging, 11(2), 123-129. 
Ahmed, R. R., Holler, C. J., Webb, R. L., Li, F., Beckett, T. L., & Murphy, M. P. (2010). 
BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem, 
112(4), 1045-1053. 
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., et al. 
(2003). Effects of rofecoxib or naproxen vs placebo on Alzheimer disease 
progression: a randomized controlled trial. Jama, 289(21), 2819-2826. 
Aisen, P. S., Schmeidler, J., & Pasinetti, G. M. (2002). Randomized pilot study of 
nimesulide treatment in Alzheimer's disease. Neurology, 58(7), 1050-1054. 
Alzheimer's_Association. (2010). 2010 Alzheimer's Disease Facts and Figures.   
Retrieved 6-15-2010, from 
http://www.alz.org/documents_custom/report_alzfactsfigures2010.pdf 
Andersen, K., Launer, L. J., Ott, A., Hoes, A. W., Breteler, M. M., & Hofman, A. (1995). 
Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's 
disease? The Rotterdam Study. Neurology, 45(8), 1441-1445. 
Antonarakis, S. E., Lyle, R., Dermitzakis, E. T., Reymond, A., & Deutsch, S. (2004). 
Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat 
Rev Genet, 5(10), 725-738. 
Argellati, F., Massone, S., d'Abramo, C., Marinari, U. M., Pronzato, M. A., Domenicotti, 
C., et al. (2006). Evidence against the overexpression of APP in Down syndrome. 
IUBMB Life, 58(2), 103-106. 
Arima, K., Murayama, S., Oyanagi, S., Akashi, T., & Inose, T. (1992). Presenile 
dementia with progressive supranuclear palsy tangles and Pick bodies: an unusual 
degenerative disorder involving the cerebral cortex, cerebral nuclei, and brain 
stem nuclei. Acta Neuropathol, 84(2), 128-134. 
Baek, K. H., Zaslavsky, A., Lynch, R. C., Britt, C., Okada, Y., Siarey, R. J., et al. (2009). 
Down's syndrome suppression of tumour growth and the role of the calcineurin 
inhibitor DSCR1. Nature, 459(7250), 1126-1130. 
Baker, M., Kwok, J. B., Kucera, S., Crook, R., Farrer, M., Houlden, H., et al. (1997). 
Localization of frontotemporal dementia with parkinsonism in an Australian 
kindred to chromosome 17q21-22. Ann Neurol, 42(5), 794-798. 
Bales, K. R., Verina, T., Cummins, D. J., Du, Y., Dodel, R. C., Saura, J., et al. (1999). 
Apolipoprotein E is essential for amyloid deposition in the APP(V717F) 
transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A, 
96(26), 15233-15238. 
32 
Barger, S. W., & Harmon, A. D. (1997). Microglial activation by Alzheimer amyloid 
precursor protein and modulation by apolipoprotein E. Nature, 388(6645), 878-
881. 
Barger, S. W., & Van Eldik, L. J. (1992). S100 beta stimulates calcium fluxes in glial and 
neuronal cells. J Biol Chem, 267(14), 9689-9694. 
Basi, G., Frigon, N., Barbour, R., Doan, T., Gordon, G., McConlogue, L., et al. (2003). 
Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 
and 2 on beta-amyloid peptide production in cells. J Biol Chem, 278(34), 31512-
31520. 
Beard, C. M., Kokman, E., & Kurland, L. T. (1991). Rheumatoid arthritis and 
susceptibility to Alzheimer's disease. Lancet, 337(8754), 1426. 
Beckmann, N., Schuler, A., Mueggler, T., Meyer, E. P., Wiederhold, K. H., Staufenbiel, 
M., et al. (2003). Age-dependent cerebrovascular abnormalities and blood flow 
disturbances in APP23 mice modeling Alzheimer's disease. J Neurosci, 23(24), 
8453-8459. 
Buee, L., Hof, P. R., Bouras, C., Delacourte, A., Perl, D. P., Morrison, J. H., et al. (1994). 
Pathological alterations of the cerebral microvasculature in Alzheimer's disease 
and related dementing disorders. Acta Neuropathol, 87(5), 469-480. 
Butterfield, D. A., Abdul, H. M., Opii, W., Newman, S. F., Joshi, G., Ansari, M. A., et al. 
(2006). Pin1 in Alzheimer's disease. J Neurochem, 98(6), 1697-1706. 
Carmeliet, P. (2003). Blood vessels and nerves: common signals, pathways and diseases. 
Nat Rev Genet, 4(9), 710-720. 
Carmeliet, P., & Tessier-Lavigne, M. (2005). Common mechanisms of nerve and blood 
vessel wiring. Nature, 436(7048), 193-200. 
Chartier-Harlin, M. C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., et 
al. (1991). Early-onset Alzheimer's disease caused by mutations at codon 717 of 
the beta-amyloid precursor protein gene. Nature, 353(6347), 844-846. 
Cheon, M. S., Kim, S. H., Yaspo, M. L., Blasi, F., Aoki, Y., Melen, K., et al. (2003). 
Protein levels of genes encoded on chromosome 21 in fetal Down syndrome 
brain: challenging the gene dosage effect hypothesis (Part I). Amino Acids, 24(1-
2), 111-117. 
Cho, Y. J., Abe, M., Kim, S. Y., & Sato, Y. (2005). Raf-1 is a binding partner of DSCR1. 
Arch Biochem Biophys, 439(1), 121-128. 
Chui, D. H., Tabira, T., Izumi, S., Koya, G., & Ogata, J. (1994). Decreased beta-amyloid 
and increased abnormal Tau deposition in the brain of aged patients with leprosy. 
Am J Pathol, 145(4), 771-775. 
Chung, S. H. (2009). Aberrant phosphorylation in the pathogenesis of Alzheimer's 
disease. BMB Rep, 42(8), 467-474. 
Claudio, L. (1996). Ultrastructural features of the blood-brain barrier in biopsy tissue 
from Alzheimer's disease patients. Acta Neuropathol, 91(1), 6-14. 
Das, S., & Potter, H. (1995). Expression of the Alzheimer amyloid-promoting factor 
antichymotrypsin is induced in human astrocytes by IL-1. Neuron, 14(2), 447-
456. 
Dasgupta, P., Sun, J., Wang, S., Fusaro, G., Betts, V., Padmanabhan, J., et al. (2004). 
Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis. 
Mol Cell Biol, 24(21), 9527-9541. 
33 
Dastur, D. K., & Razzak, Z. A. (1971). Degeneration and regeneration in teased nerve 
fibres. I. Leprous neuritis. Acta Neuropathol, 18(4), 286-298. 
Davis, D. G., Schmitt, F. A., Wekstein, D. R., & Markesbery, W. R. (1999). Alzheimer 
neuropathologic alterations in aged cognitively normal subjects. J Neuropathol 
Exp Neurol, 58(4), 376-388. 
De Jong, G. I., Farkas, E., Stienstra, C. M., Plass, J. R., Keijser, J. N., de la Torre, J. C., et 
al. (1999). Cerebral hypoperfusion yields capillary damage in the hippocampal 
CA1 area that correlates with spatial memory impairment. Neuroscience, 91(1), 
203-210. 
de la Torre, J. C. (2004). Alzheimer's disease is a vasocognopathy: a new term to describe 
its nature. Neurol Res, 26(5), 517-524. 
de la Torre, J. C. (2009). Cerebrovascular and cardiovascular pathology in Alzheimer's 
disease. Int Rev Neurobiol, 84, 35-48. 
de la Torre, J. C. (2010). Vascular risk factor detection and control may prevent 
Alzheimer's disease. Ageing Res Rev. 
de la Torre, J. C., & Stefano, G. B. (2000). Evidence that Alzheimer's disease is a 
microvascular disorder: the role of constitutive nitric oxide. Brain Res Brain Res 
Rev, 34(3), 119-136. 
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., 
et al. (1998). Deficiency of presenilin-1 inhibits the normal cleavage of amyloid 
precursor protein. Nature, 391(6665), 387-390. 
Delisle, M. B., Murrell, J. R., Richardson, R., Trofatter, J. A., Rascol, O., Soulages, X., et 
al. (1999). A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a 
tauopathy with dementia and supranuclear palsy. Acta Neuropathol, 98(1), 62-77. 
Dewji, N. N., & Singer, S. J. (1996). Specific transcellular binding between membrane 
proteins crucial to Alzheimer disease. Proc Natl Acad Sci U S A, 93(22), 12575-
12580. 
Donnini, S., Solito, R., Cetti, E., Corti, F., Giachetti, A., Carra, S., et al. (2010). A{beta} 
peptides accelerate the senescence of endothelial cells in vitro and in vivo, 
impairing angiogenesis. Faseb J. 
Duskin, A., & Eisenberg, R. A. The role of antibodies in inflammatory arthritis. Immunol 
Rev, 233(1), 112-125. 
Endoh, M., Kunishita, T., & Tabira, T. (1999). No effect of anti-leprosy drugs in the 
prevention of Alzheimer's disease and beta-amyloid neurotoxicity. J Neurol Sci, 
165(1), 28-30. 
Engidawork, E., Baiic, N., Fountoulakis, M., Dierssen, M., Greber-Platzer, S., & Lubec, 
G. (2001). Beta-amyloid precursor protein, ETS-2 and collagen alpha 1 (VI) chain 
precursor, encoded on chromosome 21, are not overexpressed in fetal Down 
syndrome: further evidence against gene dosage effect. J Neural Transm 
Suppl(61), 335-346. 
Epstein, C. J. (1990). The consequences of chromosome imbalance. Am J Med Genet 
Suppl, 7, 31-37. 
Farkas, E., De Jong, G. I., Apro, E., De Vos, R. A., Steur, E. N., & Luiten, P. G. (2000). 
Similar ultrastructural breakdown of cerebrocortical capillaries in Alzheimer's 
disease, Parkinson's disease, and experimental hypertension. What is the 
functional link? Ann N Y Acad Sci, 903, 72-82. 
34 
Farkas, E., De Vos, R. A., Jansen Steur, E. N., & Luiten, P. G. (2000). Are Alzheimer's 
disease, hypertension, and cerebrocapillary damage related? Neurobiol Aging, 
21(2), 235-243. 
Farrer, M. J., Crayton, L., Davies, G. E., Oliver, C., Powell, J., Holland, A. J., et al. 
(1997). Allelic variability in D21S11, but not in APP or APOE, is associated with 
cognitive decline in Down syndrome. Neuroreport, 8(7), 1645-1649. 
Farzan, M., Schnitzler, C. E., Vasilieva, N., Leung, D., & Choe, H. (2000). BACE2, a 
beta -secretase homolog, cleaves at the beta site and within the amyloid-beta 
region of the amyloid-beta precursor protein. Proc Natl Acad Sci U S A, 97(17), 
9712-9717. 
Fidani, L., Rooke, K., Chartier-Harlin, M. C., Hughes, D., Tanzi, R., Mullan, M., et al. 
(1992). Screening for mutations in the open reading frame and promoter of the 
beta-amyloid precursor protein gene in familial Alzheimer's disease: identification 
of a further family with APP717 Val-->Ile. Hum Mol Genet, 1(3), 165-168. 
Folkman, J. (1992). The role of angiogenesis in tumor growth. Semin Cancer Biol, 3(2), 
65-71. 
Forloni, G., Demicheli, F., Giorgi, S., Bendotti, C., & Angeretti, N. (1992). Expression of 
amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: 
modulation by interleukin-1. Brain Res Mol Brain Res, 16(1-2), 128-134. 
Form, D. M., & Auerbach, R. (1983). PGE2 and angiogenesis. Proc Soc Exp Biol Med, 
172(2), 214-218. 
Fuentes, J. J., Pritchard, M. A., Planas, A. M., Bosch, A., Ferrer, I., & Estivill, X. (1995). 
A new human gene from the Down syndrome critical region encodes a proline-
rich protein highly expressed in fetal brain and heart. Hum Mol Genet, 4(10), 
1935-1944. 
Furuzawa-Carballeda, J., Vargas-Rojas, M. I., & Cabral, A. R. (2007). Autoimmune 
inflammation from the Th17 perspective. Autoimmun Rev, 6(3), 169-175. 
Galloway, P. G. (1988). Antigenic characteristics of neurofibrillary tangles in progressive 
supranuclear palsy. Neurosci Lett, 91(2), 148-153. 
Geller, L. N., & Potter, H. (1999). Chromosome missegregation and trisomy 21 
mosaicism in Alzheimer's disease. Neurobiol Dis, 6(3), 167-179. 
Glenner, G. G., & Wong, C. W. (1984). Alzheimer's disease and Down's syndrome: 
sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res 
Commun, 122(3), 1131-1135. 
Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., et al. 
(1991). Segregation of a missense mutation in the amyloid precursor protein gene 
with familial Alzheimer's disease. Nature, 349(6311), 704-706. 
Gold, G., Bouras, C., Kovari, E., Canuto, A., Glaria, B. G., Malky, A., et al. (2000). 
Clinical validity of Braak neuropathological staging in the oldest-old. Acta 
Neuropathol, 99(5), 579-582; discussion 583-574. 
Goldgaber, D., Harris, H. W., Hla, T., Maciag, T., Donnelly, R. J., Jacobsen, J. S., et al. 
(1989). Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA 
in human endothelial cells. Proc Natl Acad Sci U S A, 86(19), 7606-7610. 
Goldgaber, D., Lerman, M. I., McBride, W. O., Saffiotti, U., & Gajdusek, D. C. (1987). 
Isolation, characterization, and chromosomal localization of human brain cDNA 
35 
clones coding for the precursor of the amyloid of brain in Alzheimer's disease, 
Down's syndrome and aging. J Neural Transm Suppl, 24, 23-28. 
Goto, M., Kimura, T., Hagio, S., Ueda, K., Kitajima, S., Tokunaga, H., et al. (1995). 
Neuropathological analysis of dementia in a Japanese leprosarium. Dementia, 
6(3), 157-161. 
Graeber, M. B., Kosel, S., Egensperger, R., Banati, R. B., Muller, U., Bise, K., et al. 
(1997). Rediscovery of the case described by Alois Alzheimer in 1911: historical, 
histological and molecular genetic analysis. Neurogenetics, 1(1), 73-80. 
Graeber, M. B., Kosel, S., Grasbon-Frodl, E., Moller, H. J., & Mehraein, P. (1998). 
Histopathology and APOE genotype of the first Alzheimer disease patient, 
Auguste D. Neurogenetics, 1(3), 223-228. 
Granic, A., Padmanabhan, J., Norden, M., & Potter, H. (2010). Alzheimer Abeta peptide 
induces chromosome mis-segregation and aneuploidy, including trisomy 21: 
requirement for tau and APP. Mol Biol Cell, 21(4), 511-520. 
Griffin, W. S., Sheng, J. G., McKenzie, J. E., Royston, M. C., Gentleman, S. M., 
Brumback, R. A., et al. (1998). Life-long overexpression of S100beta in Down's 
syndrome: implications for Alzheimer pathogenesis. Neurobiol Aging, 19(5), 401-
405. 
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V., Perrot, L. J., et al. 
(1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down 
syndrome and Alzheimer disease. Proc Natl Acad Sci U S A, 86(19), 7611-7615. 
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. 
M. (1986). Microtubule-associated protein tau. A component of Alzheimer paired 
helical filaments. J Biol Chem, 261(13), 6084-6089. 
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. 
I. (1986). Abnormal phosphorylation of the microtubule-associated protein tau 
(tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A, 83(13), 
4913-4917. 
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. 
M., et al. (2005). Interleukin 17-producing CD4+ effector T cells develop via a 
lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 6(11), 
1123-1132. 
Hasegawa, H., Nishi, S., Ito, S., Saeki, T., Kuroda, T., Kimura, H., et al. (1996). High 
prevalence of serum apolipoprotein E4 isoprotein in rheumatoid arthritis patients 
with amyloidosis. Arthritis Rheum, 39(10), 1728-1732. 
Hasle, H., Clemmensen, I. H., & Mikkelsen, M. (2000). Risks of leukaemia and solid 
tumours in individuals with Down's syndrome. Lancet, 355(9199), 165-169. 
Hauw, J. J., Verny, M., Delaere, P., Cervera, P., He, Y., & Duyckaerts, C. (1990). 
Constant neurofibrillary changes in the neocortex in progressive supranuclear 
palsy. Basic differences with Alzheimer's disease and aging. Neurosci Lett, 
119(2), 182-186. 
Heinzer, S., Krucker, T., Stampanoni, M., Abela, R., Meyer, E. P., Schuler, A., et al. 
(2006). Hierarchical microimaging for multiscale analysis of large vascular 
networks. Neuroimage, 32(2), 626-636. 
Heinzer, S., Kuhn, G., Krucker, T., Meyer, E., Ulmann-Schuler, A., Stampanoni, M., et 
al. (2008). Novel three-dimensional analysis tool for vascular trees indicates 
36 
complete micro-networks, not single capillaries, as the angiogenic endpoint in 
mice overexpressing human VEGF(165) in the brain. Neuroimage, 39(4), 1549-
1558. 
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, 
C., et al. (2005). Acute treatment with the PPARgamma agonist pioglitazone and 
ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I 
transgenic mice. Brain, 128(Pt 6), 1442-1453. 
Hernandez, G. L., Volpert, O. V., Iniguez, M. A., Lorenzo, E., Martinez-Martinez, S., 
Grau, R., et al. (2001). Selective inhibition of vascular endothelial growth factor-
mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T 
cells and cyclooxygenase 2. J Exp Med, 193(5), 607-620. 
Higuchi, S., Muramatsu, T., Matsushita, S., Arai, H., & Sasaki, H. (1996). Presenilin-1 
polymorphism and Alzheimer's disease. Lancet, 347(9009), 1186. 
Ho, A., & Sudhof, T. C. (2004). Binding of F-spondin to amyloid-beta precursor protein: 
a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta 
precursor protein cleavage. Proc Natl Acad Sci U S A, 101(8), 2548-2553. 
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., et al. 
(2008). Long-term effects of Abeta42 immunisation in Alzheimer's disease: 
follow-up of a randomised, placebo-controlled phase I trial. Lancet, 372(9634), 
216-223. 
Honda, T., Nihonmatsu, N., Yasutake, K., Ohtake, A., Sato, K., Tanaka, S., et al. (2000). 
Familial Alzheimer's disease-associated mutations block translocation of full-
length presenilin 1 to the nuclear envelope. Neurosci Res, 37(2), 101-111. 
Hoozemans, J. J., Rozemuller, A. J., Janssen, I., De Groot, C. J., Veerhuis, R., & 
Eikelenboom, P. (2001). Cyclooxygenase expression in microglia and neurons in 
Alzheimer's disease and control brain. Acta Neuropathol, 101(1), 2-8. 
Hoozemans, J. J., Veerhuis, R., Janssen, I., van Elk, E. J., Rozemuller, A. J., & 
Eikelenboom, P. (2002). The role of cyclo-oxygenase 1 and 2 activity in 
prostaglandin E(2) secretion by cultured human adult microglia: implications for 
Alzheimer's disease. Brain Res, 951(2), 218-226. 
Hopper, M. W., & Vogel, F. S. (1976). The limbic system in Alzheimer's disease. A 
neuropathologic investigation. Am J Pathol, 85(1), 1-20. 
Hussain, I., Powell, D., Howlett, D. R., Tew, D. G., Meek, T. D., Chapman, C., et al. 
(1999). Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol 
Cell Neurosci, 14(6), 419-427. 
Hussain, I., Powell, D. J., Howlett, D. R., Chapman, G. A., Gilmour, L., Murdock, P. R., 
et al. (2000). ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-
secretase site. Mol Cell Neurosci, 16(5), 609-619. 
Hyde, C. A., & Missailidis, S. (2009). Inhibition of arachidonic acid metabolism and its 
implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol, 
9(6), 701-715. 
Inoue, H., Yokoyama, C., Hara, S., Tone, Y., & Tanabe, T. (1995). Transcriptional 
regulation of human prostaglandin-endoperoxide synthase-2 gene by 
lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of 
both nuclear factor for interleukin-6 expression site and cAMP response element. 
J Biol Chem, 270(42), 24965-24971. 
37 
Iourov, I. Y., Vorsanova, S. G., Liehr, T., & Yurov, Y. B. (2009). Aneuploidy in the 
normal, Alzheimer's disease and ataxia-telangiectasia brain: differential 
expression and pathological meaning. Neurobiol Dis, 34(2), 212-220. 
Jacobs, J. M., Shetty, V. P., & Antia, N. H. (1987). Myelin changes in leprous 
neuropathy. Acta Neuropathol, 74(1), 75-80. 
Jantzen, P. T., Connor, K. E., DiCarlo, G., Wenk, G. L., Wallace, J. L., Rojiani, A. M., et 
al. (2002). Microglial activation and beta -amyloid deposit reduction caused by a 
nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor 
protein plus presenilin-1 transgenic mice. J Neurosci, 22(6), 2246-2254. 
Jenkinson, M. L., Bliss, M. R., Brain, A. T., & Scott, D. L. (1989). Rheumatoid arthritis 
and senile dementia of the Alzheimer's type. Br J Rheumatol, 28(1), 86-88. 
Job, C. K. (1971). Pathology of peripheral nerve lesions in lepromatous leprosy--a light 
and electron microscopic study. Int J Lepr Other Mycobact Dis, 39(2), 251-268. 
Johnsingh, A. A., Johnston, J. M., Merz, G., Xu, J., Kotula, L., Jacobsen, J. S., et al. 
(2000). Altered binding of mutated presenilin with cytoskeleton-interacting 
proteins. FEBS Lett, 465(1), 53-58. 
Jones, D. A., Carlton, D. P., McIntyre, T. M., Zimmerman, G. A., & Prescott, S. M. 
(1993). Molecular cloning of human prostaglandin endoperoxide synthase type II 
and demonstration of expression in response to cytokines. J Biol Chem, 268(12), 
9049-9054. 
Kage, K., Fujita, N., Oh-hara, T., Ogata, E., Fujita, T., & Tsuruo, T. (1999). Basic 
fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells 
derived from bone. Biochem Biophys Res Commun, 254(1), 259-263. 
Kalaria, R. N., & Hedera, P. (1995). Differential degeneration of the cerebral 
microvasculature in Alzheimer's disease. Neuroreport, 6(3), 477-480. 
Kalsheker, N. A. (1996). Alpha 1-antichymotrypsin. Int J Biochem Cell Biol, 28(9), 961-
964. 
Karim, S., Habib, A., Levy-Toledano, S., & Maclouf, J. (1996). Cyclooxygenase-1 and -2 
of endothelial cells utilize exogenous or endogenous arachidonic acid for 
transcellular production of thromboxane. J Biol Chem, 271(20), 12042-12048. 
Karsenty, G. (1999). The genetic transformation of bone biology. Genes Dev, 13(23), 
3037-3051. 
Kaufmann, W. E., Andreasson, K. I., Isakson, P. C., & Worley, P. F. (1997). 
Cyclooxygenases and the central nervous system. Prostaglandins, 54(3), 601-624. 
Kertesz, A., Kawarai, T., Rogaeva, E., St George-Hyslop, P., Poorkaj, P., Bird, T. D., et 
al. (2000). Familial frontotemporal dementia with ubiquitin-positive, tau-negative 
inclusions. Neurology, 54(4), 818-827. 
Kimura, N., Nakamura, S. I., Honda, T., Takashima, A., Nakayama, H., Ono, F., et al. 
(2001). Age-related changes in the localization of presenilin-1 in cynomolgus 
monkey brain. Brain Res, 922(1), 30-41. 
Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., et al. (2007). 
The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, 
bridges between beta-amyloid production and tau phosphorylation in Alzheimer 
disease. Hum Mol Genet, 16(1), 15-23. 
38 
Krucker, T., Lang, A., & Meyer, E. P. (2006). New polyurethane-based material for 
vascular corrosion casting with improved physical and imaging characteristics. 
Microsc Res Tech, 69(2), 138-147. 
Ksiezak-Reding, H., Morgan, K., Mattiace, L. A., Davies, P., Liu, W. K., Yen, S. H., et 
al. (1994). Ultrastructure and biochemical composition of paired helical filaments 
in corticobasal degeneration. Am J Pathol, 145(6), 1496-1508. 
Kukar, T., Murphy, M. P., Eriksen, J. L., Sagi, S. A., Weggen, S., Smith, T. E., et al. 
(2005). Diverse compounds mimic Alzheimer disease-causing mutations by 
augmenting Abeta42 production. Nat Med, 11(5), 545-550. 
Lee, K. J., Moussa, C. E., Lee, Y., Sung, Y., Howell, B. W., Turner, R. S., et al. (2010). 
Beta amyloid-independent role of amyloid precursor protein in generation and 
maintenance of dendritic spines. Neuroscience. 
Lee, V. M., Balin, B. J., Otvos, L., Jr., & Trojanowski, J. Q. (1991). A68: a major subunit 
of paired helical filaments and derivatized forms of normal Tau. Science, 
251(4994), 675-678. 
Lejeune, J., Gautier, M., & Turpin, R. (1959). [Study of somatic chromosomes from 9 
mongoloid children.]. C R Hebd Seances Acad Sci, 248(11), 1721-1722. 
Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, 
D. J. (1996). Sequence of deposition of heterogeneous amyloid beta-peptides and 
APO E in Down syndrome: implications for initial events in amyloid plaque 
formation. Neurobiol Dis, 3(1), 16-32. 
Li, G., Yin, H., & Kuret, J. (2004). Casein kinase 1 delta phosphorylates tau and disrupts 
its binding to microtubules. J Biol Chem, 279(16), 15938-15945. 
Li, J., Xu, M., Zhou, H., Ma, J., & Potter, H. (1997). Alzheimer presenilins in the nuclear 
membrane, interphase kinetochores, and centrosomes suggest a role in 
chromosome segregation. Cell, 90(5), 917-927. 
Li, Y. M., Xu, M., Lai, M. T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., et al. (2000). 
Photoactivated gamma-secretase inhibitors directed to the active site covalently 
label presenilin 1. Nature, 405(6787), 689-694. 
Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W., Teter, B., et al. (2000). Ibuprofen 
suppresses plaque pathology and inflammation in a mouse model for Alzheimer's 
disease. J Neurosci, 20(15), 5709-5714. 
Liu, F., Liang, Z., Shi, J., Yin, D., El-Akkad, E., Grundke-Iqbal, I., et al. (2006). PKA 
modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and 
kinase-specific manners. FEBS Lett, 580(26), 6269-6274. 
Liu, L., Li, Y., Van Eldik, L. J., Griffin, W. S., & Barger, S. W. (2005). S100B-induced 
microglial and neuronal IL-1 expression is mediated by cell type-specific 
transcription factors. J Neurochem, 92(3), 546-553. 
Liu, X. H., Kirschenbaum, A., Lu, M., Yao, S., Dosoretz, A., Holland, J. F., et al. (2002). 
Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and 
nuclear localization in a human prostate cancer cell line. J Biol Chem, 277(51), 
50081-50086. 
Lorenzo, A., Yuan, M., Zhang, Z., Paganetti, P. A., Sturchler-Pierrat, C., Staufenbiel, M., 
et al. (2000). Amyloid beta interacts with the amyloid precursor protein: a 
potential toxic mechanism in Alzheimer's disease. Nat Neurosci, 3(5), 460-464. 
39 
Lucarelli, P., Piciullo, A., Palmarino, M., Verdecchia, M., Saccucci, P., Arpino, C., et al. 
(2004). Association between presenilin-1 -48C/T polymorphism and Down's 
syndrome. Neurosci Lett, 367(1), 88-91. 
Lucca, U., Tettamanti, M., Forloni, G., & Spagnoli, A. (1994). Nonsteroidal 
antiinflammatory drug use in Alzheimer's disease. Biol Psychiatry, 36(12), 854-
856. 
Ma, J., Brewer, H. B., Jr., & Potter, H. (1996). Alzheimer A beta neurotoxicity: 
promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. 
Neurobiol Aging, 17(5), 773-780. 
Ma, J., Yee, A., Brewer, H. B., Jr., Das, S., & Potter, H. (1994). Amyloid-associated 
proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of 
Alzheimer beta-protein into filaments. Nature, 372(6501), 92-94. 
Mancardi, G. L., Perdelli, F., Rivano, C., Leonardi, A., & Bugiani, O. (1980). Thickening 
of the basement membrane of cortical capillaries in Alzheimer's disease. Acta 
Neuropathol, 49(1), 79-83. 
Matsumoto, T., & Tsurumoto, T. (2002). Inappropriate serum levels of IGF-I and IGFBP-
3 in patients with rheumatoid arthritis. Rheumatology (Oxford), 41(3), 352-353. 
Maury, C. P., Liljestrom, M., Tiitinen, S., Laiho, K., Kaarela, K., & Ehnholm, C. (2001). 
Apolipoprotein E phenotypes in rheumatoid arthritis with or without amyloidosis. 
Amyloid, 8(4), 270-273. 
Mcgeer, P. L., Harada N., Kimura H., McGeer E.G., Schulzer M. (1992). Prevalence of 
dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug 
therapy. Dementia, 3, 146-1149. 
McGeer, P. L., Klegeris, A., Walker, D. G., Yasuhara, O., & McGeer, E. G. (1994). 
Pathological proteins in senile plaques. Tohoku J Exp Med, 174(3), 269-277. 
McGeer, P. L., McGeer, E., Rogers, J., & Sibley, J. (1990). Anti-inflammatory drugs and 
Alzheimer disease. Lancet, 335(8696), 1037. 
McGeer, P. L., Rogers, J., & McGeer, E. G. (2006). Inflammation, anti-inflammatory 
agents and Alzheimer disease: the last 12 years. J Alzheimers Dis, 9(3 Suppl), 
271-276. 
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996). Arthritis and anti-inflammatory 
agents as possible protective factors for Alzheimer's disease: a review of 17 
epidemiologic studies. Neurology, 47(2), 425-432. 
Meinert, C. L., McCaffrey, L. D., & Breitner, J. C. (2009). Alzheimer's Disease Anti-
inflammatory Prevention Trial: design, methods, and baseline results. Alzheimers 
Dement, 5(2), 93-104. 
Melamed, E., Mildworf, B., Sharav, T., Belenky, L., & Wertman, E. (1987). Regional 
cerebral blood flow in Down's syndrome. Ann Neurol, 22(2), 275-278. 
Meyer, E. P., Beer, G. M., Lang, A., Manestar, M., Krucker, T., Meier, S., et al. (2007). 
Polyurethane elastomer: a new material for the visualization of cadaveric blood 
vessels. Clin Anat, 20(4), 448-454. 
Meyer, E. P., Ulmann-Schuler, A., Staufenbiel, M., & Krucker, T. (2008). Altered 
morphology and 3D architecture of brain vasculature in a mouse model for 
Alzheimer's disease. Proc Natl Acad Sci U S A, 105(9), 3587-3592. 
40 
Migliore, L., Boni, G., Bernardini, R., Trippi, F., Colognato, R., Fontana, I., et al. (2006). 
Susceptibility to chromosome malsegregation in lymphocytes of women who had 
a Down syndrome child in young age. Neurobiol Aging, 27(5), 710-716. 
Migliore, L., Botto, N., Scarpato, R., Petrozzi, L., Cipriani, G., & Bonuccelli, U. (1999). 
Preferential occurrence of chromosome 21 malsegregation in peripheral blood 
lymphocytes of Alzheimer disease patients. Cytogenet Cell Genet, 87(1-2), 41-46. 
Mori, H., Nishimura, M., Namba, Y., & Oda, M. (1994). Corticobasal degeneration: a 
disease with widespread appearance of abnormal tau and neurofibrillary tangles, 
and its relation to progressive supranuclear palsy. Acta Neuropathol, 88(2), 113-
121. 
Mosch, B., Morawski, M., Mittag, A., Lenz, D., Tarnok, A., & Arendt, T. (2007). 
Aneuploidy and DNA replication in the normal human brain and Alzheimer's 
disease. J Neurosci, 27(26), 6859-6867. 
Mrak, R. E., & Griffin, W. S. (2004). Trisomy 21 and the brain. J Neuropathol Exp 
Neurol, 63(7), 679-685. 
Murakami, M., Iwai, S., Hiratsuka, S., Yamauchi, M., Nakamura, K., Iwakura, Y., et al. 
(2006). Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase 
promotes rheumatoid arthritis through activation of monocytes/macrophages. 
Blood, 108(6), 1849-1856. 
Myllykangas-Luosujarvi, R., & Isomaki, H. (1994). Alzheimer's disease and rheumatoid 
arthritis. Br J Rheumatol, 33(5), 501-502. 
Nalbandian, A., Crispin, J. C., & Tsokos, G. C. (2009). Interleukin-17 and systemic lupus 
erythematosus: current concepts. Clin Exp Immunol, 157(2), 209-215. 
Naruse, S., Igarashi, S., Kobayashi, H., Aoki, K., Inuzuka, T., Kaneko, K., et al. (1991). 
Mis-sense mutation Val----Ile in exon 17 of amyloid precursor protein gene in 
Japanese familial Alzheimer's disease. Lancet, 337(8747), 978-979. 
Nasreddine, Z. S., Loginov, M., Clark, L. N., Lamarche, J., Miller, B. L., Lamontagne, 
A., et al. (1999). From genotype to phenotype: a clinical pathological, and 
biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-
17) caused by the P301L tau mutation. Ann Neurol, 45(6), 704-715. 
Nilsson, L. N., Bales, K. R., DiCarlo, G., Gordon, M. N., Morgan, D., Paul, S. M., et al. 
(2001). Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition 
in a transgenic mouse model of Alzheimer's disease. J Neurosci, 21(5), 1444-
1451. 
Nizzari, M., Venezia, V., Repetto, E., Caorsi, V., Magrassi, R., Gagliani, M. C., et al. 
(2007). Amyloid precursor protein and Presenilin1 interact with the adaptor 
GRB2 and modulate ERK 1,2 signaling. J Biol Chem, 282(18), 13833-13844. 
O'Banion, M. K., Sadowski, H. B., Winn, V., & Young, D. A. (1991). A serum- and 
glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related 
protein. J Biol Chem, 266(34), 23261-23267. 
Ogawa, O., Zhu, X., Lee, H. G., Raina, A., Obrenovich, M. E., Bowser, R., et al. (2003). 
Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a 
mitotic catastrophe? Acta Neuropathol, 105(5), 524-528. 
Olson, M. I., & Shaw, C. M. (1969). Presenile dementia and Alzheimer's disease in 
mongolism. Brain, 92(1), 147-156. 
41 
Padmanabhan, J., Levy, M., Dickson, D. W., & Potter, H. (2006). Alpha1-
antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease 
brain, induces tau phosphorylation in neurons. Brain, 129(Pt 11), 3020-3034. 
Paris, D., Patel, N., Ganey, N. J., Laporte, V., Quadros, A., & Mullan, M. J. (2010). Anti-
Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer's Abeta 
Peptide. Int J Pept Res Ther, 16(1), 23-30. 
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y. H., et al. (2005). A 
distinct lineage of CD4 T cells regulates tissue inflammation by producing 
interleukin 17. Nat Immunol, 6(11), 1133-1141. 
Park, J., Yang, E. J., Yoon, J. H., & Chung, K. C. (2007). Dyrk1A overexpression in 
immortalized hippocampal cells produces the neuropathological features of Down 
syndrome. Mol Cell Neurosci, 36(2), 270-279. 
Patel, N. S., Mathura, V. S., Bachmeier, C., Beaulieu-Abdelahad, D., Laporte, V., Weeks, 
O., et al. (2010). Alzheimer's beta-amyloid peptide blocks vascular endothelial 
growth factor mediated signaling via direct interaction with VEGFR-2. J 
Neurochem, 112(1), 66-76. 
Pei, J. J., Braak, H., An, W. L., Winblad, B., Cowburn, R. F., Iqbal, K., et al. (2002). Up-
regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is 
associated with the progression of neurofibrillary degeneration in Alzheimer's 
disease. Brain Res Mol Brain Res, 109(1-2), 45-55. 
Perlmutter, L. S., Myers, M. A., & Barron, E. (1994). Vascular basement membrane 
components and the lesions of Alzheimer's disease: light and electron microscopic 
analyses. Microsc Res Tech, 28(3), 204-215. 
Petersen, M. B., Karadima, G., Samaritaki, M., Avramopoulos, D., Vassilopoulos, D., & 
Mikkelsen, M. (2000). Association between presenilin-1 polymorphism and 
maternal meiosis II errors in Down syndrome. Am J Med Genet, 93(5), 366-372. 
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., et al. 
(1998). Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann 
Neurol, 43(6), 815-825. 
Pope, W. B., Lambert, M. P., Leypold, B., Seupaul, R., Sletten, L., Krafft, G., et al. 
(1994). Microtubule-associated protein tau is hyperphosphorylated during mitosis 
in the human neuroblastoma cell line SH-SY5Y. Exp Neurol, 126(2), 185-194. 
Potter, H. (1991). Review and hypothesis: Alzheimer disease and Down syndrome--
chromosome 21 nondisjunction may underlie both disorders. Am J Hum Genet, 
48(6), 1192-1200. 
Potter, H., Wefes, I. M., & Nilsson, L. N. (2001). The inflammation-induced pathological 
chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid 
formation. Neurobiol Aging, 22(6), 923-930. 
Prasher, V. P., Farrer, M. J., Kessling, A. M., Fisher, E. M., West, R. J., Barber, P. C., et 
al. (1998). Molecular mapping of Alzheimer-type dementia in Down's syndrome. 
Ann Neurol, 43(3), 380-383. 
Preuss, U., Doring, F., Illenberger, S., & Mandelkow, E. M. (1995). Cell cycle-dependent 
phosphorylation and microtubule binding of tau protein stably transfected into 
Chinese hamster ovary cells. Mol Biol Cell, 6(10), 1397-1410. 
Puri, B. K., Zhang, Z., & Singh, I. (1994). SPECT in adult mosaic Down's syndrome with 
early dementia. Clin Nucl Med, 19(11), 989-991. 
42 
Rahmani, Z., Blouin, J. L., Creau-Goldberg, N., Watkins, P. C., Mattei, J. F., Poissonnier, 
M., et al. (1989). Critical role of the D21S55 region on chromosome 21 in the 
pathogenesis of Down syndrome. Proc Natl Acad Sci U S A, 86(15), 5958-5962. 
Raut, C. P., Nawrocki, S., Lashinger, L. M., Davis, D. W., Khanbolooki, S., Xiong, H., et 
al. (2004). Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis 
in human pancreatic tumor xenografts. Cancer Biol Ther, 3(12), 1217-1224. 
Reines, S. A., Block, G. A., Morris, J. C., Liu, G., Nessly, M. L., Lines, C. R., et al. 
(2004). Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, 
blinded, controlled study. Neurology, 62(1), 66-71. 
Rich, J. B., Rasmusson, D. X., Folstein, M. F., Carson, K. A., Kawas, C., & Brandt, J. 
(1995). Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology, 
45(1), 51-55. 
Riley, K. P., Snowdon, D. A., & Markesbery, W. R. (2002). Alzheimer's neurofibrillary 
pathology and the spectrum of cognitive function: findings from the Nun Study. 
Ann Neurol, 51(5), 567-577. 
Ringman, J. M., Rao, P. N., Lu, P. H., & Cederbaum, S. (2008). Mosaicism for trisomy 
21 in a patient with young-onset dementia: a case report and brief literature 
review. Arch Neurol, 65(3), 412-415. 
Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. 
W., et al. (1993). Clinical trial of indomethacin in Alzheimer's disease. 
Neurology, 43(8), 1609-1611. 
Rovelet-Lecrux, A., Hannequin, D., Raux, G., Le Meur, N., Laquerriere, A., Vital, A., et 
al. (2006). APP locus duplication causes autosomal dominant early-onset 
Alzheimer disease with cerebral amyloid angiopathy. Nat Genet, 38(1), 24-26. 
Rowe, I. F., Ridler, M. A., & Gibberd, F. B. (1989). Presenile dementia associated with 
mosaic trisomy 21 in a patient with a Down syndrome child. Lancet, 2(8656), 
229. 
Rumble, B., Retallack, R., Hilbich, C., Simms, G., Multhaup, G., Martins, R., et al. 
(1989). Amyloid A4 protein and its precursor in Down's syndrome and 
Alzheimer's disease. N Engl J Med, 320(22), 1446-1452. 
Ryoo, S. R., Cho, H. J., Lee, H. W., Jeong, H. K., Radnaabazar, C., Kim, Y. S., et al. 
(2008). Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-
mediated phosphorylation of amyloid precursor protein: evidence for a functional 
link between Down syndrome and Alzheimer's disease. J Neurochem, 104(5), 
1333-1344. 
Ryoo, S. R., Jeong, H. K., Radnaabazar, C., Yoo, J. J., Cho, H. J., Lee, H. W., et al. 
(2007). DYRK1A-mediated hyperphosphorylation of Tau. A functional link 
between Down syndrome and Alzheimer disease. J Biol Chem, 282(48), 34850-
34857. 
Sarkar, S., Tesmer, L. A., Hindnavis, V., Endres, J. L., & Fox, D. A. (2007). Interleukin-
17 as a molecular target in immune-mediated arthritis: immunoregulatory 
properties of genetically modified murine dendritic cells that secrete interleukin-4. 
Arthritis Rheum, 56(1), 89-100. 
Save, M. P., Shetty, V. P., Shetty, K. T., & Antia, N. H. (2004). Alterations in 
neurofilament protein(s) in human leprous nerves: morphology, 
43 
immunohistochemistry and Western immunoblot correlative study. Neuropathol 
Appl Neurobiol, 30(6), 635-650. 
Scharf, S., Mander, A., Ugoni, A., Vajda, F., & Christophidis, N. (1999). A double-blind, 
placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. 
Neurology, 53(1), 197-201. 
Scheibel, A. B. (1987). Alterations of the cerebral capillary bed in the senile dementia of 
Alzheimer. Ital J Neurol Sci, 8(5), 457-463. 
Scheibel, A. B., Duong, T. H., & Tomiyasu, U. (1987). Denervation microangiopathy in 
senile dementia, Alzheimer type. Alzheimer Dis Assoc Disord, 1(1), 19-37. 
Schmedtje, J. F., Jr., Ji, Y. S., Liu, W. L., DuBois, R. N., & Runge, M. S. (1997). 
Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in 
human vascular endothelial cells. J Biol Chem, 272(1), 601-608. 
Schneider, A., & Mandelkow, E. (2008). Tau-based treatment strategies in 
neurodegenerative diseases. Neurotherapeutics, 5(3), 443-457. 
Schupf, N., Kapell, D., Lee, J. H., Ottman, R., & Mayeux, R. (1994). Increased risk of 
Alzheimer's disease in mothers of adults with Down's syndrome. Lancet, 
344(8919), 353-356. 
Schwarz, Q., Gu, C., Fujisawa, H., Sabelko, K., Gertsenstein, M., Nagy, A., et al. (2004). 
Vascular endothelial growth factor controls neuronal migration and cooperates 
with Sema3A to pattern distinct compartments of the facial nerve. Genes Dev, 
18(22), 2822-2834. 
Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, J., Perkins, W., et al. (1994). 
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 
in inflammation and pain. Proc Natl Acad Sci U S A, 91(25), 12013-12017. 
Selinfreund, R. H., Barger, S. W., Welsh, M. J., & Van Eldik, L. J. (1990). Antisense 
inhibition of glial S100 beta production results in alterations in cell morphology, 
cytoskeletal organization, and cell proliferation. J Cell Biol, 111(5 Pt 1), 2021-
2028. 
Shah, S., Lee, S. F., Tabuchi, K., Hao, Y. H., Yu, C., LaPlant, Q., et al. (2005). Nicastrin 
functions as a gamma-secretase-substrate receptor. Cell, 122(3), 435-447. 
Singh, T. J., Grundke-Iqbal, I., & Iqbal, K. (1995). Phosphorylation of tau protein by 
casein kinase-1 converts it to an abnormal Alzheimer-like state. J Neurochem, 
64(3), 1420-1423. 
Singh, T. J., Grundke-Iqbal, I., McDonald, B., & Iqbal, K. (1994). Comparison of the 
phosphorylation of microtubule-associated protein tau by non-proline dependent 
protein kinases. Mol Cell Biochem, 131(2), 181-189. 
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., et al. 
(1999). Purification and cloning of amyloid precursor protein beta-secretase from 
human brain. Nature, 402(6761), 537-540. 
Sisodia, S. S., & Price, D. L. (1995). Role of the beta-amyloid protein in Alzheimer's 
disease. Faseb J, 9(5), 366-370. 
Sleegers, K., Brouwers, N., Gijselinck, I., Theuns, J., Goossens, D., Wauters, J., et al. 
(2006). APP duplication is sufficient to cause early onset Alzheimer's dementia 
with cerebral amyloid angiopathy. Brain, 129(Pt 11), 2977-2983. 
44 
Slomnicki, L. P., & Lesniak, W. (2008). A putative role of the Amyloid Precursor Protein 
Intracellular Domain (AICD) in transcription. Acta Neurobiol Exp (Wars), 68(2), 
219-228. 
Spillantini, M. G., Yoshida, H., Rizzini, C., Lantos, P. L., Khan, N., Rossor, M. N., et al. 
(2000). A novel tau mutation (N296N) in familial dementia with swollen 
achromatic neurons and corticobasal inclusion bodies. Ann Neurol, 48(6), 939-
943. 
St George-Hyslop, P. H., Haines, J. L., Farrer, L. A., Polinsky, R., Van Broeckhoven, C., 
Goate, A., et al. (1990). Genetic linkage studies suggest that Alzheimer's disease 
is not a single homogeneous disorder. FAD Collaborative Study Group. Nature, 
347(6289), 194-197. 
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., 
Pericak-Vance, M., et al. (1993). Binding of human apolipoprotein E to synthetic 
amyloid beta peptide: isoform-specific effects and implications for late-onset 
Alzheimer disease. Proc Natl Acad Sci U S A, 90(17), 8098-8102. 
Strobel, G. (2009, 21 July 2009). Vienna: New Genes, Anyone? ICAD Saves Best for 
Last.   Retrieved 7-1-2010, from 
http://www.alzforum.org/new/detail.asp?id=2197#breitner 
Sun, X., Wang, Y., Qing, H., Christensen, M. A., Liu, Y., Zhou, W., et al. (2005). 
Distinct transcriptional regulation and function of the human BACE2 and BACE1 
genes. Faseb J, 19(7), 739-749. 
Suzuki, T., Oishi, M., Marshak, D. R., Czernik, A. J., Nairn, A. C., & Greengard, P. 
(1994). Cell cycle-dependent regulation of the phosphorylation and metabolism of 
the Alzheimer amyloid precursor protein. Embo J, 13(5), 1114-1122. 
Swift, T. R. (1974). Peripheral nerve involvement in leprosy: quantitative histologic 
aspects. Acta Neuropathol, 29(1), 1-8. 
Takashima, S., Becker, L. E., Armstrong, D. L., & Chan, F. (1981). Abnormal neuronal 
development in the visual cortex of the human fetus and infant with down's 
syndrome. A quantitative and qualitative Golgi study. Brain Res, 225(1), 1-21. 
Takashima, S., Iida, K., Mito, T., & Arima, M. (1994). Dendritic and histochemical 
development and ageing in patients with Down's syndrome. J Intellect Disabil 
Res, 38 ( Pt 3), 265-273. 
Tanaka, S., Nakamura, S., Ueda, K., Kameyama, M., Shiojiri, S., Takahashi, Y., et al. 
(1988). Three types of amyloid protein precursor mRNA in human brain: their 
differential expression in Alzheimer's disease. Biochem Biophys Res Commun, 
157(2), 472-479. 
Tanaka, S., Shiojiri, S., Takahashi, Y., Kitaguchi, N., Ito, H., Kameyama, M., et al. 
(1989). Tissue-specific expression of three types of beta-protein precursor 
mRNA: enhancement of protease inhibitor-harboring types in Alzheimer's disease 
brain. Biochem Biophys Res Commun, 165(3), 1406-1414. 
Tanzi, R. E., George-Hyslop, P. S., & Gusella, J. F. (1991). Molecular genetics of 
Alzheimer disease amyloid. J Biol Chem, 266(31), 20579-20582. 
Tezapsidis, N., Merz, P. A., Merz, G., & Hong, H. (2003). Microtubular interactions of 
presenilin direct kinesis of Abeta peptide and its precursors. Faseb J, 17(10), 
1322-1324. 
45 
Thakker, P., Leach, M. W., Kuang, W., Benoit, S. E., Leonard, J. P., & Marusic, S. 
(2007). IL-23 is critical in the induction but not in the effector phase of 
experimental autoimmune encephalomyelitis. J Immunol, 178(4), 2589-2598. 
Thambisetty, M., Beason-Held, L., An, Y., Kraut, M. A., & Resnick, S. M. (2010). 
APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in 
normal aging. Arch Neurol, 67(1), 93-98. 
Thomas, P., & Fenech, M. (2008). Chromosome 17 and 21 aneuploidy in buccal cells is 
increased with ageing and in Alzheimer's disease. Mutagenesis, 23(1), 57-65. 
Trojanowski, J. Q., Mawal-Dewan, M., Schmidt, M. L., Martin, J., & Lee, V. M. (1993). 
Localization of the mitogen activated protein kinase ERK2 in Alzheimer's disease 
neurofibrillary tangles and senile plaque neurites. Brain Res, 618(2), 333-337. 
Varvel, N. H., Bhaskar, K., Patil, A. R., Pimplikar, S. W., Herrup, K., & Lamb, B. T. 
(2008). Abeta oligomers induce neuronal cell cycle events in Alzheimer's disease. 
J Neurosci, 28(43), 10786-10793. 
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., et al. 
(1999). Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the 
transmembrane aspartic protease BACE. Science, 286(5440), 735-741. 
Vincent, I., Rosado, M., & Davies, P. (1996). Mitotic mechanisms in Alzheimer's 
disease? J Cell Biol, 132(3), 413-425. 
Vlad, S. C., Miller, D. R., Kowall, N. W., & Felson, D. T. (2008). Protective effects of 
NSAIDs on the development of Alzheimer disease. Neurology, 70(19), 1672-
1677. 
Waaler, E. (1940). On the occurrence of a factor in human serum activating the specific 
agglutination of sheep red corpuscles. Acta Pathologica et Microbiologica 
Scandinavica 17, 172-188. 
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995). Hypoxia-inducible 
factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 
tension. Proc Natl Acad Sci U S A, 92(12), 5510-5514. 
Wang, L., Chen, W., Xie, X., He, Y., & Bai, X. (2008). Celecoxib inhibits tumor growth 
and angiogenesis in an orthotopic implantation tumor model of human colon 
cancer. Exp Oncol, 30(1), 42-51. 
Wang, P., Yang, G., Mosier, D. R., Chang, P., Zaidi, T., Gong, Y. D., et al. (2005). 
Defective neuromuscular synapses in mice lacking amyloid precursor protein 
(APP) and APP-Like protein 2. J Neurosci, 25(5), 1219-1225. 
Weiger, T., Lametschwandtner, A., & Stockmayer, P. (1986). Technical parameters of 
plastics (Mercox CL-2B and various methylmethacrylates) used in scanning 
electron microscopy of vascular corrosion casts. Scan Electron Microsc(Pt 1), 
243-252. 
Weinstein, B. M. (2005). Vessels and nerves: marching to the same tune. Cell, 120(3), 
299-302. 
Whitaker-Azmitia, P. M., Wingate, M., Borella, A., Gerlai, R., Roder, J., & Azmitia, E. 
C. (1997). Transgenic mice overexpressing the neurotrophic factor S-100 beta 
show neuronal cytoskeletal and behavioral signs of altered aging processes: 
implications for Alzheimer's disease and Down's syndrome. Brain Res, 776(1-2), 
51-60. 
46 
Wisniewski, T., & Frangione, B. (1992). Apolipoprotein E: a pathological chaperone 
protein in patients with cerebral and systemic amyloid. Neurosci Lett, 135(2), 
235-238. 
Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., & Selkoe, D. J. 
(1999). Two transmembrane aspartates in presenilin-1 required for presenilin 
endoproteolysis and gamma-secretase activity. Nature, 398(6727), 513-517. 
Woodard, J. S. (1966). Alzheimer's disease in late adult life. Am J Pathol, 49(6), 1157-
1169. 
Wragg, M., Hutton, M., & Talbot, C. (1996). Genetic association between intronic 
polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. 
Alzheimer's Disease Collaborative Group. Lancet, 347(9000), 509-512. 
Wynn, T. A. (2005). T(H)-17: a giant step from T(H)1 and T(H)2. Nat Immunol, 6(11), 
1069-1070. 
Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., et al. (2003). Anti-
inflammatory drug therapy alters beta-amyloid processing and deposition in an 
animal model of Alzheimer's disease. J Neurosci, 23(20), 7504-7509. 
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., et al. 
(1999). Membrane-anchored aspartyl protease with Alzheimer's disease beta-
secretase activity. Nature, 402(6761), 533-537. 
Yan, R., Munzner, J. B., Shuck, M. E., & Bienkowski, M. J. (2001). BACE2 functions as 
an alternative alpha-secretase in cells. J Biol Chem, 276(36), 34019-34027. 
Yang, Y., Geldmacher, D. S., & Herrup, K. (2001). DNA replication precedes neuronal 
cell death in Alzheimer's disease. J Neurosci, 21(8), 2661-2668. 
Yasojima, K., Schwab, C., McGeer, E. G., & McGeer, P. L. (1999). Distribution of 
cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain 
and peripheral organs. Brain Res, 830(2), 226-236. 
Yermakova, A. V., Rollins, J., Callahan, L. M., Rogers, J., & O'Banion, M. K. (1999). 
Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of 
expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp 
Neurol, 58(11), 1135-1146. 
Zacchigna, S., Lambrechts, D., & Carmeliet, P. (2008). Neurovascular signalling defects 
in neurodegeneration. Nat Rev Neurosci, 9(3), 169-181. 
Zarow, C., Barron, E., Chui, H. C., & Perlmutter, L. S. (1997). Vascular basement 
membrane pathology and Alzheimer's disease. Ann N Y Acad Sci, 826, 147-160. 
Zhao, G., Liu, Z., Ilagan, M. X., & Kopan, R. (2010). Gamma-secretase composed of 
PS1/Pen2/Aph1a can cleave notch and amyloid precursor protein in the absence 
of nicastrin. J Neurosci, 30(5), 1648-1656. 
Zimmermann, K., Herget, T., Salbaum, J. M., Schubert, W., Hilbich, C., Cramer, M., et 
al. (1988). Localization of the putative precursor of Alzheimer's disease-specific 
amyloid at nuclear envelopes of adult human muscle. Embo J, 7(2), 367-372. 
Zitnik, G., Wang, L., Martin, G. M., & Hu, Q. (2007). Localizations of endogenous 
APP/APP-proteolytic products are consistent with microtubular transport. J Mol 
Neurosci, 31(1), 59-68. 
 
 
47 
 
 
CHAPTER 2 – RESEARCH RATIONALE 
Introduction 
 In the period leading up to 2006, our interest in the role of inflammation in AD 
led us to think that perhaps RA protected against AD not because of the use of NSAIDs 
but because of some intrinsic anti-inflammatory or possibly inflammatory factor released 
during RA. This interest came to a head as a consequence of NSAID clinical trial failures 
in AD patients and we began to look again at the inverse relationship of RA and AD. If 
indeed, the NSAIDs are not responsible for preventing AD, a neurodegenerative disorder, 
then there must be some intrinsic characteristic(s) of RA pathogenesis itself, a peripheral 
disorder, that has the capability to traverse the body and reach the brain, where it would 
exert its protective effects. Since RA is a highly-inflammatory autoimmune disease, both 
aspects of the immune system, innate and adaptive,  could potentially be acting against 
AD, including not only the various cells of the immune system, but also through their 
secreted products. This chapter will examine these cellular characteristics of RA that may 
impact AD pathogenesis and outline the research plan to investigate RA as a negative risk 
factor of AD from a non-NSAID perspective. 
Secreted Factors in RA and AD 
 Many of the factors (Chapter 1) that are up-regulated in RA pathogenesis have 
also been reported to have circumstantial relationships in AD pathogenesis.  For instance, 
Macrophage Migration Inhibitory Factor (MIF) has been found to have the ability to act 
as an Aβ-binding protein  (Flex et al., 2004; Lashuel et al., 2005),  and is absolutely 
necessary for the progression of RA, as MIF-deficient mice do not develop experimental 
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arthritis and anti-MIF neutralizing antibodies ameliorate RA in mouse models (Onodera 
et al., 2007; Popa et al., 2006). MIF has also recently been shown to be up-regulated in 
the brains of transgenic AD mice, and in the cerebrospinal fluid of MCI and AD patients, 
and it is proposed to contribute to the neuroinflammation of AD, since MIF is a known 
cytokine that elicits production of other inflammatory mediators, such as TNFα, IL-6, and 
IFNγ (Bacher et al., 2010; Bryan et al., 2008; Popp et al., 2009). In fact, in vitro studies 
show that murine and human neuronal cell lines are protected from Aβ-induced cellular 
toxicity by Iso-1, a small molecule inhibitor of MIF (Bacher et al., 2010).  On the other 
hand, MIF’s functions have not all been elucidated, as a recent paper reports that MIF is 
actually expressed by astrocytes in the CNS and is involved in hippocampal cell 
proliferation. In this study, it was found that MIF is expressed in the subgranular zone of 
the dentate gyrus within neurogenic stem cells, cells undergoing proliferation, and in 
newly proliferated cells, but not in mature neurons, microglia, or oligodendrocytes. MIF 
antagonism by Iso-1 and in MIF knockout mice resulted in behavioral dysfunction and 
impaired hippocampus-dependent memory (Conboy et al., 2010). 
Monocyte Chemoattractant Protein-1, (MCP-1, also known as CCL2: chemokine 
C-C motif ligand 2), IL-6, and IL-8 have also been reported to be up-regulated in both 
RA and AD (Ishizuka et al., 1997; Sokolova et al., 2009), but contrasting studies have 
reported that while MCP-1 is elevated in MCI patients, its expression is lost as MCI 
patients progress to AD (Dawson, Miltz, Mir, & Wiessner, 2003; Galimberti et al., 2006).  
Another study reports elevated levels of osteoprotegerin (OPG) in AD and Vascular 
Dementia patients, proposes a role for OPG in microglia function and phagocytosis of Aβ 
plaques, and suggests that OPG could be a biomarker for these diseases (Emanuele et al., 
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2004).TRAF6 (TNF receptor-associated factor 6), also known as E3 ubiquitin ligase, is 
involved in the ubiquination of Tau, as shown in TRAF6-knock out mice (Babu, Geetha, 
& Wooten, 2005). TRAF6 is also activated, along with NFκB, after proteolysis of 
membrane receptors, p75NTR and neurotrophin receptor homolog NRH2 (Kanning et al., 
2003).  Like APP and Notch, p75NTR is a ligand for γ-secretase intramembrane cleavage 
after α-secretase extracellular domain cleavage. The α-secretase that is expressed in RA 
for the cleavage of RANKL and the T lymphocyte chemokine, soluble CXCL16, is 
ADAM10. ADAM10 is found abundantly expressed by RA macrophages expressing the 
chemokine, CXCL16, which is involved in effector/memory T cell function (van der 
Voort et al., 2005), and anti-TNFα therapy for RA down-regulates this CXCL16 
expression (van Lieshout et al., 2007). In the brain, ADAM10, along with PS1, works to 
cleave N-cadherin following NMDA activation, and this activity has been found to be 
inhibited in an AD mouse model (Uemura et al., 2007). Furthermore, ADAM10 over-
expression has been shown to decrease Aβ plaque formation and prevent cognitive 
deficits in another AD murine model (Fahrenholz & Postina, 2006; Postina et al., 2004). 
There are also angiogenic factors contributing to the pannus growth in RA that are 
associated with AD pathogenesis, such as Insulin-Like Growth Factor 1 (IGF-1), which is 
upregulated in RA synovial fluid, but is reduced in the AD brain, and has been associated 
with cognitive deficits (Rivera et al., 2005; Svensson et al., 2006).  IGF-1 levels are 
similarly decreased in patients with Diabetes Type II, a positive risk factor for AD onset, 
and it is reported that systemic administration of IGF-1 in diabetic rats prevents cognitive 
deficits (Lupien, Bluhm, & Ishii, 2003, 2006). VEGF’s relationship in AD pathology is 
still not completely clear and has been debated in the literature. Although it is reported to 
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bind Aβ and to be found associated with amyloid plaques, reports also suggest VEGF to 
have neuroprotective activity (Moser & Humpel, 2005; S. P. Yang, Kwon, Gho, & Chae, 
2005).  VEGF upregulation and endothelial activation are found in AD brain, even 
though cerebrovascular degeneration occurs and correlates with Aβ deposition (Miao et 
al., 2005; Schultheiss et al., 2006). A recent study investigating cardiovascular disease in 
PS2/APP mice, reported that administration of IGF-1 improved cognitive function, 
reduced VEGF levels, reduced endothelial cell proliferation, and thus normalized 
vascular density (Lopez-Lopez, Dietrich, Metzger, Loetscher, & Torres-Aleman, 2007). 
Although many of these above-mentioned inflammatory mediators participate in 
the chronic neuroinflammation that contributes to AD pathogenesis, if they are also 
up-regulated in RA pathogenesis, it would not be expected that these specific factors are 
the reason for the inverse relationship between RA and AD. On the other hand, if they are 
deficient in AD, but are up-regulated in RA, they might provide insight into RA’s 
protective effect against AD. However, they would also have to be secreted in high 
enough concentrations to be able to circulate through the vasculature, reach the brain, 
cross the Blood Brain Barrier (BBB), and initiate a set of protective events against AD 
onset. These actions would be very improbable without affecting all other organ systems 
in the process, which would have been reported in all RA patients. Since this is not the 
case, the peripheral secretion of inflammatory mediators may not be the most likely 
reason for RA and AD’s inverse relationship. Nonetheless, they cannot all be completely 
ignored in this comparison, since they are secreted by the leukocytes of RA, which do 
have the ability to traverse the circulatory system, diapedese across the BBB, and could 
secrete these factors into the brain’s parenchyma to elicit protective effects. Of all the 
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above-mentioned factors, a couple that are deficient in AD, but are upregulated in RA, 
are IGF-1 and ADAM10, and these do have the potential to provide benefit to AD 
pathogenesis if they can localize into the brain parenchyma.  However, they are 
secondary to the RA-induced leukocytes, which must secrete them into the brain, and 
thus the primary focus for elucidating RA’s negative risk factor against AD should be on 
the leukocytes themselves. 
Leukocytes in RA and AD 
 Although up-regulated leukocytes in RA could potentially enter into the brain 
and inhibit development of AD pathology and/or neuronal dysfunction, lymphocytic 
infiltrates into AD patient brains have not been reported. The lack of lymphocyte 
infiltration suggests that RA-induced proliferation and activation of the innate immune 
system might be responsible for preventing AD pathology in RA patients. Evidence 
supporting the innate immune system’s role in AD pathogenesis show that bone marrow-
derived microglia play a critical role in restricting amyloid deposition, and indeed, 
microglia activation and many associated receptors and enzymes, such as CD36, 
scavenger receptor A, receptor for advanced glycation end products, neprilysin, insulysin, 
and matrix metalloproteinases, decline with age as risk of AD pathology increases (J. El 
Khoury et al., 2007; Hickman, Allison, & El Khoury, 2008; Simard, Soulet, Gowing, 
Julien, & Rivest, 2006).  Further evidence implicating the role of the innate immune 
system in AD are that complement proteins are highly up-regulated in AD brain, and that 
inhibition of C3 convertase significantly increases amyloid pathology in AD mice (Wyss-
Coray et al., 2002). A chronic upregulation of complement proteins in AD suggests that 
innate leukocytes need to also be increased to phagocytically remove the complement-
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bound complexes, via the complement receptors that they contain on their surface.  Both 
the complement system and the ability for peripheral phagocytes to enter the brain 
represent two broad immunological areas of active research that show many implications 
in the pathogenesis of AD, and which will be discussed further in the following sections.  
Complement System and its Involvement in AD 
Overview. The complement system is a cascade of about 30 cell bound or 
circulating proteins that aid in the clearance of immune-stimulatory molecules, whether 
contained on pathogens, on endogenous cells, or secreted within the body.  As part of the 
innate immune system, the complement system is a powerful amplifier and mediator of 
inflammation, and functions to opsonize antigens for phagocytosis, to release chemotactic 
molecules for attracting phagocytes, to lyse membranes of cells via the membrane attack 
complex (MAC), to aggregate antigenic proteins, to induce naïve B lymphocyte 
activation, and to neutralize viral activity (Carroll, 2008; Jayasekera, Moseman, & 
Carroll, 2007; Roitt IM, 1998). The complement system is activated in three biochemical 
pathways, known as the classical (since it was first identified), the lectin, and the 
alternative pathways  (see Figure 2 for an overview of the complement cascade) .   
Classical Pathway. The classical complement pathway is usually activated by 
either IgM or IgG binding to an antigen, which then triggers complement component, 
C1q, to bind to the first conserved regions of these immunoglobulins. Clq can also bind 
independent of antibodies to DNA, RNA, C-reactive protein, serum amyloid P, LPS 
(from Gram - bacteria), fungal/viral membranes, and in AD, it has been shown to bind 
directly to amyloid plaques (Afagh, Cummings, Cribbs, Cotman, & Tenner, 1996; 
Eikelenboom, Hack, Rozemuller, & Stam, 1989; Jiang, Burdick, Glabe, Cotman, & 
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Tenner, 1994; Rogers et al., 1992; Tacnet-Delorme, Chevallier, & Arlaud, 2001; 
Veerhuis, Janssen, Hack, & Eikelenboom, 1996; Zanjani et al., 2005).  C1q binding 
causes a conformational change in itself, which activates two molecules of the serine 
protease, Clr, to cleave and activate  two molecules of another serine protease, Cls. This 
process results in the formation of the C1 complex (C1q-C1r2-C1s2), which then acts to 
cleave complement components C4 and C2 into C4a, C4b, C2a, and C2b. The binding of 
C4b and C2a form the C3-convertase (C4b2a) of the classical pathway.   
Although the regulatory protein for C1 complex, C1-inhibitor, is normally 
produced in the brain and is the only known inhibitor of C1r and C1s, it has been found 
in human AD brains to be cleaved and this reacted form is localized to dystrophic 
neurites and neuropil threads (Walker, Yasuhara, Patston, McGeer, & McGeer, 1995). 
C1-inhibitor has also been found to be slightly elevated only in the regions of prominent 
AD pathology, such as the entorhinal cortex, hippocampus, medialtemporal gyrus and 
medialfrontal gyrus, but this slight over-expression is unable to inhibit complement 
activation (Yasojima, McGeer, & McGeer, 1999).  Of particular interest is the finding 
that the N-terminal 1-11 region of the Aβ1-42 peptide binds to C1q and activates the 
classical complement cascade in the absence of C1-inhibitor and at a physiological ratio 
of up to 8:0 of C1-inhibitor:C1 (Tacnet-Delorme et al., 2001).  This finding might explain 
a relationship between both ACT (Ma, Brewer, & Potter, 1996; Ma, Yee, Brewer, Das, & 
Potter, 1994; Potter, Wefes, & Nilsson, 2001) and the inhibition of the complement 
cascade to exacerbate cerebral amyloid deposition (Wyss-Coray et al., 2002). 
 
54 
 
Lectin Pathway. The lectin complement pathway is similar to the classical 
pathway, except that ficolins and mannose-binding lectin (MBL) are the opsonins, which 
then activate the MBL-associated serine proteases (MASP)-1 and -2, in a manner 
analagous to the C1r and C1s, respectively. The ficolin- or MBL-MASP1,2 complex then 
splits C4 and C2, resulting in the same C3-convertase, C4b-2a.  MBL, similar in structure 
to Clq (J. Lu, Wiedemann, Timpl, & Reid, 1993)and ficolins (types L, H, or M in 
humans) are pattern-recognition molecules, with MBL binding mannose (J. H. Lu, Thiel, 
Wiedemann, Timpl, & Reid, 1990), N-acetylglucosamine (GlcNAc, a component of 
Gram + bacterial cell walls), and some forms of LPS (Neth et al., 2000), and with ficolins 
binding various N-acetylated saccharides, including GlcNAc (Matsushita, 2009). Ficolins 
have not been implicated in AD, but H-Ficolin has been shown to be highly expressed by 
human astrocytic glioma cell lines (Kuraya, Matsushita, Endo, Thiel, & Fujita, 2003). On 
the other hand, while serum levels of MBL have been found to be associated with the 
cerebrovasculature at similar levels in both AD patients and normal controls, MBL is 
reduced in the cerebrospinal fluid of AD patients as compared to controls, suggesting 
increased MBL consumption is associated with complement activation in AD patients 
(Lanzrein et al., 1998). 
Alternative Pathway.  The alternative complement pathway is activated 
independent of C4 and C2 and initiates in a process called “C3 tickover”, which is the 
spontaneous reaction between C3 and water to break C3’s internal thioester bond and 
form iC3 (C3-H2O), which induces a conformational change that allows the serum 
protein, complement Factor B, to bind and form the iC3B complex.  This iC3B complex 
allows, in the presence of Magnesium (Mg2+), for Factor D, a serine protease also known 
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as adipsin, which is released into the blood by adipocytes, to cleave Factor B into Ba and 
Bb, leaving the fluid-phase alternative complement pathway C3-convertase (iC3Bb). This 
activated iC3Bb can then cleave circulating C3 into C3a and C3b, but fluid-phase iC3Bb 
is liable for proteolytic degradation unless it comes in contact with a surface to bind, in 
which case another serum protein, Factor P (also known as properdin), will bind and 
stabilize the complex, forming iC3Bb-P, which is now a surface-bound C3-convertase 
capable of cleaving many molecules of C3 and forming a positive feedback amplification 
loop (Roitt IM, 1998).   
It was initially thought that only the classical complement pathway was involved 
in AD, and not the alternative pathway (McGeer, Akiyama, Itagaki, & McGeer, 1989).  
However, it has recently been shown that the alternative pathway components, Ba and 
Bb, as well as the regulatory protein, Factor H, are indeed increased in AD brain 
compared to controls (Strohmeyer, Ramirez, Cole, Mueller, & Rogers, 2002; Strohmeyer, 
Shen, & Rogers, 2000). Furthermore, the Chromosome 13 dementias, familial British 
dementia (FBD) and familial Danish dementia (FDD), which present with 
neuropathological similarities as AD, such as neurodegeneration, NFTs, parenchymal and 
vascular cerebral amyloidosis, and associated gliosis, have positive immunohistochemical 
staining for activated complement components of both the classical and alternative 
pathways associated with their pathology (Rostagno et al., 2002). 
C3-Convertase.  Both the surface-bound C4b2a C3-convertase from the classical 
and lectin pathways and the iC3Bb-P C3-convertase work to amplify the production of 
the opsonin C3b and release the chemotaxin C3a. In this amplification loop, newly 
cleaved C3b can covalently bind a surface and intiate the same alternative pathway with 
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Factor B binding, then C3bB getting cleaved by Factor D in the presence of Mg2+, and 
leaving a new surface-bound C3-convertase, C3bBb which continues the amplification 
loop (Roitt IM, 1998).  
As with any feed-forward mechanism, there needs to be regulatory proteins to 
inhibit uncontrolled amplification, and if left unchecked, there would be complete 
depletion of complement component C3 (which is analogous to the effects of cobra 
venom in the body (Janssen et al., 2009)). Some regulation occurs by the released soluble 
C3b being quickly hydrolyzed and inactivated by water, unless it comes into contact with 
a surface that it can covalently bind first. Also, the fluid-phase iC3bBb undergoes rapid 
dissociation, by the binding of soluble Factor H. Surface-bound C3b can be cleaved by 
Factor I, using Factor H as a cofactor, to produce surface-bound inactive C3b, which can 
then undergo additional cleavage by Factor I to split inactive C3b into C3c and C3dg. 
This last step to produce C3c and C3dg occurs with the help of Complement Receptor 1 
(CR1, also known as CD35) and with Membrane Cofactor of Proteolysis (MCP, also 
known as CD46).  Both CR1 and MCP are membrane-bound and work in the 
disassociation of the classical C3-convertase, C4b2a. Another regulator, C4-binding 
protein (C4BP), cleaves activated C4 before it can act on C2 to inhibit the formation of 
the classical C3-convertase, as well as being another cofactor for Factor I. The final 
known human regulator of C3-convertase is surface-bound Decay Accelerating Factor 
(DAF, also known as CD55) which competes with Factor B on the cell surface to inhibit 
the C3bBb complex, as well as inducing the disassociation of Bb and C2a from 
already-formed C3-convertases (Roitt IM, 1998). In mice, the widely-expressed regulator 
on most cell membranes, Complement receptor-1related gene/protein Y (Crry), functions 
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as the structural analog of both DAF and MCP, and is the main inhibitor of 
C3-convertase in mice, blocking both the classical and alternative pathways. 
C3 and AD. Many of the components and regulators in the formation of 
C3-Convertase have been implicated in the pathogenesis of AD. Amyloid plaques have 
been examined by electron immuno-microscopy and found to contain C3b, C3c, C3d, C4, 
as well as C1q on the amyloid fibrils, but not elsewhere such as normal or degenerative 
neurites, NFTs, and glial cells (Eikelenboom & Stam, 1982; Ishii & Haga, 1984). 
Furthermore, Aβ was shown to actually induce the production of C3 in primary 
microglial cultures (Haga, Ikeda, Sato, & Ishii, 1993), and as already mentioned, the 
experimental blockage of C3-convertase, by the overexpression of soluble Crry (sCrry),  
resulted in increased amyloid deposition in transgenic AD mice. Conversely, it was also 
shown that increased C3 production resulted in decreased amyloidosis (Wyss-Coray et 
al., 2002).  
The C4BP regulator has also been found localized to amyloid plaques, to directly 
bind Aβ, to bind to apoptotic and necrotic cells, but not to bind to viable astrocytes, 
neurons, or oligodendrocytes (Trouw et al., 2008). Whether C4BP has a protective or 
deleterious effect in AD is not known. Of similar association with AD is Factor D 
(Adipsin), which is upregulated when γ-Secretase is inhibited (Searfoss et al., 2003), and 
thus may play a role in FAD with PS mutations, or since it is highly expressed in obese 
individuals, may contribute to Type II Diabetes (Flier, Cook, Usher, & Spiegelman, 
1987), a positive risk factor for AD.  Also of unknown relevancy to AD pathogenesis is 
Factor H, mentioned above to be upregulated in late onset AD (Strohmeyer et al., 2002), 
and which was reported to correlate in abundance with disease prognosis (Hye et al., 
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2006). However, polymorphisms in Factor H were not found to be related to late onset 
AD (Hamilton et al., 2007).   
One regulator of C3 that does have significant involvement with AD pathogenesis 
is Complement Receptor-1 (CR1, also known as CD35). CR1 is located on B 
lymphocytes, glomerular epithelial cells, follicular dendritic cells, 
monocytes/macrophages, neutrophils, and especially on erythrocytes (Lambert et al., 
2009; Roitt IM, 1998). While CR1’s actions to inhibit the formation of C3-convertase 
was described above and is certainly important in preventing excessive C3-convertase 
activity, CR1’s major role in the pathogenesis of AD may be peripheral, instead of 
parenchymal, since it is most abundantly expressed on erythrocytes.  CR1’s major ligands 
are C3b, iC3b, C4b, and C1q, which are all capable of binding Aβ, as described above, 
and aggregated Aβ can bind C3b and activate C3’s production (Kuo et al., 2000; Rogers 
et al., 2006; Webster, Bradt, Rogers, & Cooper, 1997) . A recent 2009 large 
genome-wide association study (GWAS) of 6010 AD patients and 8625 control 
individuals from France, Belgium, Finland, Italy, and Spain found that the genes for CR1 
and CLU (clusterin, also known as ApoJ, another complement regulator described below) 
were confirmed as risk loci for AD, in addition to the other known susceptibility locus of 
ApoE (Lambert et al., 2009). An earlier study looking at the amount of erythrocyte-bound 
Aβ within the blood of AD, MCI, and non-demented (ND) individuals, showed that AD 
patients had the least amount of bound Aβ, and that MCI patients had more bound than 
AD but significantly less than ND individuals (Rogers et al., 2006), suggesting that 
C3-dependent adherence  of Aβ to erythrocytes may provide for its clearance from the 
bloodstream (Kuo et al., 2000; Zhou, Fonseca, Pisalyaput, & Tenner, 2008). Ligand 
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bound to erythrocytic CR1 is removed via the CR1g receptors on liver Kupffer 
macrophages (Helmy et al., 2006; Wiesmann et al., 2006), and thus provide a mechanism 
for peripheral clearance of parenchymal-to-blood transport of Aβ. 
C3 Receptors.  There are 4 known receptors (CR1, CR2, CR3, and CR4) that 
bind the three surface-bound C3 products (C3b, iC3b, and C3dg). CR1, just described 
above, can bind to C3b and iC3b.  CR2 (also known as CD21), expressed on B 
lymphocytes, follicular dendritic cells, and some epithelial cells, binds iC3b and C3dg 
and functions in roles independent of AD pathogenesis. However, CR3 (also known as 
CD11b/CD18) and CR4 (also known as CD11c/CD18) are expressed on monocytic 
lineage innate leukocytes and microglia, and they both bind C3b and iC3b, and can 
function to promote phagocytosis and removal of complement-bound Aβ complexes 
(Choucair-Jaafar et al., 2010). An increase in the amount of these phagocytic receptors 
could presumably aid in the clearance of amyloid plaque from the brain. The phagocytes 
containing these receptors,will be discussed further in the section below, “Leukocyte 
Recruitment in the Brain”.  
 Formation of the Membrane Attack Complex (Figure 2). After the formation 
of either C3-convertase, complement component C3 is cleaved into C3a and C3b. C3a is 
released into the fluid phase and C3b remains to bind with either C3-convertase to form 
the two C5-convertases, C4b2a3b and iC3BbC3b-P, which then can cleave complement 
component C5 into C5a and C5b. As with C3a, C5a is also released into the fluid phase 
and C5b remains with the complex in the progression of the full complement cascade to 
the Membrane Attack Complex (MAC), which forms a hydrophobic pore through the 
cellular membrane upon which the complement is attached, usually resulting in lysis of 
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the cell. The components C6 through C9 bind stepwise and non-enzymatically, with the 
binding of C7 beginning the hydrophobic interactions within the membrane. Up to 
fourteen C9 components may bind in the formation of the MAC. As with the prior steps 
of the complement cascade, the formation of the MAC is also tightly regulated.  The 
three known regulators of the complement cascade after C5-Convertase are Vitronectin 
(also known as the S-protein), Protectin (also known as CD59), and Clusterin (CLU, also 
known as ApoJ).   
Regulation of the MAC. 
Vitronectin. Vitronectin is a plasma protein that acts to inhibit the formation of 
the MAC in either of two ways. It can prevent the C5b-7 complex from binding the 
membrane, resulting in soluble C5b-7 (sC5b-7), which is lytically-inactive, or it can 
prevent the polymerization of C9 (Podack, Kolb, & Muller-Eberhard, 1977; Podack & 
Muller-Eberhard, 1978; Sheehan, Morris, Pussell, & Charlesworth, 1995). Vitronectin is 
a multifunctional glycoprotein that has other roles besides complement regulation, such 
as cellular adhesion, coagulation, and fibrinolysis ( Reviewed in (Preissner, 1989)). 
Vitronectin has also been shown to be involved in the migration of smooth muscle cells 
through the vitronectin receptor, αVβ3 integrin (Brown, Lundgren, Nordt, & Fujii, 1994), 
and to play an essential role in vascular remodeling of human microvessel endothelial 
cells (Salasznyk et al., 2007; Wilcox-Adelman, Wilkins-Port, & McKeown-Longo, 
2000). Thus, Vitronectin may be responsible for participating in the aberrant 
vascularization around amyloid plaques, as was illustrated by the VCC of Tg AD mice in 
Figure 1 (Chapter 1). Vitronectin has also been found within AD amyloid plaques and 
thoughout the body in other amyloid pathologies, such as in deposits associated with age-
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related macular degeneration, atheroslcerosis, systemic amyloidosis, and deposits within 
the glomeruli. Furthermore, Vitronectin was recently reported to readily form soluble 
amyloid oligomers and fibrils itself, although these actions are not known to be relevant 
in vivo (Shin et al., 2008).  Thus the exact roles of Vitronectin in AD pathogenesis are 
still unclear. 
Protectin. Protectin (also known as CD59) is a membrane-bound protein that 
inhibits the final step in MAC formation, by binding to C8 and preventing the 
polymerization of the C9 subunits. CD59 is constitutively expressed at low levels in 
neurons and oligodendrocytes and it is slightly upregulated during complement activation 
(McGeer et al., 1991). Using CD59 knockout mice (Holt et al., 2001), CD59 has been 
shown to play a protective role against neurodegeneration following traumatic brain 
injury (Stahel et al., 2009), and thus CD59 might also be expected to be neuroprotective 
against dementia pugilistica. Another recent report has also shown that CD59 is 
neuroprotective after cerebral ischemia (Harhausen et al., 2010). However in AD, the 
expression of CD59 has been reported to be deficient, and that this deficiency may 
contribute to AD pathogenesis (L. B. Yang, Li, Meri, Rogers, & Shen, 2000; Yasojima et 
al., 1999). 
Clusterin. Clusterin (also known as ApoJ), like vitronectin, is a plasma protein 
that has multifunctional roles in the CNS.  Clusterin acts, along with vitronectin, to 
inhibit the insertion of the MAC into the cell membrane, by binding to the C7 and 
β-subunits of C8 and C9 and resulting in a lytically-inactive clusterin- and 
vitronectin-bound soluble MAC (SMAC) (Tschopp, Chonn, Hertig, & French, 1993).  
Systemically, SMAC has been described as part of circulaing imune complexes, which 
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have been found in renal tissue deposits and implicated in SLE pathogenesis (Chauhan & 
Moore, 2006; Murphy, Davies, Morrow, & d'Apice, 1989).  In the CNS, Clusterin was 
first demonstrated in 1990 to be increased in the hippocampus of AD patients, and to be 
expressed within pyramidal neurons and some non-pyramidal neurons of the 
hippocampus and entorhinal cortex (May et al., 1990). It was proposed that clusterin may 
be involved in the neuroprotection from complement-mediated cell lysis (May & Finch, 
1992). As mentioned above, Clusterin’s gene was also found in the GWAS to be a major 
risk locus for the development of AD (Lambert et al., 2009). Clusterin, protectin, 
vitronectin, and C5-9 components have all been detected colocalized with dystrophic 
neurites and NFTs in AD and DS (McGeer et al., 1989; McGeer, Kawamata, & Walker, 
1992; Stoltzner et al., 2000; Zanjani et al., 2005), but of these, only clusterin and 
vitronectin were found to intensely stain amyloid plaques, and clusterin had only 
scattered staining with NFTs (McGeer et al., 1992). In the study by Yasuhara et al. 
(1994) of the tauopathy, Pick’s disease, virtually all of the Pick bodies, contained within 
the dentate fascia, hippocampal pyramidal layers, entorhinal cortex, and affected 
neocortices  were strongly immunopositive for MAC and protectin, but were weakly 
stained for vitronectin, and did not stain at all for clusterin. However, clusterin did 
strongly stain pyramidal neurons in the parahippocampal gyrus, including ballooned 
ones, as well as in some scattered neurons of the affected cortical areas (Yasuhara, Aimi, 
McGeer, & McGeer, 1994).  Taken together, these studies show that Protectin, which has 
insufficient levels in AD, can be found in areas of extreme tau pathologies, while the 
soluble vitronectin and clusterin MAC inhibitors are deficiently expressed, although 
vitronectin and clusterin do strongly associate with amyloid plaques, which are not 
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colocalized with NFTs in AD pathology.  Thus, it could be hypothesized that in AD, 
clusterin and vitronectin are being sequestered by Aβ deposits, and resultingly, they are 
not in sufficient concentrations around the areas of NFTs where the MAC may be 
contributing to neurodegeneration. 
Futher support for this hypothesis comes from examining Clusterin (ApoJ) in its 
other major role within the brain.  Clusterin and ApoE are the most abundant 
apoliproteins in the CNS (May & Finch, 1992; Roheim, Carey, Forte, & Vega, 1979).  
Both clusterin and ApoE bind to Aβ and are found in amyloid plaques (Calero et al., 
2000; May et al., 1990), as well as contributing to the fibrillogenesis, neurotoxicity, and 
deposition of Aβ (DeMattos et al., 2002; Potter et al., 2001).  However, these 
apolipoproteins are also thought to help clear Aβ from the brain across the BBB, 
especially Aβ1-42 (Bell et al., 2007; DeMattos et al., 2004; Holtzman, 2004; Holtzman et 
al., 1999; Lambert & Amouyel, 2007).  Clusterin is the main protein carrier for Aβ in 
biological fluids (Calero et al., 2000) and its multiligand receptor, low-density lipoprotein 
receptor-related protein-2 (LRP2, also known as Megalin) is expressed at the BBB and at 
the blood-CSF barrier in the choroid plexus (Chun, Wang, Pasinetti, Finch, & Zlokovic, 
1999; Hammad, Ranganathan, Loukinova, Twal, & Argraves, 1997; Zlokovic et al., 
1996). The recent study by Bell et al. (2007) showed that soluble, free Aβ1-42 is cleared at 
the BBB at a rate of about 1.9-fold lower than soluble, free Aβ1-40, that LRP2 is required 
by Clusterin for efflux across the BBB, and that Aβ1-42  binding to Clusterin accelerated 
Aβ’s clearance across the BBB by over 80 percent (Bell et al., 2007). Another recent 
study by Carro et al. (2005), using two Tg AD mouse models and other murine models, 
reported that LRP2 is involved in the transport of exercise-induced IGF-1(Carro, Nunez, 
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Busiguina, & Torres-Aleman, 2000) from the blood and into the brain. The authors used 
viral-directed overexpression, as well as RNA interference of LRP2, to show that IGF-1 
is induced systemically from regular physical exercise (on a Letica treadmill for 1h/day at 
17m/min for 4 weeks at 5d/week), that circulating IGF-1 induces the clearance of Aβ 
from the brain through LRP2, that tau hyperphosphorylation and cognitive deficits were 
subsequently prevented by these actions, and that LRP2 expression is decreased in 
normal aged animals (Carro, Spuch, Trejo, Antequera, & Torres-Aleman, 2005).  
 Thus in consideration of both of Clusterin’s main roles in the CNS, it could be 
hypothesized that Clusterin’s ability to transport soluble-free Aβ across the BBB through 
LRP2 may decrease with age-related declining LRP2 expression, while allowing 
parenchymal Aβ deposition to occur, in which Clusterin is sequestered and may even 
participate in this amyloid deposition, and which subsequently causes Clusterin to be 
deficiently expressed homogeneously throughout the brain and unable to prevent MAC 
from acting on NFT-prone neurons. 
Proteolytic Fragments of Complement. The formation of the two 
C3-convertases yields three different secreted fluid-phase molecules: C2b, C4a, and Ba. 
In the classical and leptin pathways, surface-bound C4b allows C2 to bind in the presence 
of Mg2+, in which C2 is then cleaved by activated C1s or MASP-2, respectively, to form 
a surface-bound C4b2a C3-convertase and a released 30 kDa N-terminal C2b fragment 
into the fluid phase (Krishnan, Xu, Macon, Volanakis, & Narayana, 2009). The exact role 
of C2b in the fluid phase is not completely known, but one study has reported C2b to 
enhance vascular permeability and lead to angioedema (Strang et al., 1988).  Since 
complement activation is induced by amyloid in AD pathogenesis, C2b production would 
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be expected to also be increased, but whether C2b contributes to any cerebrovascular 
dysfunction in AD is unknown. Similarly, any involvement of C4a in AD pathogenesis 
has not been reported.  However, C4a may have future utility as a biomarker for Multiple 
Sclerosis (MS) prognosis (Ingram, Hakobyan, Robertson, & Morgan, 2010), for rare 
central nervous system (CNS) vasculitis (Langlois, Sharon, & Gawryl, 1989), and for 
other autoimmune diseases, such as Systemic Lupus Erythematosis (SLE) (Rupert et al., 
2002).  The role of the alternative pathway component, Ba, in AD pathogenesis is also 
not clear, but it has been reported to be significantly up-regulated in AD brain 
(Strohmeyer et al., 2002). 
The released fluid phase anaphylotoxins, C3a and C5a, from the C3- and 
C5-convertases, are involved in the activation and chemotaxis of myeloid-lineage 
leukocytes, through their surface-bound receptors C3aR and C5aR, respectively. 
Although both C3a and C5a have similar functional type roles, they have distinct 
biological activities within the brain.  For example, C3a has been shown to be 
neuroprotective against  N-Methyl-D-Aspartate (NMDA)-induced excitotoxicity (van 
Beek et al., 2001), to induce human microglial cells to produce nerve growth factor 
(NGF) (Heese, Hock, & Otten, 1998), and to have a protective anti-inflammatory effect 
in the CNS after LPS-induced septic shock (Boos, Szalai, & Barnum, 2005), while C5a 
was reported to participate in septic pathogenesis (Gerard, 2003; Guo & Ward, 2005). 
Furthermore, C3aR and C5aR have varied expression after acute focal cerebral ischemia. 
Both receptors are constitutively expressed on neurons and glial cells, but after 
experimental permanent middle cerebral artery (MCA) occlusion, they had induced 
expression on the endothelial cells of blood vessels within the ischemic cortex at 6 hours 
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and 2 days postocclusion, as well as increased expression on myeloid cells and reactive 
astrocytes one week later (Van Beek et al., 2000). However, a similar follow-up study 
found that only C5aR is highly elevated at 3 hours after acute MCA, while C3aR is 
reduced at 3 hours post-MCA to only 25 percent of the expression in control 
sham-operated animals. Interestingly, at 24 hours post-MCA, C3aR expression had 
recovered and was increased similarly to the study by Van Beek et al.(2000), and both 
C5aR and C3aR had peaked to their highest levels of the study at 24 hours (Barnum et 
al., 2002). Other studies have shown that inhibiting both C3aR and C5aR 6 hours post 
intracerebral hemmorhage can be protective (Garrett et al., 2009; Rynkowski et al., 
2009), and that complement activation contributes to injury in humans in acute ischemic 
stroke (Szeplaki et al., 2009). 
While acute ischemia is a much different pathology than the chronic 
neurodegeneration of AD, it is also suggested in AD that C3a, C5a, and their respective 
receptors may have similar differential roles, which may either be neuroprotective or 
deleterious. Amyloid plaques in AD have long been reported to contain C1q, C4, and C3 
fragments, but are devoid of C3a, indicating an activated complement cascade in which 
C3a has been released into the fluid phase (Eikelenboom et al., 1989). As already 
mentioned, blockage of C3-convertase exacerbates amyloidosis, and that increasing C3 
production reduces amyloidosis (Wyss-Coray et al., 2002). Conversely, the findings that 
the MAC is co-localized with dystrophic neurites and NFTs in human AD patients 
(Itagaki, Akiyama, Saito, & McGeer, 1994), that blockage of C5aR in transgenic AD 
mice reduces amyloidosis and improves behavior (Fonseca et al., 2009), and that C5aR is 
up-regulated in the microglia surrounding amyloid plaques (Ager et al., 2010), suggests 
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that progression from C3-convertase to C5-convertase is a critical tipping point or 
theshold in the pathogenesis of AD, with the complement cascade going from a 
neuroprotective role to that of a deleterious role. 
 Conclusion. The complement cascade plays a significant role in the pathogenesis 
of AD at almost every step of the process. Complement activation has been shown to be 
necessary for the clearance of amyloid from the brain, especially by C1q binding to Aβ at 
a site that is known to promote amyloid deposition by ACT involvement and also by the 
activation of C3-Convertase. On the other hand, a dysregulated complement system, from 
C5 through MAC insertion, appears to be deleterious and contribute to neurodegeneration 
at areas of tau pathology. The recent findings, reported at ICAD in 2009, shed light on 
both of these components of the complement cascade. These findings of CR1 and CLU 
should not be surprising considering the vast cerebrovascular damage found in AD, as 
demonstrated from VCC studies and which is illustrated in Figure 1 (Chapter 1). This 
damage begins with accumulation of Aβ (‘pompoms and cubes’) on the parenchymal 
surfaces of the microvessels, which induces some luminal crimpage at first, presumably 
from the deficient transport of Aβ across the BBB (age-dependent decrease in LRP2) or 
from the lack of receptors to bind and clear complement-bound Aβ, both within the 
parenchyma (by CR3 and CR4) and in the vasculature (by CR1, CR3, and CR4). These 
effects result in a feed-forward mechanism from age-related reductions in cerebral blood 
flow, further defects in vasculature, decreased expression of necessary Aβ clearance 
receptors, and inversely with increased amyloidosis and subsequent tau 
hyperphosphorylation. As the occlusions continue to narrow and inhibit more cerebral 
perfusion, the vessels eventually pinch off and become completely occluded and 
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truncated around a growing parenchymal anti-angiogenic amyloid plaque, which could 
essentially be described as progressive microvasculature ischemia and infarct.   
Leukocyte Recruitment in the Brain 
Bone Marrow-Derived Cells (BMDCs) in the CNS. Although the 
developmental origin of microglia has been debated (Altman, 1994; Theele & Streit, 
1993) as to whether microglia are derived from neuroepithelial cells (Kitamura, Miyake, 
& Fujita, 1984; Lewis, 1968; Neuhaus & Fedoroff, 1994) or from hematopoietic 
monocytic cells (Eglitis & Mezey, 1997; Ling & Wong, 1993; Perry & Gordon, 1988), it 
is now generally-accepted that BMDCs can cross the BBB and become functional cells 
within the CNS . One study that has demonstrated this phenomenon transplanted wild-
type male bone marrow into recipient PU.1null female mice (Reviewed in (Mezey & 
Chandross, 2000)).  PU.1 is a transcription factor expressed exclusively in hematopoietic 
lineage cells, and mice with a homozygous mutation in PU.1’s gene are born extremely 
leukopenic, with an inability to produce new macrophages, neutrophils, mast cells, 
osteoclasts, or B/T lymphocytes, and they die within 48 hours from severe septicemia 
(McKercher et al., 1996; Tondravi et al., 1997). These mice can be rescued to normal by 
intraperitoneal administration of wild-type bone marrow. Using these mice, Mezey et al. 
observed Y chromosome-containing cells thoughout both the white and gray matter of the 
brain, having phenotypes of astrocytes (GFAP immunopositivity) and neurons 
(NeuN-immunopositive nuclei within neuron-specific enolase immunopositive cells). 
There was an increased accumulation of these Y chromosome-containing cells in the 
choroid plexus, the ependyma of the ventricular system, and in the subarachnoid space , 
and up to 5% of all cells evenly distributed thoughout the areas of  the brain involved in 
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AD pathogenesis, including the cerebral cortex, hypothalamus, hippocampus, amygdala, 
periaqueductal gray, and striatum (Mezey, Chandross, Harta, Maki, & McKercher, 2000). 
Another study that was reported simultaneously with Mezey et al., administered bone 
marrow, which was harvested from 8- to 10-week-old transgenic mice and which 
ubiquitously expressed green flourescent protein (GFP+), into isogenic age-matched 
lethally-irradiated mice, and allowed the recipient mice to age for 1 to 6 months 
(Brazelton, Rossi, Keshet, & Blau, 2000). The authors found upon subsequent 
examination of the mice brains, that significant amounts of  GFP+ neurons and microglia 
populated the brain throughout the CNS, such as in the hippocampus, cerebral cortex, 
cerebellum, and olfactory bulb, a specific area of the brain where neuronal regeneration is 
frequently ongoing (Hinds, 1968; Lois & Alvarez-Buylla, 1994; Luskin, 1993). Since 
these two studies, many other investigations have used these techniques to study the roles 
of bone marrow-derived cells within the brain and CNS and under various disease and 
experimental conditions (Beck et al., 2003; Beers et al., 2006; Boissonneault et al., 2009; 
Corti et al., 2004; Hess et al., 2002; Keshet et al., 2007; Malm et al., 2005; Priller et al., 
2001; Sanchez-Ramos et al., 2009; Simard & Rivest, 2004). 
BMDCs and AD.  One such study of GFP+ bone marrow transplantation into 
recipient lethally-irradiated Tg AD mice, aimed to investigate whether the microglia that 
decorate amyloid plaques are bone marrow-derived or whether the amyloid plaques 
sequester the resident microglia already in the brain (Malm et al., 2005). The authors 
transplanted GFP+ bone marrow into young  2.5-month-old Tg mice (Study I), which had 
not yet acquired amyloidosis, and into old 21- or 25-month-old Tg mice (Studies II and 
III respectively), which already had established amyloid deposition.  In Study I, the mice 
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were aged 26 weeks post-transplantation of GFP+ bone marrow and subsequent 
examination of their brains revealed that the number of engrafted GFP+ cells were 
significantly higher in the brains of Tg AD mice, compared to age-matched wild-type 
control mice, and that about 6% of the total GFP+ cells found within the brains were 
associated with amyloid plaques. In Study II of 21-month-old Tg mice and age-matched 
controls, which received GFP+ bone marrow and were aged 14 weeks 
post-transplantation, examination of the brains did not reveal any difference in GFP+ 
bone marrow-derived microglia between the Tg and wild type groups and only 3% of the 
GFP+ microglia, that were found within the Tg AD brain parenchymas, were associated 
with amyloid plaque. However, when comparing BMDC recruitment between the young 
and old Tg mice, there was a 17-fold higher number of GFP+ microglia surrounding the 
plaques in Study I than were found in Study II, suggesting that there is significant BMDC 
recruitment into the brain as amyloid is being deposited, but not after plaque deposition is 
already established.  To examine the established amyloid plaques further, in Study III, 
25-month-old Tg AD mice were transplanted with GFP+ bone marrow, allowed to age 
for 16 weeks, and then LPS was injected ipsilaterally into the right hippocampi and saline 
control injected contralaterally. One week post-injections, the mice were sacrificed and 
examined, which revealed that the LPS-injected hippocampi had a 6-fold increase in 
GFP+ microglia (as distinguished by CD11b immunopositivity), a 5-fold increase of 
these GFP+ microglia associated with the amyloid plaques, and a significant 24% 
reduction in the total Aβ burden.  The authors concluded that the infiltration of BMDCs 
contribute to the microglial reaction in AD, and that local inflammation can recruit 
BMDCs which reduce amyloid burden.  
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A similar study followed that examined the actual role of the BMDCs in relation 
to amyloid plaques (Simard et al., 2006). Transplantation of GFP+ bone marrow into 
2-month-old lethally-irradiated Tg AD mice, and then the mice aged for 2 to 7 months 
post-transplantation, also showed that GFP+ microglia associated with amyloid plaques, 
that the average amyloid plaque area gradually increased each month up to 6 months of 
age, and that at 6 months, bone marrow-derived GFP+ plaque-associated microglia were 
significantly increased. However, at 9 months, the average amyloid plaque area had 
dramatically increased, while the number of plaque-associated GFP+ microglia had 
modestly decreased. Although this microglial decrease was just briefly mentioned by the 
authors, we took notice and hypothesized that the rapid increase in Aβ deposition might 
be due to age-related depressed hematopoiesis and that strategies to increase BMDCs 
might inhibit or reverse amyloidosis. The authors further work supports this hypothesis, 
in which they had created a new transgenic animal model (denoted here as PS/APP/TK 
mice), in which a Tg AD mouse line expressed a mutant thymidine kinase (TK) protein 
under the control of the CD11b promoter, such that when the mice were treated with 
ganciclovir, every cell expressing TK (monocytic lineage cells only) would be eliminated 
during cellular division. Since global administration of ganciclovir in these mice would 
cause severe leukopenia, and anemic or septic mortality after chronic administration for 
10 days, the authors continuously infused ganciclovir for 28 days intracerebroventicularly 
via commercial osmotic alzet pumps into the 15- to 24- week-old PS/APP/TK mice. The 
authors demonstrated that if treated with ganciclovir, these mice at 6 months of age have 
significantly increased amyloid deposition.  Furthermore, confocal microscopy of the 
brain tissue from the GFP+ bone marrow-transplanted mice at 6 months of age, showed 
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that in the GFP+ bone marrow-derived microglia, and not the resident microglia, Aβ was 
present and had been phagocytosed. Taken together the authors concluded that it is the 
bone marrow-derived microglia which are able to remove amyloid deposition via a 
cell-specific phagocytic mechanism, and that depletion of these BMDCs will exaccerbate 
AD pathology. 
In further support of the notion that BMDC recruitment into the brain could 
ameliorate AD pathogenesis comes from a study that inhibited the migration of BMDCs 
into the brains of Tg AD mice (J. El Khoury et al., 2007). In this study, the authors 
generated APP mice that were deficient in the chemokine receptor, CCR2.  CCR2 has 
been shown to be involved in mononuclear phagocyte infiltration into the brain of MS 
patients (Izikson, Klein, Charo, Weiner, & Luster, 2000), and to be required for 
macrophage infiltration into damaged areas of the hippocampus following axonal injury 
(Babcock, Kuziel, Rivest, & Owens, 2003).  CCR2 binds to its ligand Chemokine C-C 
motif Ligand 2 (CCL2, also known as MCP-1)(Charo & Peters, 2003), and as mentioned 
above, CCL2 has been reported to be upregulated in AD brain (Ishizuka et al., 1997; 
Sokolova et al., 2009), but expression may be lost as AD pathogenesis increases (Dawson 
et al., 2003; Galimberti et al., 2006). CCL2 has been shown to be produced by microglial 
and astrocytic cultures (J. B. El Khoury et al., 2003; Smits et al., 2002), and that 
neutralizing antibodies against CCL2 inhibit Aβ-stimulated chemotaxis of microglia and 
monocytes (J. B. El Khoury et al., 2003). In another study by El Khoury et al. (2007), the 
authors demonstrated that Tg AD mice, which were deficient in CCR2, had significant 
exacerbation of amyloidosis and premature mortality, and that these effects correlated 
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with expression of CCR2 gene dosage. The authors concluded that increased microglial 
density may indeed play a protective role against AD by promoting the clearance of Aβ. 
Research Plan 
The notion that NSAIDs may not account for RA being a negative risk factor 
against AD, and that secreted factors within RA pathogenesis itself were also unlikely to 
explain this phenomenon alone, we hypothesized that the RA up-regulated leukocytes, 
especially those of the innate immune system, may potentially provide beneficial effects 
against AD and provide insight into this inverse relationship between RA and AD. A 
significant amount of literature regarding different components of the innate immune 
system lent credence to this idea, from extensive involvement of the complement system 
in AD, to the critical requirement of BMDCs to infiltrate the brain and affect AD 
pathology. It was also highly consistent with the literature that increasing the cellular 
components of the innate immune system may overcome age-related depressed 
hematopoiesis and also provide therapeutic benefit. 
Thus, to investigate the interactions between the innate immune system and AD, 
we studied the effects on AD pathology of three colony-stimulating factors (M-CSF, 
G-CSF, and GM-CSF), which are up-regulated during RA pathogenesis and that drive 
much of the leukocytosis involved in RA pannus formation  (Kawaji, Yokomura, 
Kikuchi, Somoto, & Shirai, 1995; Nakamura et al., 2000; Olszewski et al., 2001; Xu, 
Firestein, Taetle, Kaushansky, & Zvaifler, 1989). These CSFs enhance the survival and 
function of their respective leukocytes and drive their proliferation and differentiation 
from myeloid lineage precursors. GM-CSF induces dendritic cells, macrophages, and 
granulocytes (neutrophils, basophils, and eosinophils), while M-CSF and G-CSF 
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respectively induce the macrophage and granulocyte subsets of the innate immune 
system. These innate cells have the ability to diapedese from the circulatory system and 
to differentiate further into various specialized immune cells within organs (microglia, 
Langerhan’s cells, etc.). Specifically, we hypothesized that the activation/differentiation 
of innate immune system cells by colony stimulating factors released during RA might 
lead to phagocytosis/removal of the pathogenic lesions of AD and to cognitive 
improvement.  
GM-CSF and G-CSF are also known to be involved in erythropoiesis, and 
GM-CSF and erythropoietin act synergistically in the maturation and proliferation of the 
burst-forming and colony-forming erythroid units to the normoblast stage of 
erythropoiesis (Emerson et al., 1985; Wu, Liu, Jaenisch, & Lodish, 1995). As noted 
above, circulating Aβ binds to complement opsonins in an antibody-independent fashion, 
and these opsonized particles bind to the complement receptor, CR1, on erythrocytes and 
subsequently to CR1g on liver-resident kupffer macrophages (Helmy et al., 2006; Rogers 
et al., 2006).  Thus these CSFs could provide function in both the peripheral clearance of 
Aβ, in neovascularization and resultant increased cerebral blood flow, and in bone 
marrow-derived microglial activity because they are involved in the proliferation, 
differentiation, and maintenance of most innate leukocytes involved in these functions 
(see Figure 3 for overview of the hematopoietic system).  
The following chapters detail the results on cerebral amyloid deposition from 
intrahippocampal administration of the three CSFs into aged transgenic AD mice, as well 
as the behavior and pathological effects from daily subcutaneous administration of 
GM-CSF, the most active of the CSFs in the hippocampal injections. 
  
 
 
Figure 2. Overview of the Complement System. Many regulatory proteins of the 
complement system are implicated in AD and all are highlighted here in red text. Figure 
adapted and redrawn from (Tegla et al., 2009). 
75 
 
 
 
Figure 3. Overview of the Hematopoietic System. G-CSF acts primarily to induce  
granulocytic cells from myeloid precursor cells, while M-CSF upregulates macrophages. 
Although not indicated here, M-CSF also induces Myeloid-Derived Suppressor Cells. 
GM-CSF induces cellular populations of each of these innate hematopoietic cells. 
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CHAPTER 3 – DEVELOPMENT OF BILATERAL BRAIN INFUSION 
METHODOLOGY 
Introduction 
In 2007, at the start of the experimental investigation into whether or not the 
hematopoietic colony stimulating factors (CSFs) would affect AD pathology in mice, 
several reports suggested that M-CSF might be the most promising CSF to reverse 
amyloidosis. For instance, it was reported that osteopetrotic (op/op) mice, that do not 
produce functional M-CSF, developed amyloid plaques in their brain, and had 
neurodegeneration (Kaku et al., 2003; Kawata et al., 2005).  When 30 day old op/op mice 
were intracranially-injected with M-CSF, they had reduced brain plaques, even though 
their microglial populations only increased to two-thirds that of wild-type mice (Kaku et 
al., 2003). Furthermore, in vitro studies showed that M-CSF was induced in Aβ-treated 
microglia cells (Ito et al., 2005), suggesting that the brain’s Aβ-activated microglial 
might secrete hematopoietic growth factors in an attempt to increase phagocytic 
microglial populations. Additionally, microglia that overexpressed the receptor for 
M-CSF were reported to be neuroprotective (Mitrasinovic et al., 2005). However, there 
were no in vivo reports that had administered M-CSF into the CNS. Since a proposed 
endpoint of our study was to show an alteration in cerebral amyloidosis, due to M-CSF 
administration, we wanted an adequate amount of M-CSF delivered. Thus we decided to 
use a novel bilateral brain infusion methodology (Bennett et al., 2009), that we were 
developing in 2007, to continuously infuse M-CSF into the lateral ventricles of aged AD 
mice. This chapter explains the construction of the bilateral brain infusion catheters, and 
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the results from the usage of these catheters in transgenic AD mice with infusion of 
alpha-1-antichymotrypsin (ACT) or M-CSF. 
Available Commercial Catheters 
The only commercially-available infusion system for delivering drugs or 
investigational materials in vivo is the Alzet® pump system. There are certain 
characteristics of this system that make it unusable for our experiment. For instance, 
since the average mouse’s skull measures between 8-9mm in width, there can physically 
be only one catheter placed into the test subject’s brain due to the 5.9mm diameter round 
catheter head (Figure 4). Additionally, the thickness of the catheter head does not allow 
for the scalp to be completely sutured closed, without tightness of the scalp and 
subsequent chronic irritation to the mouse during the trial period, in which they will rub it 
against their cage or scratch at it. There will also be chronic inflammation and propensity 
for infection, due to the scalp not closing appropriately. Moreover, the tubing that 
connects to the catheter head often lies partially outside of the skin, allowing the mouse 
to sometimes scratch it loose and compromise the experiment. Furthermore, the catheter 
head is flat and does not contour well to the skull, requiring a large amount of cement to 
be applied to secure the catheter head to the skull. Thus, the cure time for the cement 
causes the mouse to remain long times under anaesthesia, and contribute to increased 
surgery mortalities. These issues combine to make the commercial Alzet® catheters not 
ideal for our experimentation, especially since both ACT and M-CSF are mediators of the 
immune system, and their effects may be skewed throughout the trial.  
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Figure 4. Commercial Alzet® catheter. 
The 5.9mm diameter round catheter head 
glues to the skull of the test animal and has 
the 3.0mm stainless tubing extending 
through a drilled hole in the skull and into 
the brain’s parenchyma. There are 0.5mm 
washer-like plastic spacers that can be added 
underneath the catheter head to reduce the 
distance that the tubing penetrates the brain. 
The 3.4mm pedestal, used for mechanical 
placement of catheter, can be clipped off 
after the glue cures. 
Bilateral Brain Infusion Catheter Construction 
The catheters (patent pending- PCT/US08/73974) used for this experiment were 
made by first taking a 1.25 cm length of 30 gauge stainless steel tubing (Small Parts, Inc. 
Miramar, Fl) and carefully bending it at 2.5 mm under a dissecting microscope (Leica, 
Heerbruug, Switzerland), to approximately 90 degrees, being careful not to crimp the 
tube.  The remaining length of the tube was bent again at 5 mm to an angle of 120-160 
degrees, approximating the contour of each animal’s skull.  These metal cannulae were 
inserted into a 3 cm length of polyethylene (PE-10) tubing with an internal diameter of 
0.28 mm and an outer diameter of 0.61 mm.  One centimeter of the PE-10 was then itself 
inserted into a 4.5 cm length of sterile polyvinyl tubing (PV-50-I.D. 0.69 mm/ O.D. 1.14 
mm, Durect Corp., Cupertino, Ca), held in place using a bead of Locktite 454 adhesive 
(Plastics One. Roanoke, VA.), and cured overnight.  The following day, sterile water was 
forced through each catheter assembly to ensure that the lines were not obstructed.  The 
osmotic pumps were then filled with solution, attached to the catheters and primed and 
implanted as described below.  The proven catheters were later custom manufactured by 
Braintree Scientific (Braintree, MA) with some minor changes: The adhesive was 
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supplanted by heat sealing PE-10 to PE-50 tubing and, because the diameters of the PV-
50 and new PE-50 were not exactly the same, a sheath of silicone (SIL 047) was placed 
over the PE-50 with an extra 2 mm overhang to attach it to the flow modulator of the 
pump, forming a tight, leak-proof seal (Figure 7).  
Transgenic Mice 
PS/APP (presenilin 1/amyloid precursor protein) mice and PS/APP/ACT mice 
were generated by crossing heterozygous PDGF-hAPP (V717F) mice with PDGF-hPS1 
(M146L) on both Swiss Webster and C57BL/6 backgrounds.  In some cases, PS/APP 
mice were bred with mice harboring a gene for human ACT (hACT) under a GFAP 
promoter (Nilsson et al., 2001) were used to be compared to ACT-infused animals.  
Genotyping was performed using comparative real-time PCR (Bio-Rad iCycler- 
Hercules, CA).  Pathogenically, these Alzheimer’s mouse models are characterized by 
robust accumulation of amyloid plaques and the development of microgliosis between 6-
10 months.  The mice used in these studies ranged from 9-10 months of age. 
Materials 
Purified human α-1-antichymotrypsin (ACT) was purchased lyophilized from 
Fitzgerald (Concord, MA) and purified mouse M-CSF was purchased from R&D 
Systems (Minneapolis, MN). Both were reconstituted in artificial CSF (aCSF) (Harvard 
Apparatus, Holliston, MA) to a concentration of 1mg/mL.  ACT was infused directly into 
the hippocampal parenchyma or lateral ventricles for 28 days and M-CSF was infused 
into the lateral ventricles for 14 days using the novel catheters attached to Alzet osmotic 
minipumps (Alzet model 1004, Durect Corp. Cupertino, CA) with an average flow rate of 
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0.12μL/hour.  The pumps and catheters were submerged in 0.9% sterile saline at 37oC 
and primed for 48 hours prior to implantation.   
Intracranial Infusions 
All procedures involving experimentation on animals were performed in 
accordance with the guidelines set forth by the University of South Florida Animal Care 
and Use Committee.  Animals (9 month-old PS/APP- 25-35g) were anesthetized with 1-
2% isoflurane, shaved and scrubbed with 10% Betadine solution at the site of incision, 
and placed into a dual arm stereotaxic frame (Kopf Instruments. Tujunga, Ca.).  A small 
(5 cm) incision was made, exposing the skull and neck, and double bladed scissors (10 
cm curved Strabismus, Fine Science Tools, Foster City, CA.) were used to form a 
subcutaneous pocket along the back of the animal into which 2 osmotic minipumps were 
inserted with catheters attached.  One of the stereotaxic arms held an Ideal Micro-drill 
(Roboz Surgical Instrument Co., Gaithersburg, MD) holding a 0.32 mm diameter carbide 
drill bit.  Using the drill bit on the stereotaxic arm to find the proper coordinates (from 
Bregma -2.2-2.5 mm anterior-posterior, +/- 2.2-2.5 mm medial-lateral),  two holes were 
carefully drilled into the skull and a 30 gauge needle from a Hamilton syringe (Hamilton 
Co., Reno, Nevada) was attached to the second arm of the stereotaxic frame.  The needle 
was inserted to the appropriate depth (2.2-2.5 mm corresponding to the posterior portion 
of the CA1/CA2 hippocampus) and allowed to sit for 5 minutes for the surrounding tissue 
to adjust.   Alternatively, holes were drilled corresponding to the lateral ventricles at the 
following coordinates: from Bregma -0.2 mm anterior-posterior, +/- 1.0 mm medial-
lateral, and to a depth of 2.2-2.5 mm.  After removing the needle, the tips of the cannulae 
were held directly over the holes with forceps and then gently inserted straight into place.  
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Pulling back on the catheters from the base of the osmotic pumps while inserting the 
cannulae provided sheer which prevented them from moving and potentially damaging 
tissue while they were firmly affixed.  The cannulae were affixed to the skull with 
Locktite 454 adhesive (Plastics One. Roanoke, VA.) and secured down with a piece of 
nitrile, approximately 1 cm in diameter.  After the adhesive cured, the scalp was closed 
with 6-7 silk sutures.  For analgesia, the animal received an immediate subcutaneous dose 
of ketoprofen (10mg/kg) and up to every 6 hours, as needed, for a maximum of 48 hours 
post-operatively.  After the 28 day period, the animals were given an overdose 
(~150mg/kg) of sodium pentobarbital (i.p.) and were transcardially perfused with 0.9% 
saline.  The brains were carefully removed and analyzed as outlined below.  At this time, 
the integrity of the catheters was confirmed again by forcing water through them, and the 
pumps were also determined to be empty.   
Histology and Immunohistochemistry 
Mouse brain tissues were fixed in 10% formaldehyde (formalin) for 72 hours and 
then passed through a series of sucrose solutions (10-30%) over another 72 hours.  Brains 
were frozen to the peltier stage (Physitemp, Clifton, NJ) of a histoslide (Leica, 
Heerbruug, Switzerland) and sectioned coronally at 25 μm. After incubating the sections 
with blocking buffer (Tris-buffered saline with 10% normal goat serum, 0.1% Triton X-
100, and 0.02% sodium azide) for 60 min, primary antibodies against ACT (1:500- Dako, 
Glostrop, Denmark) and Aβ (6E10,1:1000- Covance, Princeton, NJ) were applied and 
incubated at 4 o C overnight.  After thorough washing, the sections were incubated with 
secondary antibodies, Alexa 488 and 594 fluorophores (1:1000, 1:4000-Invitrogen) in the 
dark at ambient temperature for 2 hours.  This incubation was followed by a Hoechst 
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(1:10,000, Sigma, St. Louis, MO) nuclear stain, and the sections were washed and sealed 
with Gel-Mount (Electron Microscopy Sciences, Hatfield, PA).  The images were 
analyzed on a Zeiss Imager Z1 fluorescence microscope with a Zeiss Axiocam Mrm 
camera (Oberkochen, Germany) using Axiovision 4.7 software, and ACT sections were 
quantified using Image J.   For animal to animal, hemisphere to hemisphere plaque 
comparison, 5 sections from 6 mice (30 total) were stained using Thioflavin S to label the 
beta-pleated amyloid deposits from anterior to posterior hippocampus in each hemisphere 
of each mouse.  Coronal sections of brain (25µm) were mounted to slides and let to 
adhere overnight.   The sections were then rinsed with deionized water and submerged in 
a 1% Thioflavin S aqueous solution (Sigma-Aldrich, St. Louis, MO) for 5 minutes.  The 
sections were differentiated in 70% ethanol for 5 minutes, rehydrated in 30% ethanol for 
5 minutes, washed with deionized water coverslipped, imaged, and quantified. 
Results 
Animal Recovery. Intracranial delivery of molecules, though invasive, is a 
common procedure to confirm results from in vitro experiments in an in vivo system and 
to test various compounds in transgenic animals via targeted delivery.  As an additional 
advantage, the novel method described here bypasses concerns related to the blood-brain 
barrier permeability of the administered compound.  ACT, a serine protease inhibitor that 
is known to contribute to the formation of amyloid pathology in Alzheimer's disease, was 
infused into the hippocampi or lateral ventricles of 9-month-old PS/APP mice for a 
period of 28 days.  ACT was infused into one hemisphere and aCSF (vehicle) into the 
other hemisphere, thus allowing a comparative analysis to be made within the same 
animal.  In all cases, the animals recovered very quickly from the procedure and resumed 
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eating and grooming within minutes of awakening.  All animals were monitored closely 
during the 4 week infusion.  In only a few instances did animals scratch at the incisions, 
but in no case were they able to open the wound and remove or damage any of the 
implanted pumps and catheters.  In most cases, the hair grew back within 2 weeks, and 
the animals became virtually indistinguishable from non-treated animals, with the 
exception of bulges on the haunches from the implanted osmotic pumps (Figure 9A).  
The implants caused minimal discomfort to the animals, and procedural mortality was 
practically eliminated from these studies. When harvesting tissues following the 28 day 
infusion, the catheters were checked to ensure they were still connected to the pumps 
(Figure 9B) and to the cannulae (Figure 9C).  The nitrile cap is indicated by the arrow in 
figure 9D. The entire assembly is shown attached to an Alzet osmotic minipump model 
1004 (Durect Corp., Cupertino, CA.) in Figure 9E.  Finally, when removing the brains 
only 2 small holes are visible (Figure 9F) showing that there is no lateral movement of 
the cannulae during infusion.  No serious damage or impairment was caused by the 
cannula, although tissue is displaced where inserted.  Figure 10 shows, on the left 
hemisphere, exactly where the cannula was placed and that surrounding tissue was intact 
following infusion.  Figure 11 A and B show a region of the hippocampus anterior to the 
infusion site which also does not show signs of damage.  To be noted, the gauge of the 
cannulae used in this experiment (30g or 0.30 mm O.D.) is the same of those used in 
commercially available cannulae (Alzet, PlasticsOne,  Braintree Scientific), but without 
the irritation to the animal, inflammation, occasional motor impairment, and high 
mortality rates associated with them.   
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Bilateral Brain Infusions. Due to the increased variability in plaque load 
between animals, even within a largely inbred transgenic mouse line, it is often difficult 
to compare treated and untreated mice with a reasonably small number of animals.   This 
phenomenon was observed upon staining the M-CSF-infused mice for amyloidosis 
(Figure 5), and can be caused by phenotypic variability and/or differential expression of 
transgenes.  Upon analysis of 6 untreated PS/APP mice at 10 months of age, we found 
that plaque load can vary significantly from animal to animal (75% mean standard 
deviation in pixel count).  This fact makes it difficult to draw conclusions on the effects 
that different molecules might have on amyloid deposition or other features of the 
transgenic brain when comparing animals where hemispheres vary only about half as 
much (39%).  Figure 6 and Figure 7 demonstrates the variation in plaque load between 
hemispheres and within untreated animals of this genotype.   Therefore, in order to study 
promoters and inhibitors of AD pathology directly in the brain, it would be preferable 
(almost twice the efficiency) to compare the individually-treated hemispheres of each 
animal rather than to compare the brains of littermates or matched cohorts from other 
litters. Immunocytochemical techniques demonstrated that our catheters functioned 
properly and that ACT was delivered successfully to the ventricles and parenchyma, 
respectively (Figures 10 and 11).  If ACT is infused into a PS/APP mouse that has 
plaques for it to interact with, it binds to the plaques and diffuses very little (Figure 11C 
& D).  However, if ACT is delivered into the hemispheres of nontransgenic mice it 
diffuses, but still remains in the intended hemisphere (Figure 11A and B).  
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Interaction of ACT and Amyloid. It is well established that ACT is localized, 
together with the Aβ peptide, in the amyloid plaques of Alzheimer’s disease (Abraham, 
Selkoe, & Potter, 1988).  However, the mechanism and effect of this interaction are still 
under investigation.  Previous in vitro experiments indicated that ACT can bind to Aβ 
and become integrated into amyloid filaments as they are formed, and the same 
mechanism was presumed to occur in vivo (Ma, Brewer, & Potter, 1996; Ma, Yee, 
Brewer, Das, & Potter, 1994; Mucke et al., 2000). Using the application method 
described here, we successfully delivered ACT into individual brain hemispheres of adult 
PS/APP mice and found that ACT binds to the perimeter of existing plaques in a similar 
manner as found for ACT association with amyloid plaques in PS/APP/ACT transgenic 
mouse (Nilsson et al., 2001) (Figure 12).  While the application of exogeneous ACT did 
not lead to increased amyloid load during the time frame of these experiments, it should 
be noted that ACT was infused for only 28 days.  A longer exposure could result in an 
increased plaque load and is currently being investigated.  At the same time, while ACT 
is known to enhance plaque formation, the perimetrical binding of ACT to pre-exisiting 
Aβ plaques, as shown here, might indicate that ACT involvement in AD pathogenesis not 
only occurs concurrent with plaque formation but also afterwards.  This conclusion is 
consistent with the fact that ACT is highly upregulated in adult AD brains (Abraham et 
al., 1988) and also induces the phosphorylation of tau (Padmanabhan, Levy, Dickson, & 
Potter, 2006).   
            Conclusions. Although there is evidence that ACT's involvement in AD is not 
restricted to its participation in plaque formation, the purpose of using ACT in this model 
was to demonstrate the utility of our system.  The catheters and cannulae described here 
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served as an outstanding tool for targeted delivery of ACT into individual brain 
hemispheres and will facilitate further examination of the mechanistic involvement of 
ACT and other molecules in the pathology of Alzheimer's disease. As for the bilateral 
M-CSF infustions into the lateral ventricles, we were not able to determine whether 
M-CSF had any affect on amyloidosis due to the significant variation in plaque load 
between animals. Nor could we be certain that the M-CSF extravasated from the 
ventricles and into the brain’s parenchyma. However, the data from the ACT infusions, of 
which the infused recombinant ACT peptide remained localized to the hemisphere in 
which it was delivered, allowed us to formulate a research plan to give bolus 
intrahippocampal injections of each CSF (M-CSF, G-CSF, and GM-CSF) into a 
respective hemisphere and artificial cerebrospinal fluid control into the contralateral 
hemisphere. The following chapter will discuss the results from these experiments. 
  
 Figure 5. Significant Variation of Amyloid Plaque Load Between Mice Infused with 
M-CSF. Standard fluorescent immunohistochemistry used 6E10/Alexa 488 and Hoechst 
nuclear stain (blue). Bright green spots indicate amyloid plaques. Pictures taken at 5X. 
Mouse numbers 148,160,171, and 211 received bilateral intracerebroventricular infusions 
of M-CSF and mice 164, 170, 176, and 177 received bilateral intracerebroventricular 
infusions of artificial cerebrospinal fluid.   
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Figure 6. Significant Variation of Amyloid Plaque Load Between Mice. Thioflavin S 
staining on 25μm coronal sections (montages) of 3 different PS/APP mice at 10 months 
of age showing plaque variability in the hippocampus and neighboring cortex.   
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Figure 7. Scatter-plot of Plaque Load Between Mice. Data from 5 brain sections 
through 6 ten-month-old PS/APP mice comparing standard deviation (plaque variance) 
between local hemspheres of the same animal (28%), between sides of the same section 
(11%), and between animals (78%). All the data from the left hemisphere are compared 
with the right for each mouse (Hemi-Hemi, 1 data point for each mouse); the left half of a 
single slice is compared wth the right side (Left-Right, 1 data point for each slice); and a 
permuted comparison of each mouse with every other mouse (Mouse-Mouse, 1 data point 
for each pair of mice). Where data were aggregated (Hemi-Hemi and Mouse-Mouse, the 
mean of the aggregared counts was used to make the standard deviation comparable to 
the single slice data (standard deviation of two numbers). 
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Figure 8. Catheter Assembly. A- First bend of 30g stainless steel tubing. B- Second 
“contour” bend. C- polyethylene PE-10 tubing. D- Heat seal. E- PE-50. F- Silicone sleeve 
(SIL047).  
 
 
 
Figure 9. Catheters Usage in vivo. A 10 month-old PS/APP mouse with 2 osmotic 
pumps following 28 days of infusion. While still active (A) and after transcardial 
perfusion showing the Alzet pumps (B) and cannulae (C) still securely attached. The 
arrow in figure D shows the nitrile cap used to affix the catheters to the skull and Figure 
E shows the entire assembly attached to an Alzet 1004 osmotic minipump. When the 
brain is removed, only small holes are visible where the cannulae were inserted (F). 
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Figure 10.  Double Immunohistochemistry of Aβ and ACT. A) A montage of images 
taken at 10x from 25μm sections of an animal treated with ACT on the left and aCSF 
control on the right. The top section is immuno-labelled with the Aβ antibody 6E10 and 
the bottom with ACT antibodies.  Inlays (40x) show Aβ in green, ACT in red, and 
Hoechst nuclear stain in blue. 
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Figure 11. Recombinant Peptides Remain Localized to Infused Hemispheres. 
Montage images of 25μm coronal sections of 10 month old nontransgenic (A & B) and 
PS/APP mice (C & D) immune-labeled with and antibody against α- 1 antichymotrypsin 
following 28 day infusion demonstrating that ACT stays on the infused hemisphere with 
or without the presence of plaques. 
 
 
  
105 
 
 
Figure 12. Replication of Transgenic Animal Models. Comparison of ACT with 
amyloid plaques (40x) from a PS/APP/ACT transgenic mouse (A) and a PS/APP ACT-
infused mouse (B) both at 9 months of age. Immuno-labeling of Aβ is shown in green 
(6E10 antibody), ACT in red, and Hoechst nuclear stain in blue. 
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CHAPTER 4 – INTRAHIPPOCAMPAL ADMINISTRATION OF CSFs 
Introduction 
To investigate the consequences of interactions between the innate immune 
system and AD, we studied the effects on AD pathology of the three colony-stimulating 
factors (M-CSF, G-CSF, and GM-CSF), which are up-regulated in the synovium and 
serum during RA pathogenesis (Kawaji, Yokomura, Kikuchi, Somoto, & Shirai, 1995; 
Nakamura et al., 2000; Olszewski et al., 2001; Xu, Firestein, Taetle, Kaushansky, & 
Zvaifler, 1989). The first objective was to induce the specific leukocytic phenotype of 
each CSF in the brains of aged transgenic AD mice. In the periphery, these CSFs enhance 
the survival and function of their respective leukocytes and drive their proliferation and 
differentiation from myeloid lineage precursors. GM-CSF primarily induces dendritic 
cells, macrophages, and granulocytes (neutrophils, basophils, and eosinophils), while 
M-CSF and G-CSF respectively induce the macrophage and granulocyte subsets of the 
innate immune system. These innate cells have the ability to diapedese from the 
circulatory system and to differentiate further into various specialized immune cells 
within organs (microglia, Langerhan’s cells, etc.). However, these specific leukocytic 
populations have not been described in the brain’s parenchyma and leukocytes are 
broadly classified as just ‘microglia’. Since the bilateral intracerebroventricular infusions 
of M-CSF into similar-aged AD mice showed significant variations in amyloidosis and 
since we observed that infused recombinant proteins remain localized within their 
respective-infused brain hemispheres (Chapter 3), we determined the effects of each CSF 
by bolus intrahippocampal injection into the ipsilateral brain hemisphere and bolus 
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vehicle injection contralaterally. This chapter shows the effects that each CSF induced 
into the brains of aged transgenic AD mice. Specific microscopy and image analysis 
procedures, and a novel device for paraffin-embedded immunohistochemistry were also 
developed to analyze these effects (Boyd et al., 2010 In Press). 
Methodology of Transgenic  Mouse Studies Involving Intrahippocampal 
Administration of CSFs 
Transgenic Mice. PS/APP mice in this study, which begin accumulating robust 
amyloid plaques at 6-8 months, were generated by crossing heterozygous PDGF-hAPP 
(V717F) mice with PDGF-hPS1 (M146L) on both Swiss Webster and C57BL/6 
backgrounds. All procedures involving experimentation on animals were performed in 
accordance with the guidelines set forth by the University of South Florida Animal Care 
and Use Committee. Transgene detections were performed using QPCR (Bio-Rad 
iCycler, Hercules, CA). 
Intrahippocampal Injections of CSFs. All three CSFs were stereotaxically-
injected (5 µg/injection) into the (ipsilateral) hippocampus, with artificial cerebrospinal 
fluid vehicle injected contralaterally into four PS/APP mice each (all 10-12 months old, 
25-35 g, both genders). Two holes were drilled into the skull (from bregma -2.5 mm 
anterior-posterior, +/- 2.5 mm medial-lateral, and the 30 gauge needle inserted to a depth 
of 2.5 mm (Figure13)). Mice were perfused with 0.9% cold saline 7 days later and their 
brains placed in 10% neutral buffered formalin. Recombinant mouse GM-CSF 
(rmGM-CSF), recombinant murine G-CSF (rmG-CSF), and recombinant mouse M-CSF 
(rmM-CSF) (R&D Systems, Minneapolis, MN) will be referred to as GM-CSF, G-CSF, 
and M-CSF throughout this publication.  
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Immunohistochemistry and Image Analysis of Intrahippocampal-injected 
Mice.  Formalin-fixed brains were either coronally cryosectioned at 14-µm, or paraffin-
embedded and sectioned at 5-µm, with standard deparaffination and antigen retrieval 
steps (boiled in 10mM Sodium Citrate buffer for 20 minutes) performed before 
immunohistochemical staining. To significantly reduce cost of reagents and antibodies 
with paraffin-embedded slides, a novel magnetic immunohistochemical staining device 
(Figure 13) was developed (patent pending, Tech ID# 09A015). Standard fluorescent 
immunohistochemical techniques used primary anti-Aβ antibodies 6E10 (Covance, 
Emeryville, CA, 1:1000), and MabTech’s 3740-5 (MabTech, Cincinnati, OH, 1:5000) to 
immunolabel amyloid deposition coupled with Alexa fluorophore-labelled secondary 
antibodies (Molecular Probes, Eugene, OR, 1:1000, 1:4000), and Hoechst (Sigma) 
nuclear staining. Immunofluorescence was detected and all pictures per section were 
taken at the same exposure on a Zeiss Imager.Z1 microscope (Oberkochen, Germany) 
using Axiovision 4.7 software. Digital images were quantified using a novel ImageJ 
protocol (see Appendix D for slides outling the complete ImageJ ).  
Microscopy and Method of Image J Analysis of Amyloid Deposition. Lateral 
rows  of photomicrographs were taken of coronal sections in a manner that ensured 
minimal overlap between each photomicrograph and corresponding anatomical areas in 
each hemisphere.  Hoechst nuclear staining was used as a tool to scroll through sections, 
allowing for minimal overlap between each photomicrograph, and then the image was 
taken with the appropriate fluorescence. After all photomicrographs of the section were 
taken, they were montaged into a full coronal picture of the section, with the outline of 
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each photomicrograph displayed (Axiovision 4.7 Panorama Module software). 
Photomicrograhs were then selected for analysis from each hemisphere (Figure 15). The 
histogram of each photomicrograph was analyzed and the resulting means and standard 
deviations were entered into a spreadsheet. One photomicrograph of the section was then 
thresholded to select the amyloid plaques. This thresholded value was used in the 
spreadsheet to normalize the threshold values of the other photomicrographs to the same 
standard deviation from their respective histogram mean (Figure 16a). Each 
photomicrograph was then analyzed for Area, Perimeter, Feret Diameter, and Integrated 
Density values from their predetermined threshold values. Any threshold-selected data, 
which came in contact with the edges of any photomicrograph, were deleted via the  
Image J “Analyze Particles” dialogue box, so that overlap of photomicrographs did not 
allow quantification of any amyloid deposition more than once. 
Within the Image J “Analyze Particles” dialogue box, the Oulines mask was also 
selected to visually confirm that the plaques were quantified accurately (Figure 16b). 
This Outline mask also numbered each plaque, which was used for selecting and 
eliminating artifact from the results. The results from each individual photomicrograph 
were copied into a 2nd separate spreadsheet, such that the data were separated into their 
respective hemispheres (CSF-treated versus artificial cerebrospinal fluid-treated). After 
all photomicrographs from a coronal section had been analyzed and data entered into the 
spreadsheet, the Area and Perimeter values were totaled and averaged. The Feret 
Diameter and Integrated Density values were also averaged.  The overall data from each 
section (sums and averages) were then entered into a 3rd spreadsheet . A total of 5 
sections per mouse, anterior to posterior, were analyzed and entered into this 3rd 
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spreadsheet. A total of 4 mice per intrahippocampal-injected CSF were analyzed. For 
GM-CSF-injected mice, each section quantified contained analysis of 15-25 individual 
10X pictures of each hemisphere, with fewer pictures quantified in the anterior brain and 
more in posterior brain. For G-CSF- and M-CSF-injected mice, each section quantified 
contained analysis of 7-9 individual 5X pictures of each hemisphere Statistical 
significance was obtained from comparing parameter values of ipsilateral CSF-injected 
hemispheres versus contralateral artificial cerebrospinal fluid-injected hemispheres. 
Significance per mouse and over all 4 mice per CSF was determined by paired Students 
t-test with p values <0.5 considered significant . 
Results  
 Bolus Intrahippocampal Injections of CSFs. M-CSF intrahippocampal 
injections into mice resulted in swelling of the entire hemisphere as compared to the 
control side, and in one mouse, an apparent hyperplasia had formed at the injection site 
(Figure 17 a-c). Quantification of amyloid plaque loads from anterior to posterior of each 
mouse showed similar deposition in the M-CSF-injected hemispheres as compared to the 
control sides (data not shown). In contrast to M-CSF, G-CSF intrahippocampal injections 
did not induce swelling and showed some modest reductions of amyloid deposition 
(Figure 18 a-b). Since the analyses were conducted on low magnification (5X) 
photomicrographs, only the area and integrated density values achieved significance 
(p<0.05). Reductions in amyloidosis was subsequently corroborated by independent 
observations from fellow investigators following peripheral G-CSF administration 
(Sanchez-Ramos et al., 2009).  
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GM-CSF-injections, however, demonstrated pronounced decreases in amyloid 
deposition, as compared to control hemispheres, in visual observations of coronal tissue 
sections (Figure 19 a-d). High magnification (10X) quantification of amyloid plaques 
anterior to posterior revealed significant reductions within individual mice and significant 
overall reductions for all plaque parameters measured (Figures 20 and 21 a-f).   
Conclusion. The differential effects from each injected CSF was surprising and 
exciting. Although M-CSF did not show any expected alteration of amyloidosis, its 
ability to rapidly induce a hyperplasia, as opposed to G-CSF and GM-CSF, supports 
similar literature and helps advance the field’s knowledge with the parenchymal 
overexpression of M-CSF (Kirma et al., 2004).  Further investigation by other researchers 
into the biology of M-CSF-induced hyperplasias would be welcomed. However, based 
upon the very pronounced and significant reductions in amyloidosis, after only one week 
of ipsilateral intrahippocampal bolus injection of GM-CSF as compared to contralateral 
vehicle injection, we wanted to investigate whether GM-CSF would also show benefit in 
cognitive function.  Although G-CSF also showed some reductions in amyloidosis, it was 
not as robust and was currently being researched by fellow investigators (Sanchez-Ramos 
et al., 2009). Therefore, we decided to immediately focus our efforts on the investigation 
of GM-CSF by subcutaneous delivery, since that would likely be the potential route of 
treatment to AD patients. The following chapter will discuss the daily subcutaneous 
treatment of mice with recombinant mouse GM-CSF and its effects thereof.  
 
 
Figure 13.  Schematic of the Intrahippocampal Injection Sites. Either M-CSF, 
G-CSF, or GM-CSF were injected into the hippocampus between the CA2 and CA3 
regions of one hemisphere, and artificial cerebrospinal fluid would have been injected in 
the same contralateral site. 
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Figure 14.  Magnetic Immunohistochemical Device. This novel device was designed to 
minimize the amount of reagents needed during the immunohistochemical staining of 
paraffin-embedded slide-mounted tissue sections. The washer-style magnets have an 
inside diameter of 0.5 inches that encircles the coronal tissue section. Once the slide and 
magnet are placed upon the bracket, the magnetic force holds the slide in place and 
provides a barrier to the liquid reagents. Further detail is provided in the patent 
application attached in Appendix E. (a) Illustration of pipetting 250 – 300µL of reagent 
to magnetic well. (b) Illustration of slide tray contain 3 tissue slides with pipet, that 
would have to have to deliver 8– 10mL of reagent to cover slides, as opposed to the 
magnetic immunohistochemical device containing 500-600 µL of reagent on two tissue 
slides.  
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Figure 15.  Method of Identifying Individual Photomicrographs for Analysis.  
(a) Montaged coronal section of individual 10X  photomicrographs that were taken in a 
lateral row proceedure with mininal overlap between each one, that was then demarcated 
to show which individual photomicrographs would be analyzed for amyloid deposition.  
  
 
 
Figure 16. Method of ImageJ Analysis of Amyloid Plaques. (a) Depiction of the 
‘Thresholding’ of one photomicrograph and the subsequent usage of its threshold value 
that was entered into a spreadsheet to find the threshold value, at the same standard 
deviation from the mean, for all other photomicrographs that are to be analyzed and 
which are contained within the same coronal section. 
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Figure 16. Method of ImageJ Analysis of Amyloid Plaques (continued). (b) Example 
of an ImageJ Oulines mask,  that allows for visual confirmation of the plaques that were 
analzyed, as well as the underlying ImageJ spreadsheet data that will be entered into a 
compilation spreadsheet containing the data of the other photomicrographs of the same 
coronal section. 
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Figure 17.  Intrahippocampal Injection of  M-CSF.  M-CSF injected left hemisphere 
and artificial cerebrospinal fluid (aCSF)-injected right hemisphere. (a) The image is a 
montage of ~35 5X pictures and is representative of the effects seen from anterior 
hippocampus to posterior in all 4 M-CSF-injected mice. (b) This photo shows 
enlargement of the M-CSF-injected left hemisphere, as seen following saline perfusion. 
Note the small bump at the site of injection (arrow). (c) Image shows cyst or tumor-like 
growth formed in the needle track at the site of M-CSF injection. Cryosectioned at 14 µm 
and stained with 6E10/Alexa 488 and Hoechst. Picture taken at 20X.  
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Figure 18. Intrahippocampal Injection of G-CSF. G-CSF injected left hemispheres 
and artificial cerebrospinal fluid (aCSF)-injected right hemispheres. (a) Images are 
montages of ~35 5X pictures each.  Amyloid plaques indicated as white spots.  
Cryosectioned at 14 µm and stained with 6E10/Alexa546 and Hoechst nuclear stain. 
Sections numbered 1 through 6 and correspond with anterior to posterior. 
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Figure 18. Intrahippocampal Injection of G-CSF (continued). (b) Amyloid plaques 
show a modest reduction of plaque in the left G-CSF-injected hemisphere. Error bars are 
± Standard Error of the Mean. (Area, Integrated Density: p < 0.05).  
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Figure 19. Intrahippocampal Injection of GM-CSF. GM-CSF injected left 
hemispheres and artificial cerebrospinal fluid (aCSF)-injected right hemispheres. (a-d) 
Representative sections of each mouse proximal to injection site. Tissue sections stained 
with MabTech α-Aβ/Alexa 488. White spots indicate amyloid plaque immunolabelling. 
Images are montages of about 145 pictures taken at 10X. Figures 18 (a-c) are from 14 µm 
frozen sections, and 18 (d) is from a 5 µm paraffin-embedded section. 
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Figure 20.  Overall Percent Reductions in Aβ Burden by GM-CSF.  Averages of all 
four GM-CSF-injected mice showing significant overall plaque reductions in all four 
plaque parameters measured from 5 quantified sections per mouse (n = 4 mice). Error 
bars are ± Standard Error of the Mean. (Area: p < 1.11E-07; Perimeter: p < 1.41E-06; 
Feret Diameter: p < 2.36E-09; Integrated Density: p < 1.11E-07). 
  
  
 
  
Figure 21. Individual Parameter Reductions in Aβ Burden by GM-CSF.  
GM‐CSF‐injected left hemispheres versus artificial cerebrospinal fluid (aCSF)‐injected 
right hemispheres. There were 5 montaged sections per mouse quantified. Each montaged 
section contained over 140 10X pictures and of these, 15 - 25 pictures per hemisphere 
were selected to quantify as described in Appendix D. Each figure shows the total or 
average values from the five sections per mouse with statistical significance per 
individual mouse and significance over all four mice. Error bars are ± Standard Error of 
the Mean: (a - b) plaque areas (c - d) perimeter values   
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Figure 21. Individual Parameter Reductions in Aβ Burden by GM-CSF (continued).  
(e) average feret diameters (f) average integrated densities. 
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CHAPTER 5 – SUBCUTANEOUS ADMINISTRATION OF GM-CSF 
Introduction 
Based upon the positive results from the GM-CSF intrahippocampal injections 
(Chapter 4), we investigated the effect of subcutaneous GM-CSF administration on 
cognitive function and AD pathology in aged transgenic AD mice. Prior to these 
experiments, there were no published reports involving in vivo behavioral tasks after 
administration of Colony Stimulating Factors. We determined an appropriate dosage of 
GM-CSF for in vivo administration, which would be comparable to dosages prescribed 
for Leukine (sargramostim), the human GM-CSF analogue.  This chapter describes the 
types of animal behavioral tasks performed, and the alteration of animal cognitive 
function and pathophysiology after 20 days of daily recombinant mouse GM-CSF 
administration (Boyd et al., 2010 In Press).  
Methodology of Behavioral Transgenic Mouse Study Involving Daily 
Subcutaneous Treatment with GM-CSF 
Transgenic Mice. Mice in this study were derived from the Florida Alzheimer’s 
Disease Research Center mouse colony, wherein heterozygous mice carrying the mutant 
APPK670N, M671L gene (APPsw) are routinely crossed with heterozygous PS1 (Tg line 
6.2) mice to obtain APPsw/PS1, APPsw, PS1, and non-transgenic (NT) genotype 
offspring with a mixed C57/B6/SW/SJL background. All procedures involving 
experimentation on animals were performed in accordance with the guidelines set forth 
by the University of South Florida Animal Care and Use Committee. Transgene 
detections were performed using QPCR (Bio-Rad iCycler, Hercules, CA).  
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Radial Arm Water Maze (RAWM) and Cognitive Interference Tasks. Eleven 
APPsw and 17 NT mice, all 12-months old, were selected and evaluated for 8 days in the 
RAWM task of working memory to obtain baseline cognitive performance before 
GM-CSF treatment (Arendash et al., 2001).  For RAWM testing, aluminum inserts were 
placed into a 100 cm circular pool to create 6 radially-distributed swim arms 30.5 cm in 
length and 19 cm wide emanating from a central circular swim area 40 cm in diameter. 
The inserts rise 5 cm above the surface of the water. A submerged escape platform (9 cm 
diameter) is placed with equal distance from the back and side walls in one of the arms 
for each day of testing. The platform location was changed daily to a different arm, with 
different start arms for each of the 5 trials semi-randomly selected from the remaining 5 
swim arms. On the outside of each arm lies a visual cue that is different for each arm. 
Mice do not prefer to be in water, and they readily seek out the submerged escape 
platform to get out of the water (Figure 22a). For any given trial, the mouse is placed into 
that trial’s start arm facing the center swim area and given 60 seconds to find the platform 
with a 30 second stay. Each time the mouse enters a non-platform containing arm it is 
gently pulled back into the start arm and an error is recorded (Figure 22b).  An error is 
also recorded and the mouse is pulled back into the start arm for that trial if the mouse 
fails to enter any arm within 20 seconds or if a mouse enters the platform-containing arm 
but does not find the platform. If the mouse does not find the platform within a 60-second 
trial, it is guided by the experimenter to the platform, allowed to stay for 30 seconds, and 
assigned a latency of 60 seconds. An error is also assigned to any animal that, for any one 
minute trial, does not find the goal arm and refuses to make at least 3 choices on their 
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own during that trial (such as just swimming in a circular pattern). This number of 
‘3-choices’ was calculated by averaging errors for all animals that do not locate the 
platform for Block 1 (day 1 through day 3) on trial 1. Both the number of errors 
(incorrect arm choices) and escape latency were recorded for each daily trial. The number 
of errors prior to locating which one of the 6 swim arms contained the submerged escape 
platform was determined for 5 trials per day. The numbers of errors during trials 4 and 5 
are both considered indices of working memory and are temporally similar to the 
standard registration/recall testing of specific items used clinically in evaluating AD 
patients.   
Following the 8 days of pre-treatment RAWM testing (Figure 23a), the 11 Tg 
mice were divided into two groups, balanced in RAWM performance. The 17 NT mice 
were also divided into two groups, balanced in RAWM performance.  Two weeks 
following pre-treatment testing, one group of Tg mice (n = 5) and one group of NT mice 
(n = 9) were started on a 10-day treatment protocol with GM-CSF (5 µg/day given 
subcutaneously), while animals in the control Tg group (n=6) and control NT group (n = 
8) concurrently received daily vehicle (saline) treatment subcutaneously.  On the 11th day 
of injections, all mice began four days of RAWM evaluation, were given 2 days of rest, 
then evaluated in 4 days of Cognitive Interference task testing.  This task was designed 
measure-for-measure from a Cognitive Interference task used to discriminate normal 
aged, MCI, and AD patients from one another (Echeverria et al., 2009; Loewenstein et 
al., 2004).  This analogous interference task for mice involves two radial arm water maze 
(RAWM) set-ups in two different rooms, each with different sets of visual cues. The task 
requires animals to remember a set of visual cues, so that following interference with a 
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different set of cues, the initial set of cues can be recalled to successfully solve the 
RAWM task. A set of four behavioral measures were examined. Behavioral measures 
were: A1–A3 (Composite three-trial recall score from first 3 trials performed in RAWM 
“A”), “B” (proactive interference measure attained from a single trial in RAWM “B”), 
A4 (retroactive interference measure attained during a single trial in RAWM “A”), and 
“A5”(delayed-recall measure attained from a single trial in RAWM “A” following a 20 
minute delay between A4 and A5). As a distracter between trials, animals are placed in a 
Y-maze and allowed to explore for 60 seconds between successive trials of the three-trial 
recall task, as well as during the proactive interference task. As with the standard RAWM 
task, this interference task involves the platform location being changed daily to a 
different arm for both of the RAWM set-ups utilized, and different start arms for each 
day of testing for both RAWM set-ups. For A1 and B trials, the animal was initially 
allowed one minute to find the platform on their own before they were guided to the 
platform. Then the actual trial was performed in each case. As with the standard RAWM 
task, animals were given 60 seconds to find the escape platform for each trial, with the 
number of errors recorded for each trial. Animals were tested for cognitive interference 
performance on four successive days, with statistical analysis performed for the two 
resultant 2-day blocks.  For both RAWM (combined T4 and T5 overall) and cognitive 
interference testing (each of the four measures overall), swim speed was analyzed by 
dividing error numbers by latency and statistical significance was determined by one-way 
ANOVA followed by post hoc Fisher’s LSD  (least significant difference) test to 
determine significant group differences at p < 0.05. 
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Daily GM-CSF and saline injections were continued throughout the behavioral 
testing period. After completion of behavioral testing at 20 days into treatment, all mice 
were euthanatized, brains fixed in 10% Formalin, and paraffin-embedded. Careful visual 
examination of all tissues upon necropsy revealed no morphological abnormalities, and 
the mice tolerated daily subcutaneous injections well. Each analysis was done by a single 
examiner blinded to sample identities, and statistical analyses were performed by a single 
examiner blinded to treatment group identities. The code was not broken until analyses 
were completed. 
Immunohistochemistry and Image Analysis of Subcutaneous GM-CSF-
treated Mice. Five 5-μm sections (150-μm apart) were made of formalin-fixed, paraffin-
embedded sections throughout the hippocampus of each mouse and immunoreactivity 
was developed using the Vectastain ABC Elite kit (Vector Laboratories, Burlingame, 
CA) coupled with the diaminobenzidine reaction, according to the manufacturer’s 
protocol. Immunostaining used biotinylated anti-Aβ clone 4G8 (Covance, Emeryville, 
CA, 1:200), synaptophysin (DAKO, Carpinteria, CA, undiluted), and Iba1 (Wako, 
Richmond, VA, 1:1000) as primary antibodies. Since the 4G8 antibody was obtained 
with biotin label, the secondary step of the ABC protocol was omitted. However, 
treatment with 70% formic acid prior to the pre-blocking step was necessary. For 4G8 
immunohistochemistry, phosphate-buffered saline (0.1 mM, pH 7.4) was used instead of 
primary antibody or ABC reagent as a negative control. For Iba 1 and synaptophysin 
immunohistochemistry, normal rabbit serum was used instead of primary antibody or 
ABC reagent as a negative control. Images were acquired using an Olympus BX60 
microscope and digital images were quantified using SimplePCI software (Compix Inc., 
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Imaging Systems, Cranberry Township, PA), according to previous methods  (Sanchez-
Ramos et al., 2009).  Briefly, a threshold optical density was obtained that discriminated 
staining from background, and each region of interest was manually edited to eliminate 
artifacts.  Data are reported as percentage of immunolabeled area captured (positive 
pixels) relative to the full area captured (total pixels). To evaluate synaptophysin 
immunoreactivity, after the mode of all images was converted to gray scale, the average 
intensity of positive signals from each image was quantified in the CA1 and CA3 regions 
of hippocampus as a relative number from zero (white) to 255 (black).  
Statistical significance between GM-CSF-treated versus saline-treated groups was 
determined by two-tailed homoscedastic Student’s t-test with a p value of < 0.05 
considered significant.  Each analysis was done by a single investigator blinded to sample 
identities and genotype. 
Results 
 Daily Subcutaneous Injections of GM-CSF. Prior to GM-CSF treatment, 
APPsw (Tg) mice were first confirmed by RAWM testing to be cognitively-impaired for 
working memory (Figure 23a). Both the non-transgenic control mice (NT) and the Tg 
mice were then sub-divided into two cognitively-balanced groups, for either GM-CSF or 
saline treatment. RAWM testing, that began on the 11th day of injections, re-confirmed 
that Tg control mice were substantially impaired compared to NT control mice. This 
impairment was not only evident in individual blocks of testing, but also over all 4 days 
of testing (Figure 23b). In sharp contrast, GM-CSF-treated Tg mice performed equally 
well or better than NT control mice during individual blocks and overall. GM-CSF-
treated NT mice performed as well as or slightly better than NT controls (Figure 23b).  
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  Before evaluation in the Cognitive Interference Task, the mice rested two days, 
while daily injections continued. This task mimics human interference testing, which 
discriminates between normal aged, MCI, and AD patients (Loewenstein et al., 2004).  In 
three of four cognitive interference measures assessed over 4 days of testing (Figure 23c), 
Tg control mice were clearly impaired compared to NT mice, and Tg mice treated with 
GM-CSF exhibited significantly better three-trial recall and delayed recall compared to 
Tg controls. Indeed, for all four cognitive measures, GM-CSF-treated transgenic AD 
mice performed similarly to NT mice. A particularly strong effect of GM-CSF treatment 
in Tg mice was evident for the proactive interference measure during the first half of 
testing (Figure 23d), wherein GM-CSF-treated Tg mice performed substantially better 
than Tg controls and identically to both groups of NT mice.  Including this strong effect 
on proactive interference testing, GM-CSF treatment resulted in significantly better 
performance of Tg mice for all four measures of cognitive interference testing.  Proactive 
interference susceptibility has been reported to be a more sensitive marker for 
differentiating MCI and AD patients from aged normals than traditional measures of 
delayed recall and rate of forgetting (Loewenstein et al., 2004).  Parenthetically, even the 
GM-CSF-treated NT mice showed a trend towards improved cognition in behavioral 
studies, albeit not statistically significant.  Analysis of swim speed for both the RAWM 
and cognitive interference tasks revealed that Tg control mice were significantly faster 
than the other three groups in the RAWM task and for two of four measures in the 
Cognitive Interference task (3-trial recall and delayed recall).  However, since error 
numbers were utilized for statistical analysis of both tasks, this difference in swim speed 
was negated since it is important only if latency measures had been used. 
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Following completion of all behavioral evaluations, subsequent analysis of brains 
from Tg mice of this study revealed that GM-CSF treatment induced large reductions in 
amyloid burdens within entorhinal cortex (↓55%) and hippocampal (↓57%) compared to 
control Tg mice (Figure 24).  The improved cognitive function and reduced cortical 
amyloidosis of GM-CSF-treated Tg mice were paralleled by increased microglial density 
as compared to saline-treated Tg mice (Figure 25), implying an augmented ability to bind 
and remove amyloid deposition (El Khoury et al., 2007; Hickman, Allison, & El Khoury, 
2008). The GM-CSF-treated Tg mice similarly demonstrated increased synaptophysin 
immunoreactivity in both CA1 and CA3 regions (Figure 26), indicating increased 
synaptic area in these hippocampal regions. Prior work has shown that adult neural stem 
cells in hippocampal dentate gyrus (DG) express GM-CSF receptors, and GM-CSF 
increases neuronal differentiation of these cells in a dose-dependent fashion (Kruger, 
Laage, Pitzer, Schabitz, & Schneider, 2007). Thus, one mechanism for the observed 
GM-CSF-induced cognitive improvement is enhanced removal of deposited Aβ in 
hippocampus, with ensuing neuronal growth/synaptic differentiation of DG mossy fiber 
innervation to CA3, resulting in increased innervation/synaptogenesis of Schaffer 
collaterals into CA1. Removal of deposited Aβ from entorhinal cortex may also increase 
perforant pathway viability to hippocampal projection fields in DG and CA1.  
Conclusions. This is the first study that has examined GM-CSF’s effects on 
cognitive function in vivo, and the reversal of pre-determined cognitive impairment gives 
hope that the human recombinant GM-CSF, Leukine (sargramostim) may have the same 
effects in AD patients.  GM-CSF-induced reduction of amyloidosis and enhancement of 
hippocampal/entorhinal cortex circuitry, critical for working (short-term) memory, may 
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underlie GM-CSF’s reversal of working memory impairment in Alzheimer’s Tg mice. 
Furthermore, there may be other mechanisms which are induced by GM-CSF 
administration, both peripherally and in the brain, that contribute to the restoration of 
cognitive function and reversal of AD pathology. The following chapter will discuss 
recent reports of GM-CSF in relation to other neurodegenerative disorders that may shed 
light on additional mechanisms for GM-CSF’s pronounced effects in AD models. 
  
 
Figure 22. Radial Arm Water Maze Task. (a) RAWM non-error. Depiction of mouse 
that has found the submerged escape platform. (b) RAWM error. Depiction of mouse 
performing an error in the RAWM task.   
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Figure 23. Behavioral analysis following daily subcutaneous GM-CSF injections.  
(a)Standard Radial Arm Water Maze Errors Prior to Treatment. The final block and 
overall performance of the Tg and NT mice during 8 days of consecutive daily 
pre-treatment testing in the RAWM maze.  The data were analyzed in four 2-day blocks 
and overall (Blocks 1-4).  (*p < 0.02 or higher significance).  
(b) Standard Radial Arm Water Maze Errors. Tg control mice (n = 6) show 
substantial impairment on working memory trials T4 and T5 compared to NT control 
mice (n = 8) in individual blocks of testing (upper), and over all 4 days of testing (lower). 
GM-CSF-treated Tg mice (n = 5) performed as well as or better than NT control mice on 
working memory trials T4 and T5 during individual blocks and over all. GM-CSF-treated 
NT mice (n = 9) performed similarly to or slightly better than NT controls (Note 
significantly better performance of NT+GMCSF group versus NT group for T4 of Block 
1), although this effect was not significant overall. (**p < 0.02 or higher significance 
versus all other groups; † p < 0.02 or higher significance versus Tg+GM-CSF and 
NT+GM-CSF).  
(c) Cognitive Interference Task. Overall (4 Days) Tg control mice are impaired 
compared to NT mice on all four cognitive measures assessed.  GM-CSF-treated Tg mice 
exhibited significantly better 3-trial recall (A1-A3) and delayed recall (A5) compared to 
Tg controls and performed similarly to NT mice in all four cognitive measures.  GM-CSF 
treatment of NT mice did not result in significantly better performance compared to NT 
controls, although trends for a beneficial GM-CSF effect in NT mice were evident 
overall. (*Tg significantly different from NT+GM-CSF, **Tg significantly different from 
all other groups). 
 (d) Cognitive Interference Task. Proactive Interference Testing (First 2 days). 
GM-CSF-treated Tg mice performed significantly better than Tg controls and equally to 
NT and GM-CSF-treated NT mice.  
 
 
Figure 24. Amyloid Deposition in Subcutaneous GM-CSF-injected Mice. (a-d) 
Photomicrographs of coronal 5-µm paraffin-embedded sections immunolabelled with 
anti-Aβ antibody (clone 4G8) in Entorrhinal cortex (E) and hippocampus (H)).  Pictures 
are representative of amyloid load closest to the mean of the GM-CSF- or saline-treated 
Tg groups. Scale bar = 50 µm. 
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Figure 24. Amyloid Deposition in Subcutaneous GM-CSF-injected Mice (continued). 
(e) Percent of amyloid burden from the average of five 5-μm sections (150-μm apart) 
through both anatomic regions of interest (hippocampus and entorhinal cortex) per mouse 
of GM-CSF-treated (n = 5) versus saline- treated (n = 6). Entorhinal cortex (*p  < 0.026), 
and Hippocampus (p = 0.12).  
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Figure 25. Microglial Immunostaining in Subcutaneous GM-CSF-injected Mice.  
(a-d) Photomicrographs of coronal 5µm paraffin-embedded sections immunolabelled 
with Iba-1 antibody in Entorrhinal cortex (E) and hippocampus (H). Pictures are 
representative of Iba-1 immunolabelling closest to the mean of the GM-CSF- or saline 
control- treated groups. Scale bar = 50µm. 
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Figure 25. Microglial Immunostaining in Subcutaneous GM-CSF-injected Mice 
(continued). (e) Percent of Iba1 burden from the average of five 5-µm sections (150 µm 
apart) through both anatomic regions of interest (H and EC) per  mouse of GM-CSF-
treated (n = 5) versus saline-treated (n = 6).   H(p  < 0.02), EC(p  < 0.05). 
 
  
 
 
 
Figure 26. Synaptophysin Immunostaining in Subcutaneous GM-CSF-injected 
Mice.  (a-d) Photomicrographs of coronal 5-µm paraffin-embedded sections 
immunolabelled with anti-synaptophysin antibody. Pictures are representative of 
synaptophysin immunolabelling closest to the mean of the GM-CSF- or saline control- 
treated groups. Scale bar = 50 µm. 
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Figure 26. Synaptophysin Immunostaining in Subcutaneous GM-CSF-injected Mice 
(continued). (e) Percent of synaptophysin immunoreactivity from the average of 5 
sections per mouse of GM-CSF-treated (n = 5) versus saline control-treated (n = 6). 
CA1(p  < 0.0013), CA3(p  < 0.0023). 
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CHAPTER 6 – DISCUSSION 
Introduction 
The disappointing results from NSAID clinical trials prompted us to consider 
immunological factors within RA pathogenesis as being protective against AD onset. 
Since it appeared most likely that cellular effects and not fluid-phase factors would 
account for RA’s protective effect, we decided to induce leukocyte populations within Tg 
AD mouse models to study whether these induced leukocytes would have effects against 
cerebral amyloidosis, which these PS/APP mice begin accumulating at about 6 months of 
age. There are three major hematopoietic factors (M-CSF, G-CSF, GM-CSF) which 
contribute to most of the pathogenic leukocytosis in RA, and under disease and 
non-disease conditions, they are known to contribute to specific peripheral innate cellular 
phenotypes. For instance, G-CSF induces granulocytic leukocytes, which are the most 
abundant type, usually constituting over half of all circulating leukocytes. On the other 
hand, M-CSF induces the differentiation of monocytic precursors towards macrophage 
phenotypes, although M-CSF can also contribute to other cellular types, such as 
osteoclasts and Myeloid Derived Suppressor Cell (MDSC) populations. Macrophages are 
usually characterized as either an M1 phenotype, in which they are classically activated 
by microbial infection and drive a T-helper (Th)-1 response,  or as an M2 phenotype,  in 
which they are described as alternatively activated and considered to be 
immunosuppressive, driving a Th-2 reponse. Although considered immunosuppressive, 
M2 macrophages also contribute to disease, such as in tumor-associated macrophages 
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(TAMs) which drive angiogenesis and tumor development (Mantovani, Sozzani, Locati, 
Allavena, & Sica, 2002; Murdoch, Muthana, Coffelt, & Lewis, 2008).   
Since peripheral leukocyte populations are greatly increased in RA and possess 
the ability to infiltrate into the brain, we wanted to differentially express each leukocyte 
phenotype by M-CSF, G-CSF, or GM-CSF induction after direct administration of these 
CSFs into the brain, in order to determine which CSF might most affect amyloidosis. In 
the vasculature, all three CSFs work to drive the proliferation, differentiation, and 
survival of their respective innate leukocytes from monocytic precursors (see Figure 3) 
and we hypothesized that they might also have similar differential effects on microglial 
populations.  
Chronology of Initial Experiments 
In our studies, we initially began with the investigation of M-CSF administration 
into the brains of Tg AD mice. In the beginning of 2007 at the time of these experiments, 
the literature suggested that a deficiency of M-CSF in osteopetrotic mice could cause a 
deficit in microglial populations, neuronal loss, and an accumulation of cerebral amyloid 
plaques (Kaku et al., 2003; Kawata et al., 2005).  Also, at that time, there was no guiding 
literature to suggest dosage amounts for intracerebral administration of M-CSF. Thus we 
decided to maximize the dosage through continuous bilateral intracerebroventricular 
infusion for two weeks using our newly-developed osmotic catheter system (Chapter 3 
and Appendix A). Subsequent immunohistochemical analyses of the plaque burden in the 
mice revealed significant unexpected variations of amyloidosis between mice of the same 
genotype and of similar age (Figures 5, 6). Furthermore, there was concern whether M-
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CSF was able to readily extravasate from the ventricles and into the brain’s parenchymya 
in order to induce an effect on amyloidosis.   
Meanwhile, we had contacted Dr. Kaku to request his expertise for M-CSF 
dosage amounts. Although he could not provide guidance for dosage, he did inform us 
that subsequent studies had shown that the antibody, in which he used for his 2003 study, 
was non-specifically immunolabeling some blood cells, and that they could not confirm 
amyloidosis in osteopetrotic mice. Moreover, a coinciding report was soon published by 
another group, which confirmed that although there was a deficiency in microglial 
density, there was no amyloid deposition or loss of dopaminergic neurons in osteopetrotic 
mice (Kondo, Lemere, & Seabrook, 2007).  
Although these results with M-CSF were contrary to our initial thoughts, we 
nevertheless wanted to investigate each CSF’s effects within the brain’s parenchyma in 
relation to already-formed amyloid deposition.  Our subsequent work with the 
development of the osmotic bilateral catheters had revealed that infused recombinant 
proteins remained localized into the respective brain hemisphere of which they are 
administered. Thus, we decided to perform intrahippocampal injections of each 
recombinant CSF protein into one hemisphere of the brain, and inject vehicle control 
contralaterally.  
Bilateral Infusion Catheters 
Our findings with the development of the bilateral catheter system has several 
important implications, not only in our work, but broadly for other future studies of 
intracerebral delivery of materials into murine models. We were the first to bilaterally 
infuse recombinant peptides and to show that the infused recombinant proteins remain 
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localized to the hemisphere in which they are infused. This concept will effectively 
reduce the number of animals that are needed for these types of experiments, since each 
animal can now be its own control and allow for comparisons of treatment or injury from 
one hemisphere of the brain versus the other. This effect will provide great cost benefit to 
researchers who will now have more flexibility in selecting murine cohorts, since they 
will no longer need age-matched controls. To further this idea of cost-effectiveness, the 
ability to infuse compounds, biologicals, etc. into one hemisphere and not the other, can 
provide for conditional transgenic models ipsilaterally versus control contralaterally, as 
we showed with replication of the triple transgenic PS/APP/ACT model in one 
hemisphere versus doube transgenic PS/APP in the other (Figures 10 - 12). As is widely 
known, a large amount of breeding, genotyping, housing, and other costs of animal 
husbandry are incurred when going from double to triple transgenicity.  
Other significant benefits are also provided by the develoment of the bilateral 
catheters. For instance, in the commercially-available Alzet® delivery system, the 
catheter head is not only too large in diameter to place two of these upon a mouse’s skull, 
it is also too thick, in that closure of the scalp after placement is difficult, if not 
impossible sometimes. Furthermore, the catheter tubing sometimes protrudes outside of 
the skin. In all of these cases, there is obvious discomfort to the animal, and the animals 
are known to scratch at the tubing and catheter head, as well as rubbing them against the 
housing cage. As a result, it can be logically-assumed that stress hormone levels are 
chronically-affected during the course of these trials, and that there is chronic 
inflammation in the open wound, as the mice will oftentimes scratch their entire scalp off. 
Both of these issues may compromise an experiment, contribute to mortality, cause 
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discomfort to the animal, increase research costs for the investigator, and possibly skew 
results due to the intrinsic immunological effects from this catheter pathology. Our 
bilateral catheter system is adhered directly in contour and upon the skull, so that the skin 
can readily close with sutures, staples, or skin adhesive and can then heal with new fur 
and absence of inflammation (Figure 9). The mice tolerate these catheter extremely well, 
and have significant reductions in mortality rate (almost non-existent). Furthermore, these 
animals, once healed in a couple of weeks, can be used in water-based behavioral tasks, 
such as the Morris or RAWM. We hope that these improvements to the current methods 
of intracerebral infusions will become standard protocol for these types of experiments in 
all research vivariums around the country. 
Thus, using our gained knowledge from the catheter development, we injected 
each CSF unilaterally into one hippocampus and vehicle contralaterally. Upon 
subsequent examination of the brains one week post-injection, we found different 
functional effects for each intrahippocampal-injected CSF. In the M-CSF injected mice, 
there was no effect on amyloidosis, but pathological changes were noticed, such as 
swelling and hyperplasia (Chapter 4). Parenchymal overexpression of M-CSF in any 
organ is probably not advisable as overexpression of M-CSF and/or its receptor within 
mammary glands has similarly resulted in tumor formation and hyperplasia (Kirma et al., 
2004). We also examined several microglial markers in each CSF-treated group of mice, 
such as Iba-1, CD68, CD11b, CDllc, F4/80, and CD45 (results not shown). However, we 
did not find any differences with any of the microglial stainings between each brain 
hemisphere, except for differences in microglial density which directly correlated with 
the amyloid plaque burden, as the microglia were found to abundantly decorate the 
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plaques. Interestly, the mice in our study do not get NFTs, but in a recent study of 
post-mortem human brains of various age and neuropathology (Streit, Braak, Xue, & 
Bechmann, 2009), microglia are shown to be dystrophic and extremely fragmented 
around degenerating neurons with tauopathy, such as neuropil threads, NFTs, and neuritic 
plaques. However, the microglia in non-diseased brains, and the microglia in DS and AD 
brains,which are colocalized with amyloid deposition, are shown to be fully ramified and 
non-activated, while the microglia in patients with systemic infectious disease were found 
to hypertrophic and activated, even in absence of identifiable CNS disease. Furthermore, 
the dystrophic microglial phenotypes preceded tau pathology, according to Braak staging 
of AD neuropathology, indicating that microglia normally play an important role in 
neuroprotection, and that a decline in their populations within the brain may contribute to 
onset of AD. 
M-CSF and AD 
Although we did not find any difference in amyloidosis from intrahippocampal 
injections of M-CSF, a recent study, reported that chronic intraperitoneal (i.p.) injection 
of M-CSF into Tg AD mice expressing  GFP+ bone marrow prevents and reverses 
amyloid deposition and cognitive impairment, while inducing a large accumulation of 
GFP+ bone marrow-derived microglia into the brain (Boissonneault et al., 2009). The 
authors also confirmed previous research (Simard, Soulet, Gowing, Julien, & Rivest, 
2006) that  bone marrow-derived microglia efficiently phagocytose and internalize Aβ. 
However, differences between these data and ours point directly to different study 
lengths, route of administration, and dosage effects, with Boissonneault et al. delivering 
153 
peripheral chronic 1.3µg M-CSF per i.p. injection, as compared to our 5µg 
intrahippocampal bolus. 
Another recent study has also revealed that M-CSF has significantly diminished 
levels in AD patients, and that M-CSF may have diagnostic potential within an AD 
biomarker panel (Britschgi & Wyss-Coray, 2008; Ray et al., 2007).  This same group also 
investigated whether M-CSF administration would improve AD pathology in vivo. They 
found that  i.p. injection of M-CSF into 7-8 month old APP transgenic mice 
(Thy1-hAPP), tested 10 months later, had improved performance in the Morris water 
maze (Luo J., 2008). Interestingly, there were no changes in microglial activation, or 
levels of soluble and insoluble Aβ levels in the brains. Moreover, i.p injection of M-CSF, 
one day prior to kainite administration, prevented neurodegeneration and microgliosis, 
but did not change microglial density.  
Although these different authors did not relate their findings to RA’s inverse 
relationship with AD, their data does provide evidence that up-regulated M-CSF in RA 
pathogenesis and systemic administration of M-CSF in AD patients may both impart 
protection against AD onset or progression. Although the authors have proposed M-CSF 
as a curative therapy against AD (Boissonneault & Rivest, 2009), M-CSF’s activation of 
mature osteoclasts, macrophages, and other innate leukocytes, its induced 
thrombocytopenia (Hubel, Dale, & Liles, 2002; Nemunaitis et al., 1991; Nemunaitis et 
al., 1993; Zeigler, Rosenfeld, Nemunaitis, Besa, & Shadduck, 1993), and its autocrine 
signaling in some tumors (Patsialou et al., 2009) may limit it’s usefulness in the clinical 
setting. 
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G-CSF and AD 
While our study of intrahippocampal administration of G-CSF showed only a 
modest reduction in amyloid burden after one week post-injection (Figure 18), other 
studies have shown greater effects against AD pathology from chronic peripheral 
administration (Sanchez-Ramos et al., 2009; Tsai, Tsai, & Shen, 2007). In the recent 
study by Sanchez-Ramos et al. (2009),  the authors used PS/APP mice which had been 
lethally-irradiated and transplanted with GFP+ bone marrow at 2 months of age. At 6 to 8 
months of age, the GFP+ mice showed a significant increase in bone marrow-derived 
microglia which corresponded with about 40% amyloid reductions. A second cohort of 
aged predetermined cognitively-impaired mice, which were treated chronically for only 
2.5 weeks with G-CSF, demonstrated restoration of cognitive function to about half of 
the difference in errors between the Tg and age-matched control group. This partial 
reversal of cognitive deficit correlated with decreased amyloid burden,  increased 
microglial density, increased neuronal synaptic area, and increased neurogenic markers. 
The prior study by Tsai et al. (2007) had also subcutaneously administered G-CSF into 
Tg AD mouse models and observed some rescue of cognitive function, which correlated 
with increased neurogenic staining and with increased expression of the neurotransmitter, 
acetylcholine.  As with M-CSF, these results were not associated with RA’s protective 
role against AD, but the increased ameliorative effects of both M-CSF and G-CSF from 
peripheral adminstration versus intracerebral administration is consistent with the 
observation that RA, a peripheral disease, can prevent onset of AD, a CNS disease.  
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GM-CSF and AD 
Although the G-CSF intrahippocampal findings were encouraging, our GM-CSF 
intrahippocampal injections into an AD mouse model demonstrated a much more 
pronounced reduction of amyloidosis (Figures 19 – 21). These data led us to further 
examine GM-CSF on the behavior of aged cognitively-impaired AD mice. Daily 
subcutaneous administration of GM-CSF for 20 days resulted in nearly complete reversal 
of cognitive impairment, resulting in function similar to that of wild-type mice, with a 
corresponding average of about 50% reduction of amyloidosis in Entorrhinal cortex and 
Hippocampus. In contrast, M-CSF and G-CSF were shown to only partially reverse 
cognitive impairment in aged AD mice, although the preventative chronic study of M-
CSF administration into young AD mice showed equal cognitive function over time 
compared to wild-type controls. One explanation for this increased benefit with GM-CSF 
could be due to GM-CSF’s overlapping functions of both M-CSF and G-CSF, resulting in 
a combinatory effect of increased macrophage and granulocyte populations derived from 
bone marrow-derived monocytic precursors in the periphery, as well as induction or 
activation of other innate leukocyte subsets in both the periphery and brain. Indeed, GM-
CSF has been shown to cross the blood brain barrier (McLay, Kimura, Banks, & Kastin, 
1997), and a recent study showed that GM-CSF injected into the brains of normal mice 
activates microglia (Reddy et al., 2009). As mentioned in Chapter 2 (Malm et al., 2005), 
only after LPS injection into the hippocampi of the 25-month-old aged mice with 
established amyloid burden, did reductions in amyloidosis and recruitment of BMDCs 
occur, as opposed to the 21-month-old non-treated and normally aged Tg mice. A 
following study also showed that LPS activation of microglia was able to reduce 
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amyloidosis, possibly through a mechanism of LPS-induced up-regulation of CR3 
(CD11b) (Herber et al., 2007). Thus GM-CSF may function to have a role in both the 
activation of resident microglia, and also in the recruitment of BMDCs to the brain.   
 There may also be further explanations for the very robust cognitive benefits of 
GM-CSF, including significant reductions in amyloidosis (Figure 24), increased neuronal 
plasticity (Figure 26), augmentation of peripheral erythropoietic amyloid-clearance 
mechanisms by increasing CR1 availability (Fisher, 2003; Helmy et al., 2006; Rogers et 
al., 2006), increased cerebral angiogenesis (U. C. Schneider et al., 2007), neuroprotection 
from apoptosis (Schabitz et al., 2008) and increased neurogenesis (Kruger, Laage, Pitzer, 
Schabitz, & Schneider, 2007). These effects may also help explain some of the benefits 
against AD that were desribed in the M-CSF and G-CSF studies. All three CSFs in the 
periphery function in the mobilization, proliferation, and differentiation of innate 
leukocyte populations, but G-CSF and GM-CSF are known to have additional roles in the 
CNS. Following is a more detailed description of these putative effects for all three CSFs. 
Angiogenic Functions of CSFs in the AD Brain 
Introduction. All three CSF’s, when given peripherally, result in the reduction of 
amyloid plaques within the brain. This may be due to the increased leukocyte populations 
that contain receptors, such as CR3 or CR4, which may aid in the phagocytosis of 
complement-bound amyloid, or by the secretion of proteases from the bone 
marrow-derived microglia, which may then proteolytically degrade the plaques. The 
exact mechanisms are not completely known, just that the plaques are decreased and that 
there is an influx of bone marrow-derived microglial cells which decorate the plaques. 
Since Aβ itself has been shown to be anti-angiogenic (Paris et al., 2010; Patel et al., 
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2010), the removal of amyloid plaque would thus remove this inhibition of angiogenesis 
and allow for neovascularization, which would in turn allow for increased cerebral blood 
flow and aid in the availability of more erythrocytes and leukocytes to the brain for 
further plaque clearance and delivery of oxygen and glucose. Much research within the 
field of tumor biology has shown the ability of innate leukocytes to play a central role in 
angiogenesis. Thus it would be logical to presume that neovascularization occurs 
simultaneously with amyloid removal, given that the same myeloid-derived leukocytes 
participate in both roles.  
Angiogenic Mediators. There are several studies that show that various 
mediators of angiogenesis are found in the AD brain, implying a need and attempt of the 
brain for neovascularization, although this effort is intrinically stymied in AD, and 
aberrant vascular protrusions emanate from the ends of truncated and occluded vessels 
around plaques (Figure 1). For instance, angiopoietin-2 and VEGF are expressed in AD 
microvessels, but are not in control microvessels (Thirumangalakudi, Samany, Owoso, 
Wiskar, & Grammas, 2006). However, the tissue inhibitors of matrix metalloproteinases 
(TIMP)-1,2 are also up-regulated in the AD microvessels and in amyloid plaques 
(Lorenzl et al., 2003; Peress, Perillo, & Zucker, 1995), while matrix metalloproteinase 
(MMP)-9 activity, which the TIMPs regulate, is undetectable (Thirumangalakudi et al., 
2006).  MMPs play a crucial role in promoting angiogenesis by degrading the 
extracellular matrix (Bergers et al., 2000; Coussens, Tinkle, Hanahan, & Werb, 2000). 
Studies in PS/APP mice show that MMP-9 and other Aβ-degrading enzymes, such as 
insulysin and neprilysin, as well as Aβ-binding receptors, such as scavenger receptor A 
(SRA), CD36, and receptor for advanced-glycation endproducts (RAGE), are all 
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decreased with age (Hickman, Allison, & El Khoury, 2008). Thus the increase of innate 
leukocytes, which contain these receptors and proteases, could help remove the plaque 
and normalize angiogenic mechanisms, that otherwise have both pro-angiogenic and 
anti-angiogenic factors being simultaneously produced in AD microvasculature. 
Macrophages. Macrophages are very versatile, multifunctional cells that can 
adapt their functions to the environment in which they reside. As mentioned earlier, they 
are usually classified at either M1 or M2 phenotypes. The LPS-induced clearance of 
amyloid (Herber et al., 2007; Malm et al., 2005) could well have been from M1 types of 
microglia, which would also induce angiogenic Cox-2 expression within them 
(Hoozemans et al., 2001). In tumors associated macrophages (TAMs), these macrophages 
obtain an M2-like phenotype that also promotes angiogenesis through the release of 
pro-angiogenic factors, such as VEGF, basic fibroblast growth factor (bFGF), TNFα, 
IL-1β, IL-8, COX-2, plasminogen activator, urokinase (uPA), platelet derived growth 
factor β (PDGFβ), and MMPs-7,-9, and -12 (Reviewed in (Dirkx, Oude Egbrink, 
Wagstaff, & Griffioen, 2006)). TAMs are chemotaxically-attracted to areas of hypoxia, 
where they up-regulate HIF-related genes, such as VEGF and NFκB, which in turn skews 
them into their M2 phenotype (Hagemann et al., 2008). Furthermore, recent studies have 
shown that under sustained stimulation of angiogenic growth factors, that monocytes are 
able to transdifferentiate into endothelial cells (Fernandez Pujol et al., 2000; Kuwana et 
al., 2006).  
Another  specific subpopulation of circulating monocytes, which have much more 
potent pro-angiogenic activity, are identified through their expression of the angiopoietin 
receptor, TIE2 (Venneri et al., 2007). These TIE2-expressing monocytes (TEMs) have 
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been found to reside in both perivascular and hypoxic, avascular areas of tumors (De 
Palma et al., 2005; Venneri et al., 2007), and although TEMs have not been identified in 
AD, its ligand, angiopoietin-2 is specifically expressed in the AD (Thirumangalakudi et 
al., 2006) truncated, and occluded microvasculature, thus implying that there may indeed 
be potential involvement of TEMs in the dysregulated vasculogenic activity surrounding 
amyloid plaques. 
Myeloid-Derived Suppressor Cells. Another group of pro-angiogenic leukocytes 
are the myeloid-derived suppressor cells (MDSCs), a heterogeneous group of immature 
precursor cells for neutrophils, monocytes, and dendritic cells (DCs). MDSC populations 
are upregulated by COX-2, prostaglandins, stem-cell factor (SCF) (Pan et al., 2008; 
Serafini et al., 2004; Sinha, Clements, Fulton, & Ostrand-Rosenberg, 2007), VEGF 
(Gabrilovich et al., 1998), IL-6, M-CSF (Bunt et al., 2007), and GM-CSF (Serafini et al., 
2004). While MDSCs are precursors cells either resembling an immature neutrophil 
phenotype (characterized as CD11b+Gr1hi) or an immature monocyte phenotype 
(characterized as CD11b+Gr1low) (Movahedi et al., 2008; Sawanobori et al., 2008), they 
are potently immunosuppressive as opposed to mature neutrophils and macrophages. 
Thus MDSCs are of great interest in cancer research, since they suppress immune 
activation against tumors, and because they contribute to angiogenesis via high 
expression of MMPs (Yang et al., 2004; Yang et al., 2008). Therefore in M-CSF and 
GM-CSF treated AD mice, it could be hypothesized  that the induced MDSCs could 
release MMPs into the vasculature around the plaques and which may counteract the 
overexpressed TIMPs, thus allowing unobstructed VEGF and angiopoietin2 vasculogenic 
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effects. However, there are no studies yet that have examined MDSC activity in Tg AD 
mice, following peripheral administration of GM-CSF or M-CSF.  
Neutrophils. Like their precursor MDSCs, neutrophils are also pro-angiogenic by 
their high expression of MMP-9 (Coussens et al., 2000), and studies show that their 
number correlates with the microvessel density within tumors (Benelli et al., 2002; 
Mentzel et al., 2001; Van Coillie et al., 2001). Furthermore, neutrophils do not express 
TIMPs, allowing them to rapidly promote angiogenesis by uninhibited release of MMP-9 
(Ardi, Kupriyanova, Deryugina, & Quigley, 2007). Factors, such as TNFα and GM-CSF 
cause the neutrophils to de-granulate and release intracellular stores of pro-angiogenic 
chemokines, CXCL1 and CXCL8, and MMP-9 (Cassatella, 1999). Neutrophils, although 
the most abundant phagocytic leukocyte, are also the shortest lived, with a half-life of 
within 24 hours from leaving the bone marrow before undergoing apoptosis (Cohen, 
1991). In DS patients, neutrophil survival is shortened by up to 30% compared to non-DS 
individuals, implying the DS patients may have even more anti-angiogenic mechanisms 
than those described in Chapter 1. Interestingly, GM-CSF and IL-5 could prevent 
apoptosis in the neutrophils of control individuals, but not in neutrophils from DS 
patients (Yasui, Shinozaki, Nakazawa, Agematsu, & Komiyama, 1999). The 
administration of G-CSF and GM-CSF into AD mice would have pro-angiogenic effects 
through induced expression of neutrophil populations by both G-CSF and GM-CSF, but 
GM-CSF administration may also sustain the neutrophil populations against apoptosis 
longer, providing for increased angiogenic and phagocytic acitivity. 
Dendritic Cells. Dendritic cells, the major antigen-presenting cells of the body 
which are critical in the regulation of the adaptive immune response,  also play a major 
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role in angiogenesis, as immature DCs (iDCs) release TNFα and CXCL8, which triggers 
other cells, like neutrophils, to secrete their various angiogenic growth factors (Caux et 
al., 1994).  iDCs release other factors, such as osteopontin, which has increased 
concentrations in the cerebrospinal fluid of AD and triggers the release of IL-1β (Comi et 
al., 2010; Wung et al., 2007), a highly angiogenic cytokine (Naldini et al., 2006). 
Cytokines, such as VEGF (Dikov et al., 2001; Laxmanan et al., 2005), hepatocyte growth 
factor (HGH) (Okunishi et al., 2005), TGFβ (Alard, Clark, & Kosiewicz, 2004), 
prostaglandin E (Pockaj et al., 2004), and osteopontin (Konno et al., 2006) suppress DC 
maturation and contribute to the maintenance of this pro-angiogenic iDC phenotype .  
Conclusion. Given the angiogenic potential of all of the innate leukocytes 
described above, and the increased cerebral blood flow that would result from 
neovascularization, it would be expected for these hematopoietic growth factors, M-CSF, 
G-CSF, and GM-CSF, to have therepeutic effects in ischemic diseases. While M-CSF has 
not been shown to be a potential therapeutic for treatment of stroke, both G-CSF and 
GM-CSF have undergone investigation in various models of ischemia. In an experimental 
model of cerebral focal ischemia, G-CSF injections up to 3 days post-infarct, was 
demonstrated to enhance angiogenesis, with increased vascular surface area, vascular 
branching, de novo endothelial cell proliferation, and eNOS/angiopoietin-2 expression, as 
compared to PBS control injected rats (Lee et al., 2005). Although, there have not been 
any further experimental cerebral ischemic studies performed with G-CSF which have 
reported on neovascularization, G-CSF has been shown in a small clinical trial of 5 
patients who received G-CSF after acute myocardial infarction (AMI), as compared to 5 
control patients, that six days of daily G-CSF treatment increased the vascular growth 
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factors, VEGF, bFGF, and MCP-1, while improving ejection fraction and myocardial 
perfusion and function (Kuethe et al., 2006).  
GM-CSF, on the other hand, has been shown to induce neovascularization in 
several models of experimental stroke. In a rat model of vertebral plus left carotid artery 
occlusion, s.c. administration of GM-CSF over a course of 3 weeks significantly 
increased arteriogenesis and functional hemodynamic measurements, via up-regulated 
macrophage populations in the posterior cerebral artery, as compared to saline-treated 
animals (Buschmann, Busch, Mies, & Hossmann, 2003). Two similar follow-up studies 
by this same group showed similar induction of arteriogenesis by GM-CSF injections 
following variations of experimental hypoperfusion in rat brain (Hossmann & 
Buschmann, 2005; Schneeloch, Mies, Busch, Buschmann, & Hossmann, 2004). Other 
groups have also subsequently shown that GM-CSF treatment completely restores 
cerebral blood flow following bilateral carotid artery occlusion (BCO) (U. C. Schneider 
et al., 2007) and restores leptomeningeal collaterals following common carotid artery 
(CCA) occlusion (Todo et al., 2008). 
Although G-CSF and GM-CSF have shown some utility in stroke models for the 
restoration of cerebral blood flow and neovascularization, they have yet to be described 
with the same effects in Tg AD mice. A very fine analyses of the microvessels would be 
needed to examine whether chronic administration of these CSFs over time would 
prevent the buildup of  amyloid deposits on the parenchymal side of the vessels before 
they progress to the large deposits and severly damaged cerebrovasculature, as seen in 
Figure 1, as well as whether the microvasculature can be repaired by the CSFs after the 
removal of amyloid deposition in aged mice. Further studies, using VCC models and with 
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chronic versus acute delivery of the CSFs, will be needed to closely examine these effects 
of innate leukocytes. 
Neuroprotective Functions of CSFs in the AD Brain 
 GM-CSF. Many of the experiments with stroke models have also found the CSFs 
to be neuroprotective after induced ischemia. A rat model of middle cerebral artery 
occlusion (MCAO) of 1 hour duration, in which an intracarotid injection of GM-CSF or 
saline upon reperfusion was administered and in which the study animals were assessed 2 
days later, showed improved neurological function in the GM-CSF-injected rats, and 
their subsequent immunohistochemistry revealed a reduction in infarct volume, an 
increase of activated microglia or macrophages, and a decrease of apoptotic cells in the 
penumbra surrounding the infarct, as compared to saline injected rats (Nakagawa, Suga, 
Kawase, & Toda, 2006). A following study examined the neuroprotective pathways that 
GM-CSF induces within two stroke models of MCAO and MCA. In this study, the 
authors identified the alpha-chain of the GM-CSF receptor (GM-CSFR), and showed 
GM-CSFR to be up-regulated after ischemia, with it broadly expressed throughout the 
brain, and with it localized on primary cortical neurons, and oligodendrocytes, as well as 
on human neuroblastoma cells.  The authors also found that GM-CSF counteracts 
apoptotosis via the induction of the phosphatidylinositol 3 kinase (PI3K)-Akt pathway, 
and by induction of the anti-apoptotic proteins Bcl-2 and Bcl-xL, as well as increasing 
intraparenchymal and leptomeningeal arterioles (Schabitz et al., 2008).  Another MCAO 
study, combining a glutamate-induced excitotoxicity neuronal injury cell culture model, 
showed similar alterations of apoptotic related genes and found GM-CSF to be 
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neuroprotective, with decreased infarct volume and improved locomotor function in 
GM-CSF-treated rats versus controls (Kong et al., 2009). 
G-CSF. Although G-CSF has only one study examining neovascularization in 
experimental ischemic models (Lee et al., 2005), it has been extensively studied since 
2003 for its neuroprotective roles after cerebral ischemia. G-CSF has also been shown to 
protect against glutamate-induced neurotoxicity (Han, Blank, Schwab, & Kollmar, 2008; 
Schabitz et al., 2003), to have induced expression following ischemia (Hasselblatt, 
Jeibmann, Riesmeier, Maintz, & Schabitz, 2007; Kleinschnitz, Schroeter, Jander, & Stoll, 
2004), to reduce infarct volume and improve function after transient focal ischemia 
(Gibson, Bath, & Murphy, 2005, 2010; A. Schneider et al., 2006) and intracebral 
hemorrhage (Park et al., 2005), and to induce the expression of anti-apoptotic proteins 
and pathways (Komine-Kobayashi et al., 2006; Solaroglu, Cahill, Tsubokawa, 
Beskonakli, & Zhang, 2009; Solaroglu, Tsubokawa, Cahill, & Zhang, 2006; Yata et al., 
2007).  
M-CSF. While M-CSF has not been reported to be used therapeutically in stroke 
models for neovascularization or neuroprotection, its receptor, M-CSFR (also known as 
c-fms) has been reported to be neuroprotective when overexpressed in a microglial-
hippocampal oganotypic coculture system, in which microglia overexpressing M-CSFR 
rescued neurons from excitoxicity (Mitrasinovic et al., 2005).  A similar follow-up study 
using the same coculture system, found that M-CSF treatment prevented NMDA-induced 
apoptosis (Vincent, Robinson, Simsek, & Murphy, 2002). Cultured microglia 
overexpressing M-CSF exhibited enhanced phagocytosis of Aβ (Mitrasinovic & Murphy, 
2002) and postmortem analyses of AD patients have increased expression of M-CSFR on 
165 
microglia (Akiyama et al., 1994), although M-CSF levels itself are decreased in AD 
patients (Ray et al., 2007). However, as mentioned above, its side effects limit its 
usefulness in the clinical setting. 
Neurogenic Functions of CSFs in the AD Brain 
Both GM-CSF and G-CSF have been reported to have neurogenic capabilities. 
The human analogues to both have been FDA-approved since early 1990’s for the 
mobilization and collection of peripheral blood stem cells (PBSCs) for transplantation 
(Reviewed in (Hubel et al., 2002)).  As was discussed in Chapter 2, bone marrow-derived 
cells have the ability to enter the brain and become neuronal or other types of brain cells. 
However, GM-CSF and G-CSF can both cross the BBB, as well as be secreted by 
neurons and oligodendrocytes. Not only do these neuronal cell types contain receptors for 
each CSF (Schabitz et al., 2003; Schabitz et al., 2008), neural stem cells (NSCs) have 
also been shown to contain receptors for both (Kruger et al., 2007; A. Schneider et al., 
2005), and binding of either CSF to their respective receptor on NSCs induces time and 
dosage dependent proliferation and subsequent differentiation. A recent report examining 
both bone marrow-derived neuronal progenitors versus brain-derived NSCs found that 
the brain-derived NSCs have a higher capacity for proliferation (Song, Song, Zhang, 
Cuevas, & Sanchez-Ramos, 2007), although both neuronal progenitors types would be 
expected to be involved from peripheral adminstration of the CSFs. In fact the recent 
study by fellow investigators show parenchymal incorporation of bone marrow-derived 
neurons after G-CSF peripheral administration (Sanchez-Ramos et al., 2009). Although 
our studies were not conducted in a manner to examine this effect, it is also expected that 
bone marrow-derived neuronal cells were present within our study, given that GM-CSF 
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induction encompasses both bone marrow-derived macrophage and granulocyte subsets 
of leukocytes, which have independently been shown to become neuronal and glial cells 
following their respective peripheral CSF induction . 
Research Theory Summary 
To restate our theory of what is needed to inhibit and reverse AD pathology, there 
must first be simultaneous strategies to remove the cerebral amyloidosis and to provide 
neuroprotection to the micro-penumbras that surround the plaques and occluded vessels. 
We have shown a remarkable reduction in plaque burden from GM-CSF after just one 
week following intrahippocampal administration, and then similarly by 20 days of 
subcutaneous delivery. Although, G-CSF had modest effects intrahippocampally, and M-
CSF did not, other researchers have shown significant reversal of amyloidosis from 
peripheral administration. Additionally, many studies that have also shown each CSF to 
have neuroprotective properties, which actions would simultaneously be needed in the 
penumbras around the amyloid plaques as the plaques are being cleared. 
Next after removal of amyloid, we theorized that there must be strategies to 
immediately induce neovascularization in the infarcted areas where the plaques were 
located and to also induce neuritogenesis and/or neurogenesis to rebuild the neural and 
vascular networks in order to restore cognitive function. While we did not have 
appropriate models to examine neovascularization, many other models and studies have 
shown both GM-CSF and G-CSF to be highly pro-angiogenic. Other studies have also 
shown both of these CSFs to also be neurogenic to NSCs, as well as to be peripheral 
blood progenitor cell mobilizers. Furthermore, it has been found that neurogenesis and 
neovascularization occur simultaneously with the same cues guiding each together. Thus 
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with both G-CSF and GM-CSF showing increased synaptic area, with G-CSF showing 
evidence of induced neurogenesis, and with all three CSF’s demonstrating reversal of 
cognitive deficits, all aspects of our theory are explained by intrinsic mechanisms of 
RA’s leukocytic pathogenesis. Furthermore, with GM-CSF’s pronounced effects over 
such a short period of time, we are encouraged that the recombinant human GM-CSF will 
show similar effects in AD patients.  
Clinical Implications 
Our results mirror those reported for G-CSF (Sanchez-Ramos et al., 2009), and 
supports the current practice of interchangeable prescription of either recombinant human 
GM-CSF (Leukine) or G-CSF (Granocyte, Neupogen, and Neulasta) into patients with 
depressed bone marrow function. G-CSF primarily treats neutropenia while GM-CSF 
treats all leukopenia, and both have long records of safety data from two decades of 
FDA-approved usage. Rare adverse events are usually mild febrile incidents that quickly 
subside upon cessation of administration. G-CSF is currently in clinical trial for stroke 
and was recently approved for an AD Phase II clinical trial. However, GM-CSF/Leukine 
is more effective in the AD mouse model and while neutrophils are short-lived 
leukocytes, the fact that GM-CSF induces the up-regulation of all innate cells means that 
it could potentially impart prolonged protective effects against AD. Furthermore, Leukine 
is the only FDA-approved drug to prevent fatal infections in acute myelogenous leukemia 
(AML) patients, and thus would also be expected to provide antibiotic-free prophylaxic 
immunity against onset of infection in the recipient AD patients, who at their age and 
immunodeficient state are highly susceptible to microbial opportunism. 
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Conclusion 
The failure of NSAID clinical trials in AD and the multiple studies which show 
that a defective innate immune system propagates AD pathology, encouraged us to 
develop and test our hypothesis that intrinsic pathogenic properties of RA are protective 
against AD.  The recent 2009 ICAD news by Dr. Breitner of the ADAPT consortium, 
which reported a 0.33 hazard ratio for dementia, within cognitively-normal individuals 
taking naproxen for over two years, is still more than that of RA patients, in which less 
than 5% ever develop concomitant AD, further strengthening our hypothesis that other 
intrinsic factors within RA pathogenesis must underlie the protective effect of RA against 
AD onset. Indeed the beneficial effects of all three RA-upregulated CSFs, especially 
GM-CSF, in mouse models of AD point to a potential new approach to AD therapy and 
indicate that age-related depressed hematopoiesis may be etiological for AD 
pathogenesis. 
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APPENDIX A:  A NOVEL TECHNIQUE FOR SIMULTANEOUS BILATERAL 
 INFUSIONS IN A MOUSE MODEL OF NEURODEGENERATIVE DISEASE 
 
 
 
The manuscript entitled, “A novel technique for simultaneous bilateral infusions 
in a mouse model of neurodegenerative disease”, by Steven P. Bennett et al.,  was 
accepted for publication on August 27, 2009 in the Journal of Neuroscience Methods.  
The device developed and described within this manuscript provided the scientific and 
technological framework upon which the findings of GM-CSF against AD were made. 
Following is a copy of this manuscript as it can be found in the Journal of Neuroscience 
Methods and as it can be accessed through a search of the online PubMed database.
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APPENDIX B:  GM-CSF UP-REGULATED IN RHEUMATOID ARTHRITIS 
REVERSES COGNITIVE IMPAIRMENT AND AMYLOIDOSIS IN 
ALZHEIMER’S MICE 
 
 Following is the acceptance email from the Journal of Alzheimer’s Disease of the 
latest revision of the manuscript entitled, “GM-CSF Up-regulated in Rheumatoid 
Arthritis Reverses Cognitive Impairment and Amyloidosis in Alzheimer’s Mice”. 
Curently, we are expecting back proofs of the manuscript as it will be presented in the 
journal, and thus the final version is not available for this dissertation.
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ABSTRACT 
Rheumatoid arthritis (RA) is a negative risk factor for the development of Alzheimer’s 
disease (AD). While it has been commonly assumed that RA patients’ usage of non-
steroidal anti-inflammatory drugs (NSAIDs) helped prevent onset and progression of AD, 
NSAID clinical trials have proven unsuccessful in AD patients. To determine whether 
intrinsic factors within RA pathogenesis itself may underlie RA’s protective effect, we 
investigated the activity of colony-stimulating factors, up-regulated in RA, on the 
pathology and behavior of transgenic AD mice. 5μg bolus injections of macrophage, 
granulocyte, and granulocyte-macrophage colony-stimulating factors (M-CSF, G-CSF, or 
GM-CSF) were administered unilaterally into the hippocampus of aged cognitively-
impaired AD mice and the resulting amyloid load reductions determined one week later, 
using the artificial cerebrospinal fluid-injected contralateral sides as controls. G-CSF and 
more significantly, GM-CSF reduced amyloidosis throughout the treated brain 
hemisphere one week following bolus administration to AD mice. 20 daily subcutaneous 
injections of 5µg of GM-CSF (the most amyloid-reducing CSF in the bolus experiment) 
were administered to balanced cohorts of AD mice after assessment in a battery of 
cognitive tests. Reductions in amyloid load and improvements in cognitive function were 
assessed. Subcutaneous GM-CSF administration significantly reduced brain amyloidosis 
and completely reversed the cognitive impairment, while increasing hippocampal 
synaptic area and microglial density. These findings, along with two decades of accrued 
safety data using Leukine, recombinant human GM-CSF, in elderly leukopenic patients, 
suggest that Leukine should be tested as a treatment to reverse cerebral amyloid 
pathology and cognitive impairment in AD. 
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Introduction 
Although numerous studies have reported Rheumatoid arthritis (RA) to reduce the risk of 
Alzheimer’s disease (AD), the mechanisms for RA’s protective effect are still unknown 
[1]. It was proposed and commonly assumed that RA patients’ usage of non-steroidal 
anti-inflammatory drugs (NSAIDs) may help prevent the onset and progression of AD [1]. 
However, the largest NSAID clinical trials have not demonstrated efficacy in reducing the 
incidence of dementia, and recently Naproxen was reported to be detrimental, with 
increased risk of cardiovascular and cerebrovascular events [2]. These results 
suggested to us that intrinsic, probably immunological factors within RA pathogenesis 
itself may underlie RA’s protective effect against AD. We surmised that up-regulated 
local cellular populations in RA would have the highest potential to enter into the brain 
and inhibit the development of AD pathology and/or neuronal dysfunction. 
Alzheimer’s disease is an age-related, progressive neurodegenerative disorder 
that presents as increasing decline in cognitive and executive function. Alzheimer 
dementia is associated with cerebrovascular dysfunction [3], extracellular accumulation 
of amyloid β (Aβ) peptides in the brain parenchyma and vasculature walls [4, 5] 
(predominantly Aβ1-42 and Aβ1-40), and intraneuronal accumulation of neurofibrillary 
tangles consisting of hyperphosphorylated Tau proteins[6].  Associated 
neuroinflammation may contribute to AD pathogenesis [7], as the inflammatory proteins 
apolipoprotein E (apoE) and α1-Antichymotrypsin (ACT) catalyze the polymerization of 
Aβ peptides into amyloid filaments in vivo and in vitro [8-11], and ACT has been shown 
to induce the phosphorylation of Tau [12]. Conversely, it has also been shown that 
amyloid plaques form rapidly and then become decorated by microglia [13, 14], both 
resident and bone marrow-derived, suggesting an ability and intention to remove 
amyloid [15-17]. Thus it is unclear whether neuroinflammation is deleterious or beneficial 
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in the AD brain, and indeed the role of microglia in AD is complex and may involve 
different states of activation with different activities. 
  Rheumatoid arthritis is an autoimmune disease in which inflamed synovial tissue 
and highly vascularized pannus form, irreparably damaging the cartilage and bone. In 
this inflammatory pannus, leukocyte populations are greatly expanded, perhaps as an 
endogenous, but ineffective attempt to remove the inflammatory insult.   As a result, 
many proinflammatory factors are produced that work together in feed-forward 
mechanisms, further increasing leukocytosis, cytokine/chemokine release, 
osteoclastogenesis, angiogenesis, and autoantibody production (rheumatoid factors and 
anti-citrullinated protein antibodies) [18, 19]. Additionally, the adaptive immune system 
presents a Th17 phenotype within CD4+ lymphocytes, with ultimate production of 
interleukin 17 (IL-17) which is then responsible for inducing much of the 
pro-inflammatory effects [20, 21]. Further enhancements of leukocyte populations come 
from increased expression of structurally-unrelated colony-stimulating factors: M-CSF 
(macrophage), G-CSF (granulocyte), and GM-CSF (granulocyte-macrophage) [22-25]. 
Although up-regulated leukocytes in response to RA could potentially enter into 
the brain and inhibit development of AD pathology and/or neuronal dysfunction, 
lymphocytic infiltrates into AD patient brains have not been reported. The lack of 
infiltration suggests that RA-induced proliferation and activation of the innate immune 
system by the CSFs described above might be responsible for preventing AD pathology 
in RA patients. Evidence supporting the innate immune system’s role in AD 
pathogenesis show that complement proteins are up-regulated in AD brain, and that 
inhibition of C3 convertase significantly increases amyloid pathology in AD mice [26]. 
Bone marrow-derived microglia also play a critical role in restricting amyloid deposition, 
and indeed, microglia activation and many associated receptors and enzymes, such as 
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CD36, scavenger receptor A, and receptor for advanced glycation end products, 
neprilysin, insulysin, and matrix metalloproteinases, decline with age as risk of AD 
pathology increases [17, 27, 28].  
To investigate the interplay of the innate immune system and AD, we studied the 
effects on AD pathology of the three colony-stimulating factors (M-CSF, G-CSF, and 
GM-CSF), which are up-regulated during RA pathogenesis [22-25]. These CSFs 
enhance the survival and function of their respective leukocytes and drive their 
proliferation and differentiation from myeloid lineage precursors. GM-CSF induces 
dendritic cells, macrophages, and granulocytes (neutrophils, basophils, and eosinophils), 
while M-CSF and G-CSF respectively induce the macrophage and granulocyte subsets 
of the innate immune system. These innate cells have the ability to diapedese from the 
circulatory system and to differentiate further into various specialized immune cells 
within organs (microglia, Langerhan’s cells, etc.). GM-CSF and G-CSF are also known 
to be involved in erythropoiesis, and GM-CSF and erythropoietin act synergistically in 
the maturation and proliferation of the burst-forming and colony-forming erythroid units to 
the normoblast stage of erythropoiesis [29, 30]. Circulating Aβ binds to complement 
opsonin C3b in an antibody-independent fashion, and C3-opsonized particles bind to the 
complement receptor, CR1, on erythrocytes and to CR1g on liver-resident kupffer 
macrophages [31, 32].  Thus GM-CSF could function in both the peripheral clearance of 
Aβ and in bone marrow-derived microglial activity, since it is involved in the proliferation, 
differentiation, and maintenance of most innate leukocytes. 
Here, we report on experiments that investigated the effect of CSF administration 
on amyloid plaque deposition, microglial activation, synaptic function, and associated 
cognitive decline in a mouse model of AD. Our results, particularly with GM-CSF, 
provide a compelling explanation for RA’s inverse relationship with AD. Moreover, the 
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reduction of amyloidosis and enhancement of cognition by GM-CSF warrant clinical 
investigation of Leukine for the treatment of Mild Cognitive Impairment (MCI) and AD 
patients, especially with Leukine’s long-standing safety history in leukopenic patients.  
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Materials and Methods 
All procedures involving experimentation on animals were performed in accordance with 
the guidelines set forth by the University of South Florida Animal Care and Use 
Committee. Transgene detections were performed using QPCR (Bio-Rad iCycler, 
Hercules, CA). 
Transgenic  Mouse Studies Involving Intracerebral Administration of CSFs 
PS/APP mice in this study, which begin accumulating robust amyloid plaques at 6-8 
months, were generated by crossing heterozygous PDGF-hAPP (V717F) mice with 
PDGF-hPS1 (M146L) on both Swiss Webster and C57BL/6 backgrounds. 
Bilateral Intracerebroventricular infusion of M-CSF 
M-CSF was bilaterally infused directly into the lateral ventricles (5 µg/day) for 14 days 
using a novel intracranial catheter infusion system (patent pending - PCT/US08/73974) 
[33]. This completely subcutaneously-contained system allows bilateral intracerebral 
infusion of test substances ipsilaterally and vehicle contralaterally, and overcomes the 
problem of amyloidosis variance between animals (Supplementary Fig. 1), effectively 
making each animal its own control. Briefly, animals (PS/APP, all 8.8 -9.6 months, 
numbered sequentially according to date of birth, 25-35 g, both genders) were 
anesthetized with 1-2% isoflurane, shaved and scrubbed with 10% Betadine solution at 
the site of incision, and placed into a stereotaxic frame (Kopf Instruments, Tujunga, Ca.).  
A small (3 cm) incision was made, exposing the skull, and curved Strabysmus surgical 
scissors were used to form a subcutaneous pocket along the animal’s back into which 2 
osmotic minipumps (Alzet model 1004, average flow rate of 0.12 µL/hour, Durect Corp., 
Cupertino, CA) were inserted.  Two holes were drilled into the skull (from Bregma -0.1 
mm anterior-posterior, +/- 0.9 mm medial-lateral), and 30 gauge catheters were inserted 
at a depth of 3.0 mm, corresponding to the lateral ventricles. Leading from the Alzet 
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pump was a proprietary catheter system  with the delivery tips fashioned to the contours 
of the skull rather than the commercially-available pedestal cannula. The cannulae are 
affixed to the skull using Locktite 454 adhesive (Plastics One, Roanoke, VA) and 
secured with 1 cm diameter nitrile, followed by silk sutures to close the scalp. 
 After 2 weeks of M-CSF infusions, mice were perfused, brain tissues were fixed 
in 10% neutral buffered formalin, and cryosectioned at 14 µm. 
Intrahippocampal injections of CSFs 
All three CSFs were stereotaxically-injected (5 µg/injection) into the (ipsilateral) 
hippocampus, with artificial cerebrospinal fluid vehicle injected contralaterally into four 
PS/APP mice each (all 10-12 months old, 25-35 g, both genders). Two holes were drilled 
into the skull (from bregma -2.5 mm anterior-posterior, +/- 2.5 mm medial-lateral, and the 
30 gauge needle inserted to a depth of 2.5 mm). Mice were perfused with 0.9% cold 
saline 7 days later and their brains placed in 10% neutral buffered formalin. 
Recombinant mouse GM-CSF (rmGM-CSF), recombinant murine G-CSF (rmG-CSF), 
and recombinant mouse M-CSF (rmM-CSF) (R&D Systems, Minneapolis, MN) will be 
referred to as GM-CSF, G-CSF, and M-CSF throughout this publication.  
Immunohistochemistry and Image Analysis of Intrahippocampal-injected Mice  
Formalin-fixed brains were either coronally cryosectioned at 14-µm, or paraffin-
embedded and sectioned at 5-µm, with standard deparaffination and antigen retrieval 
steps (boiled in 10mM Sodium Citrate buffer for 20 minutes) performed before 
immunohistochemical staining. To significantly reduce cost of reagents and antibodies 
with paraffin-embedded slides, a novel magnetic immunohistochemical staining device 
was developed (patent pending, Tech ID# 09A015). Standard fluorescent 
immunohistochemical techniques used primary anti-Aβ antibodies 6E10 (Covance, 
Emeryville, CA, 1:1000), and MabTech’s 3740-5 (MabTech, Cincinnati, OH, 1:5000) to 
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immunolabel amyloid deposition coupled with Alexa fluorophore-labelled secondary 
antibodies (Molecular Probes, Eugene, OR, 1:1000, 1:4000), and Hoechst (Sigma) 
nuclear staining. Immunofluorescence was detected and all pictures per section were 
taken at the same exposure on a Zeiss Imager.Z1 microscope (Oberkochen, Germany) 
using Axiovision 4.7 software. Digital images were quantified using ImageJ (method 
described in Supplementary Fig. 6 online). Briefly, each analyzed picture per coronal 
section was thresholded equally to the same standard deviation from the histogram 
mean, and analyzed for area, perimeter, feret diameter, and integrated density 
parameters of each plaque. Area and Perimeter data were calculated from the total and 
average number of plaque values in each hemisphere per section, and Feret Diameter 
and Integrated Density were calculated from the average values of the plaques 
measured in each hemisphere per section. For GM-CSF-injected mice, each section 
quantified contained analysis of 15-25 individual 10X pictures of each hemisphere, with 
fewer pictures quantified in the anterior brain and more in posterior brain. For G-CSF- 
and M-CSF-injected mice, each section quantified contained analysis of 7-9 individual 
5X pictures of each hemisphere Statistical significance was obtained from comparing 
parameter values of ipsilateral CSF-injected hemispheres versus contralateral artificial 
cerebrospinal fluid-injected hemispheres. Significance was determined by paired 
Students t-test with p values <0.5 considered significant. 
Behavioral Transgenic Mouse Study Involving GM-CSF Treatment  
Mice in this study were derived from the Florida Alzheimer’s Disease Research Center 
mouse colony, wherein heterozygous mice carrying the mutant APPK670N, M671L gene 
(APPsw) are routinely crossed with heterozygous PS1 (Tg line 6.2) mice to obtain 
APPsw/PS1, APPsw, PS1, and non-transgenic (NT) genotype offspring with a mixed 
C57/B6/SW/SJL background. Eleven APPsw and 17 NT mice, all 12-months old, were 
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selected and evaluated for 8 days in the RAWM task of working memory (as previously 
described [34] (Supplementary Fig. 7).  Briefly, an aluminum insert was placed into a 
100 cm circular pool to create 6 radially distributed swim arms emanating from a central 
circular swim area. The number of errors prior to locating which one of the 6 swim arms 
contained a submerged escape platform (9 cm diameter) was determined for 5 trials per 
day. The platform location was changed daily to a different arm, with different start arms 
for each of the 5 trials semi-randomly selected from the remaining 5 swim arms. The 
numbers of errors during trials 4 and 5 are both considered indices of working memory 
and are temporally similar to the standard registration/recall testing of specific items 
used clinically in evaluating AD patients.  Following 8 days of pre-treatment RAWM 
testing, the 11 Tg mice were divided into two groups, balanced in RAWM performance. 
The 17 NT mice were also divided into two groups, balanced in RAWM performance.  
Two weeks following pre-treatment testing, one group of Tg mice (n = 5) and one 
group of NT mice (n = 9) were started on a 10-day treatment protocol with GM-CSF (5 
µg/day given subcutaneously), while animals in the control Tg group (n=6) and control 
NT group (n = 8) concurrently received daily vehicle (saline) treatment subcutaneously.  
On the 11th day of injections, all mice began four days of RAWM evaluation, were given 
2 days of rest, then evaluated in 4 days of Cognitive Interference task testing as 
previously described [35, 36].  We designed this task measure-for-measure from a 
Cognitive Interference task used to discriminate normal aged, MCI, and AD patients from 
one another [34].  Our analogous interference task for mice involves two radial arm 
water maze (RAWM) set-ups in two different rooms, each with different sets of visual 
cues. The task requires animals to remember a set of visual cues, so that following 
interference with a different set of cues, the initial set of cues can be recalled to 
successfully solve the RAWM task. A set of four behavioral measures were examined. 
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Behavioral measures were: A1–A3 (Composite three-trial recall score from first 3 trials 
performed in RAWM “A”), “B” (proactive interference measure attained from a single trial 
in RAWM “B”), A4 (retroactive interference measure attained during a single trial in 
RAWM “A”), and “A5”(delayed-recall measure attained from a single trial in RAWM “A” 
following a 20 minute delay between A4 and A5). As a distracter between trials, animals 
are placed in a Y-maze and allowed to explore for 60 seconds between successive trials 
of the three-trial recall task, as well as during the proactive interference task. As with the 
standard RAWM task, this interference task involves the platform location being changed 
daily to a different arm for both of the RAWM set-ups utilized, 
and different start arms for each day of testing for both RAWM set-ups. For A1 and B 
trials, the animal was initially allowed one minute to find the platform on their own before 
they were guided to the platform. Then the actual trial was performed in each case. As 
with the standard RAWM task, animals were given 60 seconds to find the escape 
platform for each trial, with the number of errors recorded for each trial. Animals were 
tested for cognitive interference performance on four successive days, with statistical 
analysis performed for the two resultant 2-day blocks.  For both RAWM (combined T4 
and T5 overall) and cognitive interference testing (each of the four measures overall), 
swim speed was analyzed by dividing error numbers by latency and statistical 
significance was determined by one-way ANOVA followed by post hoc Fisher’s LSD  
(least significant difference) test to determine significant group differences at p < 0.05. 
Daily GM-CSF and saline injections were continued throughout the behavioral 
testing period. After completion of behavioral testing at 20 days into treatment, all mice 
were euthanatized, brains fixed as described above, and paraffin-embedded. Careful 
visual examination of all tissues upon necropsy revealed no morphological 
abnormalities, and the mice tolerated daily subcutaneous injections well. Each analysis 
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was done by a single examiner blinded to sample identities, and statistical analyses 
were performed by a single examiner blinded to treatment group identities. The code 
was not broken until analyses were completed. 
Immunohistochemistry and Image Analysis of Subcutaneous GM-CSF-treated 
Mice 
Five 5-μm sections (150-μm apart) were made of formalin-fixed, paraffin-embedded 
sections throughout the hippocampus of each mouse and immunoreactivity was 
developed using the Vectastain ABC Elite kit (Vector Laboratories, Burlingame, CA) 
coupled with the diaminobenzidine reaction, according to the manufacturer’s protocol. 
Immunostaining used biotinylated anti-Aβ clone 4G8 (Covance, Emeryville, CA, 1:200), 
synaptophysin (DAKO, Carpinteria, CA, undiluted), and Iba1 (Wako, Richmond, VA, 
1:1000) as primary antibodies. Since the 4G8 antibody was obtained with biotin label, 
the secondary step of the ABC protocol was omitted. However, treatment with 70% 
formic acid prior to the pre-blocking step was necessary. For 4G8 
immunohistochemistry, phosphate-buffered saline (0.1 mM, pH 7.4) was used instead of 
primary antibody or ABC reagent as a negative control. For Iba 1 and synaptophysin 
immunohistochemistry, normal rabbit serum was used instead of primary antibody or 
ABC reagent as a negative control. Images were acquired using an Olympus BX60 
microscope and digital images were quantified using SimplePCI software (Compix Inc., 
Imaging Systems, Cranberry Township, PA), according to previous methods [37].  
Briefly, a threshold optical density was obtained that discriminated staining from 
background, and each region of interest was manually edited to eliminate artifacts.  Data 
are reported as percentage of immunolabeled area captured (positive pixels) relative to 
the full area captured (total pixels). To evaluate synaptophysin immunoreactivity, after 
the mode of all images was converted to gray scale, the average intensity of positive 
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signals from each image was quantified in the CA1 and CA3 regions of hippocampus as 
a relative number from zero (white) to 255 (black).  
Statistical significance between GM-CSF-treated versus saline-treated groups was 
determined by two-tailed homoscedastic Student’s t-test with a p value of < 0.05 
considered significant.  Each analysis was done by a single investigator blinded to 
sample identities and genotype.
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RESULTS 
Intracerebral administration of CSFs  
Following bilateral intracerebroventricular infusion of M-CSF for two weeks into PS/APP 
mice, immunohistochemical analysis of both experimental and control mice showed 
considerable variances of amyloid deposition between mice of similar age 
(Supplementary Fig 1), significantly compromising our ability to determine M-CSF’s 
effect in a limited mouse cohort. While improving our drug delivery system by developing 
novel bilateral brain infusion catheters [33], we found that parenchymally-infused 
recombinant peptides remained localized to the infused hemisphere. These findings led 
us to administer the CSFs as a unilateral intrahippocampal bolus with a contralateral 
injection of vehicle as control, thus obviating the need for large numbers of transgenic 
mice and age-matched littermate controls to obtain statistical significance. Each CSF 
was stereotaxically injected into the hippocampus of 4 mice, with artificial cerebrospinal 
fluid vehicle injected contralaterally. The mice were sacrificed 7 days post-injection. 
M-CSF intrahippocampal injections into mice resulted in swelling of the entire 
hemisphere as compared to the control side, and in one mouse, an apparent hyperplasia 
had formed at the injection site (Supplementary Fig 2). Quantification of amyloid plaque 
loads from anterior to posterior of each mouse showed similar deposition in the M-CSF-
injected hemispheres as compared to the control sides (data not shown). In contrast to 
M-CSF, G-CSF intrahippocampal injections did not induce swelling and showed some 
modest reductions of amyloid deposition (Supplementary Fig 3). Since the analyses 
were conducted on low magnification (5X) photomicrographs, only the area and 
integrated density values achieved significance (p<0.05). Reductions in amyloidosis was 
subsequently corroborated by independent observations from fellow investigators 
following peripheral G-CSF administration [37].  
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GM-CSF-injections, however, demonstrated pronounced decreases in amyloid 
deposition, as compared to control hemispheres, in visual observations of coronal tissue 
sections (Fig 1a; Supplementary Fig 4). High magnification (10X) quantification of 
amyloid plaques anterior to posterior revealed significant reductions within individual 
mice and significant overall reductions for all plaque parameters measured (Fig 1b and 
Supplementary Fig 5).   
 
Daily subcutaneous injection of GM-CSF 
Based upon the positive results from intrahippocampal injections, we investigated the 
effect of subcutaneous GM-CSF injection on AD pathology and cognitive function. Prior 
to GM-CSF treatment, APPsw (Tg) mice were first confirmed by RAWM testing to be 
cognitively-impaired for working memory (Fig 2a). Both the non-transgenic control mice 
(NT) and the Tg mice were then sub-divided into two cognitively-balanced groups, for 
either GM-CSF or saline treatment. RAWM testing post-injection re-confirmed that Tg 
control mice were substantially impaired compared to NT control mice. This impairment 
was not only evident in individual blocks of testing, but also over all 4 days of testing (Fig 
2b). In sharp contrast, GM-CSF-treated Tg mice performed equally well or better than 
NT control mice during individual blocks and overall. GM-CSF-treated NT mice 
performed as well as or slightly better than NT controls (Fig 2b).  
  Before evaluation in the Cognitive Interference Task, the mice rested two days. 
This task mimics human interference testing, which discriminates between normal aged, 
MCI, and AD patients [36].  In three of four cognitive interference measures assessed 
over 4 days of testing (Fig 2c), Tg control mice were clearly impaired compared to NT 
mice, and Tg mice treated with GM-CSF exhibited significantly better three-trial recall 
and delayed recall compared to Tg controls. Indeed, for all four cognitive measures, GM-
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CSF-treated transgenic AD mice performed similarly to NT mice. A particularly strong 
effect of GM-CSF treatment in Tg mice was evident for the proactive interference 
measure during the first half of testing (Fig 2d), wherein GM-CSF-treated Tg mice 
performed substantially better than Tg controls and identically to both groups of NT 
mice.  Including this strong effect on proactive interference testing, GM-CSF treatment 
resulted in significantly better performance of Tg mice for all four measures of cognitive 
interference testing.  Proactive interference susceptibility has been reported to be a 
more sensitive marker for differentiating MCI and AD patients from aged normals than 
traditional measures of delayed recall and rate of forgetting [36].  Parenthetically, even 
the GM-CSF-treated NT mice showed a trend towards improved cognition in behavioral 
studies, albeit not statistically significant.  Analysis of swim speed for both the RAWM 
and cognitive interference tasks revealed that Tg control mice were significantly faster 
than the other three groups in the RAWM task and for two of four measures in the 
Cognitive Interference task (3-trial recall and delayed recall).  However, since error 
numbers were utilized for statistical analysis of both tasks, this difference in swim speed 
was negated since it is important only if latency measures had been used. 
Following completion of all behavioral evaluations, subsequent analysis of brains 
from Tg mice of this study revealed that GM-CSF treatment induced large reductions in 
amyloid burdens within entorhinal cortex (↓55%) and hippocampal (↓57%) compared to 
control Tg mice (Fig 3).  The improved cognitive function and reduced cortical 
amyloidosis of GM-CSF-treated Tg mice were paralleled by increased microglial density 
as compared to saline-treated Tg mice (Fig 4), implying an augmented ability to bind and 
remove amyloid deposition [27, 28]. The GM-CSF-treated Tg mice similarly 
demonstrated increased synaptophysin immunoreactivity in both CA1 and CA3 regions 
(Fig 5), indicating increased synaptic area in these hippocampal regions. Prior work has 
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shown that adult neural stem cells in hippocampal dentate gyrus (DG) express GM-CSF 
receptors, and GM-CSF increases neuronal differentiation of these cells in a dose-
dependent fashion [38]. Thus, one mechanism for the observed GM-CSF-induced 
cognitive improvement is enhanced removal of deposited Aβ in hippocampus, with 
ensuing neuronal growth/synaptic differentiation of DG mossy fiber innervation to CA3, 
resulting in increased innervation/synaptogenesis of Schaffer collaterals into CA1. 
Removal of deposited Aβ from entorhinal cortex may also increase perforant pathway 
viability to hippocampal projection fields in DG and CA1.  
Thus GM-CSF-induced reduction of amyloidosis and enhancement of 
hippocampal/entorhinal cortex circuitry, critical for working (short-term) memory, may 
underlie GM-CSF’s reversal of working memory impairment in Alzheimer’s Tg mice. 
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DISCUSSION 
Since peripheral leukocyte populations are increased in RA and possess the ability to 
infiltrate into the brain, we initially investigated M-CSF, G-CSF, and GM-CSF to 
determine which CSF might affect amyloidosis after direct injection into the brain. In the 
vasculature, all three CSFs work to drive the proliferation, differentiation, and survival of 
their respective innate leukocytes from monocytic precursors and would be expected to 
have similar effects on microglial precursors.  
In our study, we found different functional effects for each intrahippocampal-
injected CSF. In the M-CSF injected mice, there was no effect on amyloidosis, but 
pathological changes were noticed, such as swelling and hyperplasia (Supplementary 
Fig 2). Parenchymal overexpression of M-CSF in any organ is probably not advisable as 
overexpression of M-CSF and/or its receptor within mammary glands has similarly 
resulted in tumor formation and hyperplasia [39]. In a study by Boissonneault et al. 
(2009), the authors published that chronic intraperitoneal injection of M-CSF prevents 
and reverses amyloid deposition and cognitive impairment and induces a large 
accumulation of bone marrow-derived microglia in the brain [40]. The authors also 
confirmed previous research [17] that  bone marrow-derived microglia efficiently 
phagocytose and internalize Aβ. Although the authors did not relate their findings to RA’s 
inverse relationship with AD, their data provide evidence that up-regulated M-CSF in RA 
pathogenesis and systemic administration of M-CSF in AD patients may impart 
protection against AD onset or progression. However, M-CSF’s activation of mature 
osteoclasts, macrophages, and other innate leukocytes, induced thrombocytopenia, and 
autocrine signaling in some tumors may limit it’s usage in the clinical setting. 
Peripheral administration of G-CSF has also been found to ameliorate amyloid 
pathology and reduce cognitive defects in AD models [37, 41], which corroborates our 
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observations of modest amyloid reduction by intrahippocampal injection. In the study by 
Sanchez-Ramos et al. [37], the authors also show a large increase in bone marrow-
derived microglia with corresponding amyloid reductions, increased synaptic area, and 
partial reversal of cognitive impairment. 
Although the M-CSF and G-CSF intrahippocampal findings are encouraging, our 
GM-CSF intrahippocampal injections into an AD mouse model demonstrated a much 
more pronounced reduction of amyloidosis. These data led us to further examine 
GM-CSF on the behavior of aged cognitively-impaired AD mice. Subcutaneous 
administration of GM-CSF resulted in almost complete reversal of cognitive impairment, 
resulting in function similar to that of wild-type mice, with a corresponding average of 
about 50% reduction of amyloidosis in Entorrhinal cortex and Hippocampus. In contrast, 
M-CSF and G-CSF have been shown to only partially reverse cognitive impairment in 
aged AD mice, although the preventative chronic study of M-CSF administration into 
young AD mice showed equal cognitive function over time compared to wild-type 
controls. This cognitive advantage of peripherally-administered GM-CSF into aged AD 
mice could result from a combinatory effect of increased macrophage and granulocyte 
populations from bone marrow-derived monocytic precursors in the periphery, as well as 
induction of other innate leukocyte subsets in both periphery and brain. Indeed, GM-CSF 
has been shown to pass the blood brain barrier[42], and a recent study showed that GM-
CSF injected into the brains of normal mice activates microglia[43]. Further explanations 
for the very robust cognitive benefits of GM-CSF in our experiments are multiple, 
including the aforementioned augmentation of peripheral erythropoietic amyloid-
clearance mechanisms [31, 32, 44], as well as increased neurogenesis,[38] increased 
cerebral angiogenesis [45], neuroprotection from apoptosis[46], reduction in amyloidosis 
(Figs 1,3, and Supplementary Fig 5), and increased neuronal plasticity (Fig 5).  
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Our results mirror those reported for G-CSF [37], and supports the current 
practice of interchangeable prescription of either recombinant human GM-CSF (Leukine) 
or G-CSF (Granocyte, Neupogen, and Neulasta) into patients with depressed bone 
marrow function. G-CSF primarily treats neutropenia while GM-CSF treats all 
leukopenia, and both have long records of safety data from two decades of FDA-
approved usage. Rare adverse events are usually mild febrile incidents that quickly 
subside upon cessation of administration. G-CSF is currently in clinical trial for stroke 
and was recently approved for an AD Phase II clinical trial. However, GM-CSF/Leukine 
is more effective in the AD mouse model and while neutrophils are short-lived 
leukocytes, the fact that GM-CSF induces the up-regulation of all innate cells means that 
it could potentially impart prolonged protective effects against AD.  
The failure of NSAID clinical trials in AD and the multiple studies that show that a 
defective innate immune system propagates AD pathology encouraged us to develop 
and test our hypothesis that intrinsic pathogenic properties of RA are protective against 
AD.  Indeed the beneficial effects of all three RA-upregulated CSFs, especially GM-CSF, 
in mouse models of AD point to a potential new approach to AD therapy and indicate 
that age-linked depressed hematopoiesis may be etiological for AD pathogenesis. 
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Fig 1. Intrahippocampal injection of GM-CSF (left) and artificial cerebrospinal fluid 
(aCSF) (right).  (a) Representative coronal tissue cryo-sectioned at 14 µm and stained 
with MabTech α-Aβ/Alexa 546. Image is a montage of about 145 pictures taken at 10X. 
White spots indicate amyloid plaque immunolabelling (see Supplementary Fig. 4 online 
for representative montaged sections of all 4 mice). (b) Significant overall plaque 
reductions seen in all 4 plaque parameters measured from 5 quantified sections per 
mouse (n = 4 mice). Error bars are ± Standard Error of the Mean. (Area: p < 1.11E-07; 
Perimeter: p < 1.41E-06; Feret Diameter: p < 2.36E-09; Integrated Density: p < 1.11E-
07). 
  
Fig 2. Behavioral analysis following daily subcutaneous GM-CSF injections.  
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(a)Standard Radial Arm Water Maze errors prior to treatment. The final block and 
overall performance of the Tg and NT mice during 8 days of consecutive daily 
pre-treatment testing in the RAWM maze.  The data was analyzed in four 2-day blocks 
and overall (Blocks 1-4).  (*p < 0.02 or higher significance).  
(b) Standard Radial Arm Water Maze errors after treatment. Tg control mice (n = 6) 
show substantial impairment on working memory trials T4 and T5 compared to NT 
control mice (n = 8) in individual blocks of testing (upper), and over all 4 days of testing 
(lower). GM-CSF-treated Tg mice (n = 5) performed as well as or better than NT control 
mice on working memory trials T4 and T5 during individual blocks and over all. GM-CSF-
treated NT mice (n = 9) performed similarly to or slightly better than NT controls (Note 
significantly better performance of NT+GMCSF group versus NT group for T4 of Block 
1), although this effect was not significant overall. (**p < 0.02 or higher significance 
versus all other groups; † p < 0.02 or higher significance versus Tg+GM-CSF and 
NT+GM-CSF).  
(c) Cognitive Interference Task. Overall (4 Days) Tg control mice are impaired 
compared to NT mice on all four cognitive measures assessed.  GM-CSF-treated Tg 
mice exhibited significantly better 3-trial recall (A1-A3) and delayed recall (A5) compared 
to Tg controls and performed similarly to NT mice in all four cognitive measures.  GM-
CSF treatment of NT mice did not result in significantly better performance compared to 
NT controls, although trends for a beneficial GM-CSF effect in NT mice were evident 
overall. (*Tg significantly different from NT+GM-CSF, **Tg significantly different from all 
other groups). 
 (d) Cognitive Interference Task. Proactive Interference testing (First 2 days). 
GM-CSF-treated Tg mice performed significantly better than Tg controls and equally to 
NT and GM-CSF-treated NT mice. 
  
Fig 3. Amyloid deposition in subcutaneous GM-CSF-injected mice. (a-d) 
Photomicrographs of coronal 5-µm paraffin-embedded sections immunolabelled with 
anti-Aβ antibody (clone 4G8) in Entorrhinal cortex (E) and hippocampus (H)).  Pictures 
are representative of amyloid load closest to the mean of the GM-CSF- or saline-treated 
Tg groups. Scale bar = 50 µm. (e) Percent of amyloid burden from the average of five 
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5-μm sections (150-μm apart) through both anatomic regions of interest (hippocampus 
and entorhinal cortex) per mouse of GM-CSF-treated (n = 5) versus saline- treated (n = 
6). Entorhinal cortex (*p  < 0.026), and Hippocampus (p = 0.12).  
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Fig 4. Microglial immunostaining in subcutaneous GM-CSF-injected mice.  
(a-d) Photomicrographs of coronal 5µm paraffin-embedded sections immunolabelled 
with Iba-1 antibody in Entorrhinal cortex (E) and hippocampus (H). Pictures are 
representative of Iba-1 immunolabelling closest to the mean of the GM-CSF- or saline 
control- treated groups. Scale bar = 50µm. (e) Percent of Iba1 burden from the average 
of five 5-µm sections (150 µm apart) through both anatomic regions of interest (H and 
EC) per  mouse of GM-CSF-treated (n = 5) versus saline-treated (n = 6).  
 H(p  < 0.02), EC(p  < 0.05). 
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Fig 5. Synaptophysin immunostaining in subcutaneous GM-CSF-injected mice.  
(a-d) Photomicrographs of coronal 5-µm paraffin-embedded sections immunolabelled 
with anti-synaptophysin antibody. Pictures are representative of synaptophysin 
immunolabelling closest to the mean of the GM-CSF- or saline control- treated groups. 
Scale bar = 50 µm. (e) Percent of synaptophysin immunoreactivity from the average of 5 
sections per mouse of GM-CSF-treated (n = 5) versus saline control-treated (n = 6). 
CA1(p  < 0.0013), CA3(p  < 0.0023). 
 
Supplementary Figure 1. Significant variation of amyloid plaque load between 
mice.  
Standard fluorescent immunohistochemistry used 6E10/Alexa 488 and Hoechst nuclear 
stain (blue). Bright green spots indicate amyloid plaques. Pictures taken at 5X. Mouse 
numbers 148,160,171, and 211 received bilateral intracerebroventricular infusions of M-
CSF and mice 164, 170, 176, and 177 received bilateral intracerebroventricular infusions 
of artificial cerebrospinal fluid.  
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Supplementary Figure 2.  Intrahippocampal injection of  M-CSF-injected left 
hemisphere and artificial cerebrospinal fluid (aCSF)‐injected right hemisphere.  
(A) The image is a montage of ~35 5X pictures and is representative of the effects seen 
from anterior hippocampus to posterior in all 4 M-CSF-injected mice. (B) This photo 
shows enlargement of the M-CSF-injected left hemisphere, as seen following saline 
perfusion. Note the small bump at the site of injection (arrow). (C) Image shows cyst or 
tumor-like growth formed in the needle track at the site of M-CSF injection. 
Cryosectioned at 14 µm and stained with 6E10/Alexa 488 and Hoechst. Picture taken at 
20X. 
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Supplementary Figure 3. Intrahippocampal injection of G-CSF-injected left 
hemispheres and artificial cerebrospinal fluid (aCSF)‐injected right hemispheres. 
(A) Images are montages of ~35 5X pictures each.  Amyloid plaques indicated as white 
spots.  Cryosectioned at 14 µm and stained with 6E10/Alexa546 and Hoechst nuclear 
stain. Sections numbered 1 through 6 and correspond with anterior to posterior. (B) 
Amyloid plaques show a modest reduction of plaque in the left G-CSF-injected 
hemisphere. Error bars are ± Standard Error of the Mean.  
(Area, Integrated Density: p < 0.05). 
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Supplementary Figure 4. Intrahippocampal injection of GM‐CSF‐injected left 
hemispheres and artificial cerebrospinal fluid (aCSF)‐injected right hemispheres. 
Representative sections of each mouse proximal to injection site. Tissue sections 
stained with MabTech α-Aβ/Alexa 488. White spots indicate amyloid plaque 
immunolabelling. Images are montages of about 145 pictures taken at 10X. Figures 4A-
C are from 14 µm frozen sections, and 4D is from a 5 µm paraffin-embedded section. 
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Supplementary Figure 5.Quantification of reduced amyloid deposition in 
GM‐CSF‐injected left hemispheres versus artificial cerebrospinal fluid 
(aCSF)‐injected right hemispheres. 
There were 5 montaged sections per mouse quantified. Each montaged section 
contained over 140 10X pictures and of these, 15 ‐ 25 pictures per hemisphere were 
selected to quantify as described in Supplementary Figure 6 online. Each figure shows 
total or average values from the 5 sections/mouse with significance per individual mouse 
and significance over all 4 mice. Error bars are ±SEM : (a - b) plaque areas (c - d) 
perimeter values (e) average feret diameters (f) average integrated densities 
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Supplementary Figure 6. Microscopy and method of Image J analysis of 
amyloid deposition 
Lateral rows  of photomicrographs were taken of coronal sections in a manner that 
ensured minimal overlap between each photomicrograph and corresponding anatomical 
areas in each hemisphere.  Hoechst nuclear staining was used as a tool to scroll through 
sections, allowing for minimal overlap between each photomicrograph, and then the 
image was taken with the appropriate fluorescence. After all photomicrographs of the 
section were taken, they were montaged into a full coronal picture of the section, with 
the outline of each photomicrograph displayed (Axiovision 4.7 Panorama Module 
software). Photomicrograhs were then selected for analysis from each hemisphere 
(Figure 6A). The histogram of each photomicrograph was analyzed and the resulting 
means and standard deviations were entered into a spreadsheet. One photomicrograph 
of the section was then thresholded to select the amyloid plaques. This thresholded 
value was used in the spreadsheet to normalize the threshold values of the other 
photomicrographs to the same standard deviation from their respective histogram mean 
(Figure 6B). Each photomicrograph was then analyzed for Area, Perimeter, Feret 
Diameter, and Integrated Density values from their predetermined threshold values. Any 
threshold-selected data, which came in contact with the edges of any photomicrograph, 
were deleted via the  Image J “Analyze Particles” dialogue box, so that overlap of 
photomicrographs did not allow quantification of any amyloid deposition more than once. 
Within the Image J “Analyze Particles” dialogue box, the Oulines mask was also 
selected to visually confirm that the plaques were quantified accurately (Figure 6C). This 
Outline mask also numbered each plaque, which was used for selecting and eliminating 
artifact from the results. The results from each individual photomicrograph were copied 
into a 2nd separate spreadsheet, such that the data was separated into their respective 
hemispheres (CSF-treated versus artificial cerebrospinal fluid-treated). After all 
photomicrographs from a coronal section had been analyzed and data entered into the 
spreadsheet, the Area and Perimeter values were totaled and averaged. The Feret 
Diameter and Integrated Density values were also averaged.  The overall data from 
each section (sums and averages) were then entered into a 3rd spreadsheet . A total of 5 
sections per mouse, anterior to posterior, were analyzed and entered into this 3rd 
spreadsheet. A total of 4 mice per intrahippocampal-injected CSF were analyzed. 
Significance per mouse and over all 4 mice per CSF was determined by paired Students 
t-test with p values <0.5 considered significant  
 
Supplementary Figure 6A. Coronal section taken at 10X, showing demarcation 
of individual photomicrographs to be analyzed for amyloid deposition.  
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Supplementary Figure 6B. Thresholding of one photomicrograph and using its 
threshold value to find the threshold value for all other photomicrographs within 
the coronal section at the same standard deviation from the mean. 
 
Supplementary Figure 6C. Example of the Oulines mask and underlying 
ImageJ spreadsheet data. 
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Supplementary Fig 7. Behavioral Tasks 
 
Radial Arm Water Maze.  For the RAWM task of spatial working memory, an 
aluminum insert was placed into a 100cm circular pool to create 6 radially-
distributed swim arms emanating from a central circular swim area. An 
assortment of 2-D and 3-D visual cues surrounded the pool. The number of 
errors prior to locating which one of the 6 swim arms contained a submerged 
escape platform (9cm diameter) was determined for 5 trials/day. There was a 30-
min time delay between the 4th trial (T4; final acquisition trial) and 5th trial (T5; 
memory retention trial). The platform location was changed daily to a different 
arm, with different start arms for each of the 5 trials semi-randomly selected from 
the remaining 5 swim arms. During each trial (60 s maximum), the mouse was 
returned to that trial’s start arm upon swimming into an incorrect arm and the 
latency time required to locate the submerged platform was recorded. If the 
mouse did not find the platform within a 60-s trial, it was guided to the platform 
for a 30-s stay. The numbers of errors and escape latency during trials 4 and 5 
are both considered indices of working memory and are temporally similar to 
standard registration/recall testing of specific items used clinically in evaluating 
AD patients. 
 
Cognitive Interference Task. This task was designed to mimic, measure-for-
measure, a cognitive interference task recently utilized clinically to discriminate 
between normal aged, MCI, and AD patients. The task involves two RAWM set-
ups in two different rooms, with two sets of visual cues different from those 
utilized in standard RAWM testing. The task requires animals to remember a set 
of visual cues (in RAWM-A), so that following interference with a different set of 
cues (in RAWM-B), the initial set of cues can be recalled to successfully solve 
the RAWM task. Five behavioral measures were examined: A1-A3 (Composite 
three-trial recall score from first 3 trials performed in RAWM-A), B (proactive 
interference measure attained from a single trial in RAWM-B), A4 (retroactive 
interference measure attained during a single trial in RAWM-A), and A5 (delayed-
recall measure attained from a single trial in RAWM-A following a 20-min delay 
between A4 and A5). As with the standard RAWM task, this interference task 
involves the platform location being changed daily to a different arm for both 
RAWM set-ups. For A1 and B trials, the animal is initially allowed one minute to 
find the platform on their own before being guided to the platform. Then the 
actual trial is performed in each case. As with the standard RAWM task, animals 
were given 60s to find the escape platform per trial, with the number of errors 
and escape latency recorded per trial. 
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APPENDIX C:  COPYRIGHT INFORMATION 
 
 In the United States, whenever an author or creator puts their work onto a tangible 
media, they automatically obtain copyright protection, for any “original work of 
authorship”.  Thus the manuscripts that authors submit to various journals are regulated 
by copyright laws, and some journal policies require explicit permissions for any further 
usage of the works that they publish within their journals, sometimes even by the original 
authors themselves. Not only does this dissertation have copyright protections, but also 
do the original figures and text which are enclosed within, and which have also been 
published in the Journal of Neuroscience Methods and the Journal of Alzheimer’s 
Disease. Both journals’ publishers have provided explicit terms regarding authorship and 
copyright permissions on their websites. The following pages, obtained directly from 
each publisher’s website, explicitly state each publisher’s copyright policies. These 
policies give permission for  the original materials from both journal articles to be used 
within this dissertation.  
  
The Journal of Neuroscience Methods, is published by Elsevier, a part of the Reed 
Elsevier group based out of Amsterdam, which has the following policy stated on its 
website, and which can be found at the web link: 
http://www.elsevier.com/wps/find/authorshome.authors/copyright 
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APPENDIX D: IMAGEJ ANALYSIS PROTOCOL 
 
 
 This protocol was developed to quantify parameters of amyloid deposition in each 
brain hemisphere and enable comparisons to be made between each side. It was critical 
that the tissue sections were properly-aligned under the microscope so that the 
photomicrographs could be taken in horizontal lateral rows continuously across both 
hemispheres of the coronal sections. We examined the Axiovision version 4.7 software 
which was used in the acquisition of the photomicrographs to see if it had the capability 
to accurately quantify amyloid plaques. However, it did not provide the capability to 
select artifactual or non-specific immunopositivity, so that these selections could be 
eliminated from the analyses. Thus, we examined several software packages for these 
capabilities, and found that the freely-available ImageJ software, which is provided 
through the National Institute of Health, could perform these tasks. Following is the 
protocol that we developed using the ImageJ software to analyze specific plaque 
parameters in the mouse brains, following acquisition of the photomicrographs from 
Axiovision version 4.7 software. The compilation of the photomicrographs was 
performed using the Axiovision version 4.7 Panorama Module.
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APPENDIX E: MAGNETIC IMMUNOHISTOCHEMICAL 
 STAINING DEVICE AND METHODS OF USE  
 
 This device was constructed in order to spare the usage of valuable antibody 
solutions and other reagents during the immunohistochemical (IHC) staining of tissues, 
which had been paraffin-embedded and mounted onto glass slides. During traditional 
staining protocols of these types of tissue preparations, there was no adequate procedure 
for mounting a hydrophobic barrier around the edges of the slide or tissue, which would 
allow for concentration of reagent solutions, instead of full submersion of slides in said 
solutions. Upon demonstration of this device’s utility in said IHC application, it was 
submitted for provisional patent application at the United States Patent and Trademark 
Office (USPTO) on June 24, 2008, and subsequently a non-provisional patent application 
was filed with the USPTO on June 24, 2009. Following is a copy of the patent application 
file on Jun 24, 2009, followed by the higher resolution figures.  
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APPENDIX F: METHODS OF TREATING COGNITIVE IMPAIRMENT  
 
 
 Given the quick and remarkable effects of GM-CSF in transgenic (Tg) mouse 
models of AD, especially the reversal of already-established cognitive impairment in 
these aged Tg mice, implies that the recombinant human GM-CSF 
(sargramostim/Leukine) protein may impart the same beneficial effects wtihin AD and 
other cognitively-declining patients. Since we were the first to identify GM-CSF to have 
these effects, we filed to protect USF’s and our intellectual property rights for the usage 
of GM-CSF in the amelioration of pathologies found in specific neurodegenerative 
diseases. A provisional patent entitled  “Methods of Treating Cognitive Impairment” was 
filed with the United States Patent and Trademark Office (USPTO) on August 5, 2008. 
On August 5, 2009, a regular patent application, containing some revisions to the 
provisional patent application, was filed with the USPTO, as well as in international 
filings. Following is a copy of the provisional patent application that was received by the 
USPTO on August 18, 2008.
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